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ABSTRACT 
Kara Lindsey Jensen:  CHARACTERIZATION OF A NOVEL MYCOBACTERIUM 
TUBERCULOSIS-SIMIAN IMMUNODEFICIENCY VIRUS VACCINE TO PREVENT 
ORAL PEDIATRIC HIV TRANSMISSION 
 (Under the direction of Kristina Abel) 
 
Over 3.3 million children are living with HIV, infected primarily by mother-to-child 
transmission (MTCT).  Breast milk exposure of HIV accounts for up to 44% of MTCT 
events.  Despite serious efforts to prevent vertical HIV transmission, infant testing is often 
delayed and access to antiretroviral therapies is still limited.  Compared to adults, HIV-
infected infants experience enhanced disease progression and more severe co-morbidities 
with pathogens like Mycobacterium tuberculosis (Mtb).  The live attenuated BCG vaccine is 
the only licensed tuberculosis vaccine but BCG can disseminate in immunosuppressed, HIV-
infected infants.  Considering the significant geographical overlap of the HIV and TB 
epidemics and the high vulnerability of infants to both pathogens, a pediatric vaccine to 
safely protect against HIV and Mtb is urgently needed. 
 We hypothesized that human-adapted attenuated Mtb strains engineered to co-
express HIV genes (rAMtb-HIV) would safely induce the development of dually-
immunogenic HIV- and Mtb-specific cellular and humoral responses.  Three distinct 
attenuated Mtb-SIV strains were evaluated in the neonatal rhesus macaque model.  Oral 
priming with strain mc26435 plus systemic MVA-SIV boosts successfully induced the 
development of Mtb- and SIV-specific cellular and humoral responses and was identified to 
be safe in healthy and immunosuppressed, SIV-infected neonatal macaques. 
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However, despite vaccine-induced immunity, vaccination did not protect infants 
against low-dose oral SIV challenges designed to mimic oral MTCT during breastfeeding.  
Two important results emerged from the challenge study.  First, higher Env-specific mucosal 
IgA activities and plasma IgG avidities positively correlated with controlled viremia in a 
subset of vaccinated animals.  These animals also maintained peripheral CD4+ T cell 
populations and IL-17-expressing lymphocytes in the intestinal mucosa.  However, the 
majority of vaccinated animals required fewer low-dose SIV exposures to become infected 
than unvaccinated animals.  Enhanced viral acquisition was associated with vaccine-induced 
persistent immune activation.  At the time of challenge, CCR5-expressing CD4+ T cells were 
observed with greater frequencies in blood, oral and intestinal tissues in vaccinated animals 
only, providing increased frequencies of SIV target cells.  Due to the potential impact of 
these data on BCG vaccine safety and pediatric HIV and TB vaccine development, additional 
studies are required to confirm these complex and intriguing results.  
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CHAPTER 1:  INTRODUCTION 
 
THE PEDIATRIC HIV EPIDEMIC 
Multiple distinct zoonotic transmission events of simian immunodeficiency viruses 
(SIV) in western Africa resulted in the first cases of human immunodeficiency virus (HIV) 
sometime in the 1930s (62, 67, 101, 102, 114, 161, 170, 234, 306).  Although HIV had not 
yet been identified through the 1970s, symptoms such as Kaposi’s sarcoma, wasting disease, 
opportunistic infections and unusual pneumonias became hallmarks of a fatal infection that 
appeared to disproportionately afflict African sex and migrant workers and western 
homosexual men and injection drug users (143, 199).  Retrovirologists Françoise Barré-
Sinoussi and Luc Montagnier performed fundamental experiments identifying HIV as the 
etiological agent of AIDS in 1983 (17).  An estimated 34 million people currently live with 
HIV, with 2.5 million new infections annually.  Over 350,000 of the new annual infections 
occur in infants (384).   
Mother-to-child transmission (MTCT) events are accountable for over one new 
pediatric HIV infection per minute, with >90% occurring in sub-Saharan Africa (338, 382, 
383).   MTCT of HIV occurs via multiple mechanisms including in utero, intrapartum or 
following oral exposure to virus in breast milk (185) and up to 44% of MTCT infections 
occur following oral breast milk exposure in the absence of preventative interventions (237).  
The risk of vertical transmission positively correlates with maternal viremia in breast milk 
and, even with maternal HAART, oral transmission events are only reduced but not 
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eliminated (280, 338, 384).  
Viral transmission during breastfeeding is poorly understood.  Due to the 
immunosuppressive state induced by pregnancy, viral replication, and thus virus levels in 
breast milk, increase during pregnancy and the postpartum period, translating to increased 
risk of HIV transmission during breastfeeding (97, 153, 168, 171, 233, 300, 343). Pregnancy-
induced immunosuppression accounts for increased levels in both cell-free virus particles and 
cell-associated virus, both of which are potentially infectious following oral exposure 
although the relative contributions of each route remain controversial.  Recent findings in 
humans implicate cell-associated virus as a correlate of early MTCT oral transmission (0-6 
weeks) (233), while studies in humanized mice identify transmission of cell-associated virus 
at both oral and intestinal mucosal surfaces and only cell-free virus as infectious at mucosal 
sites distal to the esophagus (356).  Similarly, the specific location(s) of viral entry following 
oral exposure is/are unknown. The palatine tonsil, salivary glands and other organized oral 
lymphoid tissues, along with upper gastrointestinal mucosal surfaces have been implicated as 
likely sites of entry due to the presence of HIV-infected cells in these tissues.  
Considering the frequency of exposure to virus during the breastfeeding period, HIV 
infection following oral exposure is inefficient.  In vitro experiments have demonstrated that 
breast milk can inhibit HIV infectivity, has explicit antiviral properties and contains many 
innate factors that exhibit immunoprotective effects (e.g. antibodies, cytokines, lactoferrin, 
mucins, defensins, tenascin-C, secretory leukocyte protease inhibitor (SLPI), bile-stimulated 
lipase, lipids, long chain polyunsaturated fatty acids and β-globins)(88, 94, 112, 113, 120, 
185, 215, 231, 272, 289, 310, 323, 332, 382).  In fact, the inhibitory components in HIV-
naïve human breast milk appear to render cell-free HIV unable to orally infect humanized 
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mice (356).   
Factors such as human and viral genetics, commensal microbiome and/or localized 
innate defenses may also contribute to reduced transmission frequencies following oral HIV 
exposure.  There is likely interplay between the virus and those maternal and infant factors 
operating to protect against transmission.  Despite the viral inhibitory properties of breast 
milk, oral exposure to virus in breast milk remains an important route of pediatric HIV 
acquisition and protective interventions are urgently needed to curb the pediatric HIV 
epidemic.   
PEDIATRIC HIV PATHOGENESIS 
Most of our knowledge about pediatric HIV pathogenesis stems from observational 
studies of infected infants.  We know that the HIV disease course is accelerated in the young 
and that both morbidity and mortality are exacerbated compared to infection in older 
individuals (246).  In the absence of therapy, neonatal infections progress rapidly to 
symptoms of AIDS; about 35% of infected individuals will die before their first birthday and 
50% will die before their second, often from secondary infections like tuberculosis (26, 228, 
237, 302). HIV-infected infants represent just 4% of the HIV-1-infected individuals 
worldwide but account for over 20% of HIV-associated fatalities (111).   
HIV replicates to high viral titers that are roughly equivalent between infants and 
adults, peaking at about two weeks post-infection (peak viremia).  Following peak viremia 
and dependent on a number of factors such as comorbidities, viral strain and immune 
function, the amount of virus in the periphery drops and stabilizes at the viral set point (209).  
While ART-naïve adults are usually able to reduce plasma viremia significantly between 
peak viremia and set point, infants are typically much less able to resolve viremia, resulting 
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in a phenotypic age-associated difference in control of viral replication (Figure 1.1).  High 
viremia along with weak antiviral immune responses in infants accelerates the elimination of 
T cells, destroys the integrity of the intestinal mucosa, increases systemic bacterial 
translocation and leads to sustained inflammation (29, 81, 248, 249, 263, 284, 287).   
Additionally, pediatric HIV infections can manifest as central nervous system (CNS) 
disease following viral transfer across the blood-brain barrier (BBB)(20, 52, 98, 164, 220, 
222, 253).  CNS disease is associated with pediatric AIDS and high levels of 
compartmentalized virus within the CNS have been associated with accelerated disease (98, 
269, 329, 345).  Because the BBB requires several years to fully mature, infants are at higher 
risk of HIV-associated CNS disease compared to older individuals (254, 269).  Importantly, 
CNS disease can prevent normal brain development, resulting in delays in motor skills, 
speech and other neurocognitive functions, as well as growth and physical development. 
Further, the immaturity of the immune response at birth predisposes infants, and 
particularly infants further immunosuppressed by HIV infection, to comorbidities like 
tuberculosis (TB).  Sub-Saharan Africa is heavily burdened by both the HIV and TB 
epidemics, and the significant geographic overlap results in the high prevalence of 
comorbidities (Figure 1.2).  Due to HIV-induced immunosuppression, species of 
mycobacteria that were not pathogenic in healthy individuals (e.g. Mycobacterium avium) 
now have a susceptible host population in which to propagate (39, 106, 131, 163, 242).  TB 
disease is the leading killer of HIV-infected individuals of any age and the WHO predicts 
that HIV-infected individuals have up to 50% lifetime risk of TB (371).  TB is responsible 
for 21-52% of deaths in HIV-infected individuals (384) and infants co-infected with HIV and 
M. tuberculosis are more likely to die from TB (228, 318).   
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A synergistic relationship exists between HIV and Mtb that serves to exacerbate 
disease morbidity (257).  HIV infection reduces immune system function, allowing Mtb to 
freely replicate/disseminate and Mtb infection activates immune cells that are the preferential 
infection target of HIV.  Co-morbidity appears to occur in a similar manner independent of 
the order of infection, with HIV infections well documented to reactivate bacterial replication 
in individuals latently infected with Mtb (257).  In fact, infants exposed to HIV through 
breastfeeding are more likely to become co-infected with TB than infants not exposed to the 
virus, suggesting again that co-infection is advantageous for these two pathogens, especially 
in infants (380). 
Decades of global antibiotic use have caused the emergence of multi-drug (MDR) and 
extensively drug-resistant (XDR) strains of M. tuberculosis that are undeterred with most 
first-line antibiotics, significantly boosting the financial and economic costs associated with 
treatment and care of individuals infected with these strains. The severity of MDR strains is 
illustrated in the tragic outbreak in KwaZulu-Natal, South Africa, killing 52 of 53 patients 
co-infected with HIV+ (99).  Independent of HIV status, there are an estimated 1 million new 
pediatric TB infections annually (375).  Historically endemic alongside conditions of poverty, 
recent TB outbreaks even in the developed world have prompted new focus on vaccine and 
therapeutic development, but as TB therapies become less effective, it is essential to consider 
dual HIV-TB immunogen development as a possible and efficient approach. Here, I describe 
my research towards the goal of developing a novel pediatric HIV-TB vaccine using the 
rhesus macaque model. 
EFFORTS TO PREVENT PEDIATRIC HIV 
Most vertical HIV transmissions occur in resource-limited regions with low testing 
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rates, restricted access to antiretroviral drugs and/or where the benefits of breastfeeding 
outweigh potential transmission risk (383).  While abstinence from breastfeeding can reduce 
the risk of pediatric HIV transmission, it does not reduce infant morbidity or mortality 
because the presence of immunologically protective factors in breast milk can be so effective 
at reducing other pediatric health concerns and infections (e.g. nutritional deficiencies, 
diarrheal disorders, sepsis and pneumonia).  In the developing world, breastfed children have 
at least a six-times greater chance of survival in the early months than non-breastfed children 
(14, 25).   
Previously, public health advisories recommended early and abrupt weaning to avoid 
MTCT.  However, it is now clear that mixed feeding (formula, water, juice and/or solid foods 
in addition to breast milk) drastically enhances the risk of infection, suggesting that long-
term exclusive breastfeeding may be more protective (61, 64, 177, 286, 339).  Studies 
concluded that reductions in breastfeeding frequency due to alternate calorie sources caused 
breast milk viral loads to increase and that enhanced transmission resulted from periodic 
breastfeedings after premature weaning (128).  Now mothers are recommended to 
exclusively breastfeed (>1year), followed by slow weaning with infant ART prophylaxis 
treatment for the full duration of the breastfeeding period.  
Antiretroviral therapies (ART) have drastically improved the longevity and quality of 
life for those living with HIV (344), but these therapies are not readily available to all 
infected individuals.  Limited access to therapy has aggravated the HIV epidemic 
disproportionately in resource-constricted regions.  In addition, fewer resources are 
specifically allocated to HIV-infected children.  In 2012, access to ART for adults was 
predicted to be 65% but estimated to be 34% for infants or lower, depending on the region 
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(384) (Table 1.1).  Pediatric ART access was also improving more slowly (up just 11% 
between 2011-12) compared to access for adults (up 21% between 2011-12) (384).  The 
WHO Global Plan 2015 target of providing ART to all ART-eligible children will require a 
“huge effort” to reach its goal (384).  Because pediatric ART is not accessible to all children 
in need and efforts to improve ART dispersal are failing to accommodate all those in need, 
alternative approaches to limit HIV MTCT are urgently needed.  Our goal of testing new 
pediatric HIV vaccines for immunogenicity and efficacy in the infant macaque model of SIV 
infection are part of the preclinical development of such alternative interventions. 
HIV VACCINE DESIGN 
There are several types of vaccine strategies that could reduce the prevalence of HIV, 
and each approach provides a unique mechanism.  For example, an effective oral vaccination 
regimen capable of eliciting broadly neutralizing antibodies at the oral and intestinal mucosa 
but not at the vaginal mucosa could result in sterilizing immunity from MTCT in breast milk 
but provide little benefit following vaginal exposure.  Alternatively, a vaccine that induces 
the development of robust cytotoxic lymphocyte populations could work to reduce viremia in 
an HIV-infected individual sufficiently to prevent subsequent transmission events but could 
unlikely prevent the initial transmission event.  It is important to apply our understanding of 
the mechanisms of HIV pathogenesis and transmission to vaccine design in a rational way 
such that even without sterilizing immunity, the appropriate responses are elicited at the 
site(s) of exposure to stifle replication and limit transmission. 
HIV has a complex array of phenotypes that make vaccine design particularly 
challenging.  HIV has a RNA genome and a high rate of mutation leading to patterns of rapid 
viral escape following immune pressure; high mutation rates have produced multiple strains 
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and numerous viral clades, further expanding the variant repertoire for the immune cells to 
recognize.  Rapid viral evolution can also lead to drug resistance (216, 226, 238, 250, 260).  
The HIV Envelope protein is comprised of variable loops, dense glycosylation patterns, 
inaccessible conserved regions and a trimeric configuration, which makes viral neutralization 
difficult (16, 115, 158, 169, 186, 357, 358).  HIV preferentially targets the CD4+ T helper 
cells and long-lived memory T cells, providing opportunities for infection latency, genome 
integration and the establishment of a viral reservoir (18, 134, 240). HIV-infected adults who 
maintain higher levels of CD4+ T cells experience reduced viremia.  While data are scarce for 
children, long-term non-progressor (LTNP) children similarly have higher HIV-specific 
CD4+ T cell responses than children with poorer prognoses (44). Host genetic factors such as 
HLA and TRIM5α genotypes have been identified to affect virus transmission or control, 
with specific HLA types having either positive or negative associations with infection rates 
(232, 291, 315, 316).  Despite what we have learned, there is still much unknown about the 
correlates of immune protection against HIV, which offers an additional challenge for 
effective HIV vaccine design. 
HIV vaccine candidates have consisted of an impressive variety of platforms, 
antigens and regimens including recombinant proteins, inactivated viruses, live attenuated 
recombinant viral vectors and even antigen-pulsed autologous dendritic cells.  Although 
much time and effort has been dedicated to its pursuit, the HIV vaccine human phase II/III 
clinical trials list is short.  Just three vaccine candidates have progressed through the clinical 
trials process to reach large-scale testing in human subjects.  First in 1998, the VaxGen 
Corporation initiated trials in the U.S. and Thailand using an HIV Envelope (Env) gp120 
subunit platform mixed with alum adjuvant; vaccinated subjects produced limited 
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neutralizing antibodies and vaccination had no protective efficacy (55).  A monovalent Env 
subunit vaccine was unlikely to be effective for a number of reasons.  Subunit vaccines offer 
limited immunogenic breadth because they contain only a portion of one viral variant.  Viral 
quasi-species diversity- estimated at up to 1 billion distinct HIV variants produced each day- 
defines the need for a highly diverse repertoire of neutralizing antibodies- a nearly 
impossible task (38, 186).  HIV envelope contains multiple epitopes with particularly high 
variability, termed ‘variable loops’.  The variability and flexibility of these loops account for 
the restricted development of robust neutralizing antibodies that can require years of HIV 
infection to develop.  Substantial efforts have focused on mapping and mechanisms of 
eliciting Env-specific broadly neutralizing antibodies (bNAbs) to simultaneously target 
multiple variants of the Env protein (115, 158, 169, 358).  However, despite studying bans 
isolated from LTNPs, it is difficult to assess just how these antibodies are generated in the 
context of a rapidly evolving pathogen and as a result, it remains unclear exactly how to elicit 
potent and broadly neutralizing antibodies using vaccination.  
The second clinical trial, the STEP or Merck trial, began in 2005 (37, 50, 78, 85, 146, 
167, 187, 212).  STEP subjects were vaccinated with an immunogenic adenovirus 5 (Ad5) 
recombinant vector expressing HIV-1 Gag, Pol and Nef.  Adenoviruses work well to induce 
the production of vaccine-specific T cell responses, which was observed in male (MSM) 
subjects participating in this trial.  Despite robust T cell responses, no protection, delayed 
transmission or viremia control after HIV acquisition were noted in vaccinees.  Further, 
additional analyses revealed a number of positive associations, such as the ability to produce 
HIV Gag- and Nef-specific CD8+ T cells and the subject’s HLA genoytype, along with 
negative associations like preexisting Ad5 immunity and lack of circumcision with delayed 
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transmission or reduced viremia.  The STEP trial was terminated prematurely at 18 months 
because vaccinees experienced no protective efficacy but instead Ad5 seropositive, 
uncircumcised men exhibited enhanced transmission.  Despite other adenoviral vectors 
without robust seroprevalence concerns that could be used instead of Ad5 (259, 267), the 
failure of this trial significantly halted adenovirus-based approaches in HIV vaccine design. 
The RV144 trial, or Thai trial, began in 2003 and used a combination vaccine 
approach of the attenuated canarypox ALVAC prime (HIV Env, Gag and Pol)/HIV Env 
protein boost regimen in serodiscordant couples (8, 28, 70, 110, 124, 157, 188, 193, 223, 251, 
278, 333, 398).  This combination of immunogens offered 31% protection compared to 
mock-vaccinated couples, and represents the best HIV vaccine result from human trials to 
date.  While 31% protection is relatively low, the trial offered conceptual proof that HIV 
infection is preventable following vaccination.  An additional finding from the Thai trial was 
a positive correlation between protection and HIV Env-specific IgG antibodies in plasma, 
although these antibodies were determined to be working by antibody-dependent cell-
mediated cytotoxicity (ADCC) and not neutralization (110, 193).  Alternatively, there was an 
inverse relationship with plasma IgA anti-Env antibodies to protection, where high 
concentrations of plasma IgA had an interference effect on IgG binding function (333).  
Future studies should include the measurement of mucosally secreted pathogen-specific IgA 
because this antibody, working at the site of viral exposure, is more likely to affect 
transmission events.   
One feature of HIV that has led to incredible challenges for eradication is its ability to 
integrate into host DNA.  While integration events may not always occur (65, 336), 
integrated HIV plus HIV infection of latent memory cells are responsible for establishing the 
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viral reservoir (65).  The reservoir is capable of providing new infectious particles in the 
absence of HAART or reactivation events, leading to patient life-long dependency on ART 
drug cocktails.  A vaccine that induces potent immunity prior to reservoir establishment has 
the potential to prevent the development of these ‘sleeper’ cells could make great strides 
towards HIV eradication.  
Despite failure in clinical trials, we have learned much about what components are 
essential for an effective HIV vaccine (38).  We understand that the antibodies, in particular 
broadly neutralizing antibodies at the mucosal surface of exposure, play an integral role in 
preventing initial transmission events and limiting dissemination (125, 130, 210, 224, 258).  
Conversely, the CTL response likely is more important early after transmission to eliminate 
infected cells, control viral replication and reduce genomic integration events (194, 305).  For 
example, Hansen et al. have recently observed effector cell-mediated 50% protection against 
SIV challenge in macaques vaccinated with persistent rhesus cytomegalovirus vectors 
expressing SIV proteins (RhCMV-SIV), followed remarkably by seemingly complete viral 
clearance after documented systemic SIV infection (117, 118).  And, although RhCMV-SIV 
vaccination only prevented SIV infection by 50%, viral clearance was reported even in the 
absence of vaccine-induced antibody responses. So, while we understand that immune 
correlates like neutralizing antibodies and CTLs are important, a successful vaccine may not 
have to elicit both before the vaccine can be considered effective. 
SPECIFIC CHALLENGES FOR PEDIATRIC HIV VACCINES 
Some infants will acquire HIV in utero or peripartum and, for these infants, 
vaccination at birth would not be protective.  However, the primary objective of this 
discussion aims to detail the specific challenges of a vaccine designed to protect against oral 
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MTCT in breast milk.  A protective neonatal vaccine against a pathogen with immediate and 
repeated exposures, such as HIV in breast milk, must exhibit all features important in an 
adult vaccine with the additional requirements of i) safety in healthy and immunosuppressed 
neonates, ii) an accelerated regimen starting at birth capable of rapidly inducing immune 
development and iii) potent immunogenicity in the context of the developing infant immune 
system.   
Safety is an integral component of any vaccine, but safety is of utmost importance in 
vaccine candidates with potential applications in immunosuppressed neonates.  Some infants 
born to HIV-infected mothers will be infected with HIV in utero and some will be infected 
peripartum, inducing a state of immunosuppression.  Despite efforts to improve neonatal HIV 
testing, only 28% of infants born to HIV-infected mothers are tested by 6 weeks of age (377).  
Further, more than one infant sample may be required to correctly confirm HIV status, 
inducing inherent delays in diagnoses for infants that do get tested (378). Therefore, 
vaccination regimens that begin at birth could include both HIV-naïve and HIV-infected 
groups, requiring any vaccine candidate to have an outstanding safety profile in healthy and 
immunosuppressed infants.  Although worldwide we have a broad array of effective pediatric 
vaccines against numerous infectious diseases, some vaccines, e.g. BCG, while safe in 
healthy infants can be pathogenic in infants immunosuppressed by HIV infection (40, 69, 77, 
288). 
Abstinence from breastfeeding effectively negates the risk of oral MTCT by 
breastfeeding but many HIV-infected mothers breastfeed by choice or necessity.  Low-level 
but frequent exposure to virus in breast milk results in low risk of transmission at any one 
exposure, but cases of nonexclusive breast milk diets, preexisting maternal and/or infant 
	   13 
morbidities, viral concentration in breast milk and damage to the infant oral mucosal surfaces 
can increase the transmission rate per exposure (61, 64, 75, 147, 172, 175, 176, 344, 382, 
388).  A breastfed infant born to an HIV-infected mother will be exposed to virus within 
hours after birth, and therefore, any vaccine regimen aimed at reducing oral HIV 
transmission events must be administered soon after birth and work quickly.   
With the exception of BCG, currently licensed vaccines for neonates rely on 
antibody-mediated mechanisms of pathogen clearance.  Antibody-mediated protection 
developed in response to vaccination is highly effective in infants against certain pathogens 
like Hepatitis B, tetanus and pertussis, although protection against these pathogens requires 
multiple vaccinations and is mediated by serum IgG antibodies only (Table 1.2) (312).  There 
is evidence of cross-placental and breast milk transfer of maternal antibodies that could also 
provide protective effects to neonates prior to the development of vaccine-induced immunity, 
although the beneficial effects of oral IgG exposure is debated (49, 63, 138, 189, 236, 362).  
Early passive maternal antibody transfer is particularly important since infants are unable to 
produce antibodies for several weeks after birth.  In addition, there is evidence that even 
more time is required for neonates to develop pathogen-specific effective antibodies since 
their early humoral responses are highly restricted in VDJ arrangement breadth (84, 105, 227, 
264, 277, 322, 392).  The frequencies of B cells in PBMC are also slow to establish, 
constituting less than 5-10% of the total PBMC population at birth and requiring many 
months to stabilize at the 10-20% frequencies observed in adults (139, 225).   
In addition to delayed development of the antibody repertoire, infants also encounter 
difficulties clearing pathogens that require cell-mediated immune responses.  To protect the 
infant against hyperimmune activation following the transition from a sterile environment to 
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one teeming with pathogens, several age-dependent mechanisms evolved to delay the 
development of robust cellular immunity; these mechanisms account for the immaturity of 
the infant immune system.  In particular, infants exhibit immune limitations within several 
key components necessary for the development of the Th1 lineage that drives pathogen-
specific cellular immunity (Figure 1.3) (198, 342).   
There are multiple characterized mechanisms of infant immune restrictions, including 
i) epigenetic age-associated differences like the reduced capacity of infants to produce the 
proinflammatory cytokine interferon gamma (IFN-γ) due to promoter hypermethylation (367, 
368), ii) less efficient antigen processing/presentation capacity of infant antigen presenting 
cells (APCs) (53), iii) reduced expression of MHC class II and costimulatory molecules by 
APCs (203, 261), iv) reduced ability of APCs to produce the heterodimeric IL-12 cytokine 
important for driving the T helper 1 (Th1) response (108, 109, 173, 229), and v) a decreased 
ability to respond to Toll-like receptor ligation compared to older individuals (204, 205).  All 
of these mechanisms specifically dampen the quality of the CD4+ T cell response, and 
subsequent immune development requiring T cell help. 
In addition, the impaired infant immune response is dampened by greater frequencies 
of regulatory T cells (Treg; CD4+CD25+FoxP3+) present in both blood and tissues (122).  
Tregs, important for shutting off the immune response following pathogen clearance, play a 
major role in restricting the activation of APCs and the development and activation of 
antigen-specific T cell responses by producing suppressive mediators IL-10 and TGF-β.  
Tregs also interfere with the induction and function of virus-specific CD4+ T cells in infants 
leading to reduced CD8+ CTLs and neutralizing antibody development (19, 122).  Infants, 
however, also have significantly fewer CD8+ T cells and, therefore, less CD8+ effector T 
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cells, at birth compared to adults (139).  In addition, the cytolytic ability of CTLs to 
degranulate upon stimulation develops gradually in infants (22, 271).  The reduced frequency 
and function of infant CTLs contribute to their inability to substantially reduce viral 
replication following peak viremia (154). 
As a result, infants are characterized as having instead a T helper 2 (Th2)-driven 
immune response, which typifies the development of humoral responses and anti-parasitic 
immunity (198, 342).  The Th2 immune skew importantly illustrates again that the infant 
immune response performs in a muted or altered way compared to responses generated by 
adults.  One way to illustrate this phenomenon is to quantify the response of infant and adult 
cells to a non-specific immune activator and measure the ensuing immune response (Figure 
1.4).  Of note, the ability of infant PBMC to produce IL-2 following stimulation mirrors or 
exceeds the magnitude of this response in adult PBMC, but induction of other cytokines, 
particularly IFN-γ, is robustly muted in the infant samples.  The polyfunctional T cell 
response (T cells producing  ≥ two cytokines) is robustly effective at combating pathogens 
and individuals producing greater frequencies of pathogen-specific polyfunctional cells 
typically experience better prognoses.  However, there is an age-associated delay also in the 
production of dual and triple polyfunctional T cells in infants, which are clearly ablated 
compared to adults (Figure 1.4).   
The culmination of multiple inefficient immune processes in the infant results in a 
less robust response to foreign pathogen invasion compared to adults and further validates 
the need for protective vaccinations to complement known immune immaturities (265).  In 
the context of infection, the mechanisms of how HIV eventually monopolizes host immunity 
are far beyond the scope of this work, but it is important to note that infants exhibit altered 
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immune responses compared to adolescents and adults.  Although the correlates of protection 
and controlled infection are not fully understood, the ongoing immune development of the 
infant makes it particularly more susceptible to HIV infection. 
One approach to improve pediatric immune responses to vaccination is to include an 
adjuvant.  Adjuvants can help overcome known immunological delays in infants, particularly 
acting on the antigen-presenting myeloid dendritic cell (mDC) populations.  Adjuvants can 
increase antigen presenting cell (APC) activation, uptake and processing of antigen, 
migration to organized lymphoid tissues and presentation of antigen to cognate T cells, as 
well as upregulate expression of co-stimulatory and adhesion molecules important for the 
formation of the immunological synapse.  For example, CD40 ligand (CD40L) can bypass 
the requirement for T cell help prior to B cell activation and improve antibody responses, 
providing a surrogate for functional T cell help in the immature immune system of the infant 
(6, 123, 190, 311, 328).  Other adjuvants, such as known TLR agonists, GM-CSF and 
cytokines can serve as APC activators (31, 74, 144, 155, 173, 181, 182, 204, 274, 311, 394).  
While other cells can serve as APC, mDC are the most efficient, with important roles in both 
innate and adaptive immune maturation.  T cell priming by mDCs and the ensuing cytokine 
milieu determines the lineage fate of the T cell and instructs the type of immune response 
that will be produced upon presentation of cognate antigen.  The immune maturation events 
that delineate the T cell lineages in the context of immune ontogeny are not fully elucidated, 
but proper adjuvant use could work to preferentially drive the infant Th1 lineage towards 
effector and memory T cell responses. 
The gestational age at birth, infant and maternal morbidities, exposure to breast milk 
and bacterial colonization, vaccination record, exposure to environmental and pathogenic 
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agents and genetic factors all contribute to the rate of immune maturation with age.  And, 
while many phenotypic immune distinctions between infants and adults are described, what 
we lack is a mechanistic understanding of how immunity develops with age.  Ongoing 
research in our lab and others seeks to characterize age-associated immune maturation events 
using longitudinal and cross-sectional sampling approaches in human and macaque infants to 
elucidate the mechanistic changes responsible for age-specific immune phenotypes.  A 
comprehensive understanding of immune maturation will improve the efficacy of pediatric 
interventions.   
DEVELOPMENT OF A PEDIATRIC HIV-TB VACCINE 
One hallmark benefit of the live attenuated mycobacterial vaccine BCG is its ability 
to drive the development of robust and persistent cellular immunity, despite the immaturity 
of the infant immune system.  In fact, BCG itself has intrinsic adjuvant activity and can be 
administered in tandem with other infant vaccines to enhance dual immunogenicity (255, 270, 
314).  Early acceptance of BCG vaccination was slow following disastrous attempts to prove 
its safety and efficacy but despite early setbacks, BCG vaccination was adopted by the WHO 
predecessor, the League of Nations, in 1928, implementing large-scale infant vaccination 
efforts.  By 1980, global BCG vaccination hovered around 20% and has jumped to 90% 
coverage in the past 30 years, making it the most widely administered immunogen (Figure 
1.5) (126, 140, 183, 196).  The BCG vaccine remains largely unchanged since its first use in 
humans in 1921 and remains the only live attenuated vaccine licensed for use at birth (87).  
BCG vaccination dramatically reduces the incidence of miliary and meningeal TB disease in 
infants (5, 140, 325). Further, BCG can effectively induce the development of cellular 
immunity via a Th1 lineage, which is a significant accomplishment considering the immature 
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immune system of infants (159, 202, 206, 353).  The live attenuated nature of BCG ensures 
that the immune response is continually primed with antigen throughout childhood, 
eliminating the need for boosts.   
There is much we have learned after nearly a century of BCG use.  Perhaps most 
notably, BCG vaccination has a variable 0-80% efficacy rate.  Studies conducted in the U.K., 
India and South Africa report substantial variation in the protective efficacy of BCG 
vaccination, although uncontrollable variables like BCG strain genetics (e.g. virulence 
factors and biochemical properties (218)), population genetics and environmental 
mycobacteria make vaccine efficacy results difficult to interpret (1, 319, 335).  In addition, 
BCG protection wanes significantly by adolescence and offers little to no protection against 
the pulmonary disease phenotype that most commonly afflicts older individuals (276). 
Although elements of multiple mechanisms are likely responsible for the observed variation 
in BCG efficacy, a retrospective analysis of studies conducted across multiple sites using 
different vaccine strains in diverse population cohorts suggest the following common themes: 
i) vaccinating older children with more developed immune systems (4 months to 15 years) 
does not improve rates of protection (15, 35, 57, 59, 326), ii) boosting with BCG provides 
little benefit, iii) BCG-induced protection wanes within about 15 years and iv) adult BCG 
vaccination does not protect against pulmonary TB infections.   
The specific attenuations that render BCG less pathogenic include deletions in 
regions of known immunodominance, like the RD1 locus harboring the ESAT-6 and CFP-10 
genes, the loss of which occurred during the initial attenuation of virulent M. bovis.  In fact, 
when the ESAT-6 gene was reintroduced into a BCG backbone, the altered vaccine was more 
immunogenic (206).  Other important deletions in BCG include mutations/deletions in 
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known Mtb virulence factors ESX-1, PDIM/PGL and PhoP (1, 100, 142, 192).  
Polymorphisms present in a subset of BCG strains have also been implicated as virulence 
factors but are not conserved across standard vaccine strains.  The loss of virulence factors 
was important for BCG safety but came at the cost of immunodominant factors. 
In the context of the HIV epidemic, the live attenuated nature of the BCG vaccine 
relies on a minimum level of infant immune capacity to maintain low levels of replication 
and restrict bacterial dissemination.  HIV-infected infants, however, experience variable 
levels of virus-induced immunosuppression compounded by age-specific immune immaturity 
and BCG vaccination in immunosuppressed infants can result in BCG-osis, a disease 
resulting from failure of the immune system to adequately regulate the bacterial replication 
(40, 69, 77, 126, 201, 288).  BCG-osis results in lymphadenopathy and TB-like symptoms 
including granuloma formation in the axillary lymph nodes that drain the dermal inoculation 
site (126, 364).  To limit BCG-osis, the WHO advises against BCG vaccination for infants 
infected with HIV or at high risk of becoming HIV-infected (379) but the high prevalence of 
TB has prompted some countries to vaccinate all infants with BCG (e.g. South Africa) with 
the intent to treat BCG-osis if it presents rationalizing that accurate neonatal HIV testing 
typically requires several weeks and the risk of TB infection far outweighs that of BCG 
complications (126, 241, 400).  In light of the safety and immunological concerns 
surrounding use of the BCG vaccine, we proposed vaccinating with attenuated 
Mycobacterium tuberculosis strains instead of M. bovis, hypothesizing that a human-adapted 
attenuated Mycobacterium tuberculosis backbone may provide enhanced protection and 
greater immune persistence and improved safety compared to BCG. 
To engineer a safe vaccine strain, genes important for bacterial replication and host 
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immune evasion were deleted in H37Rv M. tuberculosis.  Specifically, the panCD and leuCD 
loci, which encode for pantothenate and leucine, respectively, were deleted to generate 
auxotroph strains (45, 184).  Pantothenate and leucine are essential nutrients for 
mycobacterial growth and their deletion severely ablates bacterial replication in 
unsupplemented cultures.  Deletion of the lysA gene also reduces replication (132, 256).  
Further, the SecA2 gene locus was removed to limit host immune cell evasion and nuoG was 
deleted to enhance immunogenicity (33, 179, 330, 355).  However, in contrast to BCG, the 
RD1 operon was maintained in two of three strains evaluated here because of its 
immunodominant properties.  Table 2.1 lists the attenuations that have been tested in 
neonatal macaques as potential vaccine candidates. 
BCG was first administered orally but was transitioned to the intradermal route 
following reports of cervical lymphadenopathy (196, 365).  Intradermal vaccination, done 
using a scarification needle or syringe at birth on the upper arm, delivers live attenuated 
bacteria to dermal-resident Langerhans cells.  However, Mtb can selectively bind mucosal M 
cells, a primary cell type at the tonsil mucosa that passes antigen basally to dendritic cells (32, 
235).  Therefore, attenuated Mtb with an improved safety profile and reduced replication 
compared to BCG could be administered effectively by the oral route without risk of adverse 
pathology while inducing the potent Th1 response important for neonatal cellular immune 
development (90, 239, 243, 353). 
With the overlap of the HIV and TB epidemics and the emergence Mtb antibiotic 
resistance, efforts have resurged to improve the current BCG vaccine (21, 36, 135, 141, 200, 
244, 283, 317).  One formulation, the lysine auxotroph BCG.HIVA (HIVA consists of the 
HIV Gag consensus sequence and HIV-specific CD8+ T cell epitope peptides) followed by 
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MVA.HIVA boosting, is currently undergoing phase IIb clinical trials in African children (7, 
116, 137, 281, 282, 298, 299).  However, even auxotroph BCG strains may present some 
safety risk to immunosuppressed neonates.  Instead, we have applied lessons learned from 
BCG vaccination to hypothesize that a molecularly attenuated Mtb strain recombinantly 
expressing HIV genes and administered orally could safely result in persistent immunity 
against both HIV and Mtb.  We predict that this approach provides greater advantages 
compared to BCG because: 
i) specific bacterial loci important for replication, virulence and immune evasion in 
Mtb were eliminated to produce a safer vaccine candidate while maintaining the 
RD1 immunodominant domain 
ii) the live attenuated human-adapted Mtb pathogen will retain the ability to 
potently induce cellular immune activation but offer greater immunogenicity 
against Mtb 
iii) oral vaccination will specifically target the M cell-rich palatine tonsil and oral 
lymphoid tissues, shown to readily take up vaccines (174, 235) and induce a 
robust immunological response at the oral mucosa to protect against oral MTCT 
of HIV in breast milk 
iv) using bacterial strains expressing a variety of HIV antigens will induce both 
broad and persistent cellular and humoral responses 
v) vaccinees may maintain specific cellular responses into adulthood with conferred 
protection against pulmonary TB. 
Although direct comparisons to BCG were not within the scope of these studies, in the 
chapters to follow the predicted advantages of attenuated Mtb strain vaccine candidates are 
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explored using an infant macaque model. 
NONHUMAN PRIMATE MODEL OF PEDIATRIC SIV 
Because we aimed to evaluate specific immune development in response to 
vaccination in neonates, it was important that we identified an animal model able to best 
recapitulate the HIV disease that occurs in human infants.  The development of HIV vaccine 
candidates has relied heavily on preclinical research in the rhesus macaque model of SIV 
infection, particularly because macaques are susceptible to simian immunodeficiency virus 
(SIV), which behaves in macaques analogously to HIV-1 infection in humans (166, 221, 346, 
396).  In addition, macaques are also highly susceptible to the same Mycobacterium 
tuberculosis strains as humans, experience similar disease pathology and are a widely 
validated animal model for TB research (89, 160).  Dual immunogenicity studies could best 
be completed in the nonhuman primate model. 
Humanized mice have become an important small animal model for HIV research 
(71), but the oral anatomy of the mouse lacks potential HIV target tissues in humans (e.g. 
tonsils), solely relying instead on a patch of nasal associated lymphoid tissue (NALT) for 
oral antigen sampling, inaccurately modeling oral vaccination and MTCT in humans.  We 
postulated that using a nonhuman primate infant model was superior to the humanized mouse 
because infant macaques are highly immunologically, developmentally and anatomically 
similar to human infants.  Suckling macaque infants closely mimics human infant nursing, 
and the macaque oral cavity contains human-like organized lymphoid tissues (including 
palatine tonsil, submandibular and retropharyngeal lymph nodes) that could be important for 
oral transmission events following HIV exposure in breast milk.  Oral exposure of SIV in 
infant rhesus macaques mimics viral acquisition via breast milk in humans (9) and the model 
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has been developed to study oral infection and pathogenesis of HIV (27, 207, 209, 350).  
Orally infected infant macaques rapidly progress to simian AIDS (SAIDS) following viral 
dissemination within one week (4, 219) and experience a dramatic and irreversible loss of 
intestinal CD4+ T cells (360), accurately mimicking disease progression in human infants.   
Despite many benefits, there are some limitations of the macaque model.  Macaques 
are exclusively outbred population, which is more representative of human populations but 
can provide substantial individual variation.  In addition, studies requiring the use of neonatal 
macaque studies are restricted to a single breeding season without the benefit of staggered 
experiments.  Like human infants, neonatal macaques are small, provide limited blood 
sample volumes and can only be sampled sparingly from the periphery without cull 
experiments.  Due to the high expense to purchase and house infant macaques, group sizes 
are highly restricted, which can limit power and statistical calculations.  Despite the 
limitations of our chosen model, we propose that neonatal macaques provided the best 
available animal model in which to evaluate the safety (Chapter 2), immunogenicity (Chapter 
3) and protective capacity (Chapter 4) of pediatric HIV-TB vaccine candidates.  
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TABLES 
 
 
 
Table 1.1  Pediatric HIV infection and access to ART.  A. The prevalence of HIV 
infection in children aged 0-14 years, estimated to total 3.3 million, and the burden value 
indicates the percentage of the pediatric epidemic in each region (2011).  B.  Frequencies of 
HIV-infected children accessing ART in resource-limited countries with the percentage of 
ART coverage reported in the right column (2012).  Data in A and B are adapted from (376, 
384); North America and Australia were omitted for simplicity.   
 
 
Table 1.2  Childhood vaccine schedules.  Recommended immunization schedules for 
infants from birth to one year.  The vaccination schedule issued from the World Health 
Organization, Geneva, Switzerland (left; adapted from (372)) and Centers for Disease 
Control, Atlanta, GA, U.S. (right; adapted from (41)) were designed for global or domestic 
populations, respectively.  BCG vaccination for infants born in non-western countries is the 
primary difference between the advised pediatric immunization schedules.  a BCG 
vaccination is advised for all infants unless contraindicated due to HIV infection.  The WHO 
vaccination schedule advises immunizations in addition to those listed here for infants less 
than 12 months of age on a region- and population risk-specific basis, but were omitted here 
for simplicity.  The WHO guidelines were last updated August 1, 2013 and those from the 
CDC on March 20, 2013. 
Region Infected,Children Burden,(%) On,ART ART,Coverage,(%)
Sub$Saharan)Africa 3100000 92.31 544,000 17.55
South/East)Asia 166000 4.94 12,000 7.23
Latin)America 60000 1.79 19,100 31.83
North)Africa/Middle)East 15000 0.45 1,100 7.33
Europe/Central)Asia 12600 0.38 8,500 67.46
Totals ~3.3,million 100 584,700 17.72
A.,,Number,of,children,living,with,HIV,
(2011)
B.,,Pediatric,access,to,ART,in,resourceN
limited,countries,(2012)
Antigen Etiological,Target Age,at,First,Dose
No.,of,Doses,in,
Primary,Series Antigen Etiological,Target Age,at,First,Dose
No.,of,Doses,in,
Primary,Series
BCGa M.#tuberculosis birth 1
HepB Hepatitis/B birth 314 HepB Hepatitis/B birth 3
RV Rotavirus ≥/6/weeks 3 RV Rotavirus 2/months 3
DTP
Diptheria///////////
Tetnus//////////////
Pertussis
≥/6/weeks 3 DTaP
Diptheria//////////////
Tetnus////////////////
Pertussis
2/months 4
Hib H.#influenzae ≥/6/weeks 3 Hib H.#influenzae 2/months 4
Pneumococcal/
conjugate
Pneumococcal ≥/6/weeks 3 PCV Pneumococcal 2/months 4
OPV/or/IPV Polio 112/months 3 IPV Polio 2/months 3
Influenza Influenza 6/months annually Influenza Influenza 6/months annually
HepA Hepatitis/A 12/months 2 HepA Hepatitis/A 12/months 2
Measles Measles 6112/months 2
Mumps Mumps ≥/6/months 2
Rubella Rubella 9112/months 1
Varicella V/zoster 12/months 2
Global,Routine,Childhood,Immunization,Schedule U.S.,Routine,Childhood,Immunization,Schedule
MMR
Measles////////////////
Mumps///////////////
Rubella
12/months 2
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FIGURES 
 
Figure 1.1  Schematic age-associated 
differences in HIV plasma viremia.  
HIV/SIV infection in the young is often less 
controlled due to immature immune 
function, resulting in little-to-no decrease in 
plasma viremia at the viral set point 
compared to recently infected adults.  RM= 
rhesus macaques. 
 
 
 
 
Figure 1.2  Global perspective of HIV prevalence in new TB cases (2012).  Geographic 
representation of the global prevalence of HIV infection in patients reporting new TB 
infections.  While co-infections are reported globally, sub-Saharan Africa is burdened with 
the highest rates of co-infection.  Reproduced, with permission from the publisher, from 
(375). 
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Figure 1.3  Schematic of Th1 lineage development.  A simplified Th1 lineage development 
diagram, illustrating steps at which age-dependent limitations have been identified; red 
octagons indicate known immune immaturities in infants. 
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Figure 1.4  Age-dependent differences in T cell responses to nonspecific stimulation.  
Infant and adult peripheral blood from rhesus macaques was stimulated using a non-specific 
stimulant PMA and Ionomycin for 6 hours before evaluating the percentages of CD4+ and 
CD8+ T cells expressing TNF 
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Figure 1.5  Global BCG vaccination 
rates.  The percentage of infants 
vaccinated with BCG at birth 
experienced dramatic increases in 
coverage since the late 20th century.  
Adapted from (373). 
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CHAPTER 2:  A RECOMBINANT ATTENUATED MYCOBACTERIUM 
TUBERCULOSIS VACCINE STRAIN IS SAFE IN IMMUNOSUPPRESSED SIMIAN 
IMMUNODEFICIENCY VIRUS-INFECTED INFANT MACAQUES1 	  
OVERVIEW 
Many resource-poor countries are faced with concurrent epidemics of AIDS and 
tuberculosis (TB), caused by HIV and Mycobacterium tuberculosis (Mtb), respectively. Dual 
infections with HIV and M. tuberculosis are especially severe in infants. There is, however, 
no effective HIV vaccine and the only licensed TB vaccine, the Bacille Calmette-Guérin 
(BCG) vaccine, can cause disseminated disease in HIV-infected children. Thus, a pediatric 
vaccine to prevent HIV and TB infections is urgently needed. We hypothesized that a highly 
attenuated M. tuberculosis strain (AMtb) containing HIV antigens could be safely 
administered at birth and induce mucosal and systemic immune responses to protect against 
HIV and TB infection, and we rationalized that vaccine safety could be most rigorously 
assessed in immunocompromised hosts. Among three vaccine candidates tested, the 
recombinant AMtb strain mc26435 encoding an SIV Gag expression plasmid and harboring 
attenuations in genes critical for replication (panCD and leuCD) and immune evasion 
(secA2), was found to be safe after oral or intradermal administration in SIV-uninfected and 
SIV-infected infant macaques. Safety was defined by absence of clinical symptoms, 
histopathological changes indicative of TB infection, and lack of mycobacterial 
dissemination. These data represent an important step in the development of novel TB 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  This chapter has been reproduced/amended from Jensen et al. (152).	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vaccines and suggest that a combination rAMtb-HIV vaccine could be a safe alternative to 
BCG for the pediatric population as a whole, but importantly for the extreme at-risk group of 
HIV-infected infants. 
INTRODUCTION 
About one third of the world’s population is infected with Mycobacterium 
tuberculosis (Mtb) (374). Every year, 8-10 million new individuals become infected with M. 
tuberculosis, and almost 1.5 million people die of tuberculosis (TB) (374). The recent 
development of multi-drug and extensively multi-drug resistant strains of circulating M. 
tuberculosis further underscores the need for novel approaches to combat TB infections. The 
only licensed TB vaccine, the Bacille Calmette Guérin (BCG), is a live attenuated vaccine 
derived from the bovine Mycobacterium bovis strain. It is the oldest and most widely used 
vaccine worldwide. Although the BCG vaccine can induce potent cellular immune responses 
in infants and protect against disseminated TB in children (202, 230, 354), the duration of 
protection is questionable since immunity wanes with time in many vaccinated individuals 
and the vaccine shows only variable protection in adults (58, 275, 337). In addition, BCG 
vaccination offers little to no protection against pulmonary TB, cannot eliminate latent M. 
tuberculosis and is ineffective at preventing subsequent TB infections.  
TB is the leading cause of death in HIV-infected individuals (369, 374). Given the 
large geographical overlap between M. tuberculosis and HIV infection, BCG vaccination was 
recommended at birth for all infants because infants with HIV-induced immune suppression 
have a higher risk than adults of contracting TB (381). Recently, however, it became 
apparent that the annual risk for disseminated BCG disease in untreated HIV-infected infants 
(~0.42%) that is associated with a 75% mortality rate (127-129) clearly outweighs the 
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potential benefits of BCG vaccination in children with HIV (128). Therefore, the WHO now 
advises against BCG vaccination in any infant infected with HIV or at risk for HIV infection 
(385). As a result, the number of infants co-infected with HIV and TB in resource-poor 
countries is expected to remain the same or even rise.  
Alternative methods to control TB in infants with HIV are urgently needed. In 
response to this challenge, we aim to develop a novel infant combination HIV-TB vaccine 
based upon a safe, orally administrable attenuated M. tuberculosis strain expression HIV 
antigens. Although the rate of in utero and perinatal mother-to-child-transmission (MTCT) of 
HIV has been significantly reduced with the introduction of antiretroviral therapy (ART) to 
mother and/or child (369), breast milk transmission of HIV remains a serious problem. 
Ideally, a vaccine to prevent oral HIV acquisition by breast-feeding should be administered 
orally. BCG-based vaccines are advantageous because they can be administered at birth, are 
effective orally, and rapidly generate long-lived T cell responses against dually administered 
mycobacterial and co-expressed non-mycobacterial antigens when administered 
simultaneously in human infants (245).  
To address the safety concern associated with the current BCG vaccine, we 
hypothesized that a rationally attenuated strain of human M. tuberculosis might be a better 
vaccine platform than the bovine-adapted M. bovis BCG. We developed auxotroph mutants 
of the human M. tuberculosis strain H37Rv in which mycobacterial genes important for 
replication and persistence were deleted or modified to attenuate replication. In addition, in 
an attempt to increase immunogenicity, several genes important for the evasion of host 
immune responses were deleted. The construction of these attenuated M. tuberculosis (AMtb) 
strains, their safety and immunogenicity profile in comparison to the licensed BCG vaccine 
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in SCID mice have been reportedly previously (145, 184, 268, 293-295). Some of these TB 
vaccine candidates were also characterized in nonhuman primates as an important step 
towards potential human clinical trials. Vaccine safety, immunogenicity and efficacy data 
obtained in nonhuman primates would be expected to be highly relevant to humans (184). 
The AMtb vaccine strains mc26020 and mc26030 were safe and well tolerated in adult 
cynomolgus macaques and did not cause TB-disease, but provided only partial protection 
against an intrabronchial M. tuberculosis challenge (184). Based on these data, we developed 
novel replication-attenuated M. tuberculosis vaccine strains with increased immunogenicity.  
Due to obvious ethical concerns, pediatric HIV-TB vaccine safety assessments and 
challenge studies for efficacy cannot be performed in HIV-infected human infants. To 
account for the infant’s relatively inexperienced and still developing immune system early 
after birth, we therefore choose to test vaccine safety in infant macaques that show similar 
immune system ontogeny after birth compared to human infants. Thus, in a first step towards 
the generation of a pediatric combination HIV-TB vaccine, we constructed AMtb strains that 
express the SIV Gag gene. The safety profile of three distinct rAMtb-SIV vaccine candidates 
with different degrees of attenuation in replication and/or immunogenicity (Table 2.1) was 
initially tested in healthy, SIV-uninfected infant macaques. None of these vaccine candidates 
induced clinical symptoms of TB. The vaccine strain (mc25157) that was predominantly 
attenuated for immune evasion and less for replication caused M. tuberculosis dissemination 
to multiple tissues and was therefore excluded as a potential pediatric vaccine. The safety of 
the two other vaccine candidates, rAMtb-SIV mc26020 and mc26435, was then evaluated 
under even more stringent conditions in immunosuppressed SIV-infected infant macaques, 
analogous to HIV-infection in human infants.  
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The infant macaque model of SIV infection is a well established animal model of 
pediatric HIV infection and is suitable for the testing of safety and efficacy of intervention 
strategies for a wide range of infectious diseases (3, 9, 10, 209, 350). Vaccination of SIV-
infected infant macaques with these two rAMtb-SIV strains did not cause TB-like lung 
pathology. Importantly, in animals vaccinated with mc26435, local or systemic dissemination 
of mycobacteria did not occur, and live mycobacteria could not be recovered from any 
tissues under optimal culture conditions. The data represent an important step in the clinical 
testing of these novel live-attenuated M. tuberculosis vaccine candidates and suggest that a 
combination rAMtb-HIV vaccine could be a safe alternative to BCG for the pediatric 
population as a whole, but importantly for the extreme at-risk group of infants infected with 
HIV. 
MATERIALS AND METHODS 
Animals. 
Newborn rhesus macaques (Macaca mulatta) from the SIV negative and type D 
retrovirus-free colony were hand-reared in a nursery at the California National Primate 
Research Center (CNPRC, Davis, CA).  Animals were housed according to the “Guide for 
Care and Use of Laboratory Animals” and the standards outlined by the American 
Association for Accreditation of Laboratory Animal Care; all animal protocols were 
reviewed and approved by the UC Davis Institutional Animal Care and Use Committee prior 
to study initiation.  Animals were randomly assigned to the various study groups and were 
between 3 and 7 days of age at the first immunization (see Table 2.2). For vaccinations and 
blood collections, animals were immobilized by intramuscular injection of 10mg/kg body 
weight of ketamine-HCl (Parke-Davis, Morris Plains, NC).  Trained veterinary staff 
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monitored the animals daily for clinical symptoms associated with TB (e.g. difficulties in 
breathing, coughing, mucus secretions, lethargic behavior, weight loss) and/or SIV infection.  
 
Vaccine Strains. 
The three rAMtb vaccine strains tested in the current study were rationally attenuated 
from the wild-type M. tuberculosis strain H37Rv. M. tuberculosis H37Rv was modified 
through several deletions in genes that attenuated replication to increase vaccine safety, and 
in genes important for mycobacterial immune evasion to enhance the immunogenicity (13). 
As outlined in Table 2.1, strain mc26020 was predominantly attenuated for replication with 
deletions in the lysA and panCD loci (ΔlysA, ΔpanCD), no loci important for immune 
evasion were deleted. In contrast, strain mc25157 was designed primarily to test for enhanced 
immunogenicity (ΔnuoG, ΔRD1) and contained only the panCD locus deletion to attenuate 
replication. Strain mc26435 was developed based on the initial results obtained with strains 
mc26020 and mc25157 to harbor replication (ΔleuCD, ΔpanCD) and immune evasion 
(ΔsecA2) attenuations. The construction of the rAMtb vaccine strains has been previously 
described (184, 268, 294-296, 363, 397). In these prior studies, the introduced deletions were 
stable and reversions were not observed (184, 268, 294-296, 363, 397). Prior to use in rhesus 
macaques, the safety and immunogenicity of all three rAMtb strains was confirmed in mice 
(184, 268, 294-296, 363, 397).  The rAMtb mc25157 and mc26435 vaccine strains were 
further manipulated to incorporate a mycobacterial expression plasmid with a full length 
SIVmac239 Gag insert (268).  Expression of SIV Gag in vaccine preparations was confirmed 
by Western blot immunolabeled with a V5 antibody-HRP, as previously described (Figure 
2.1A) (268). The immunogenicity was confirmed in C57BL/6 mice (Figure 2.1B). 
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Immunization Regimens. 
An overview of the vaccination schedule including route and dose is provided in 
Table 2.2. Briefly, strain mc26020 was administered both orally (PO) and intradermally (ID) 
at one week of age, and animals were followed for 6 months (Group A). Animals vaccinated 
with mc25157 were primed orally and received a homologous ID booster vaccination at 
either 2 (Group C) or 3 weeks (Group E). Animals were then euthanized at week 4 or 6, 
respectively, to test for vaccine-induced immune responses and M. tuberculosis 
dissemination in various tissues. The time intervals were selected based on our previous 
pathogenesis and pediatric HIV/SIV vaccine studies in the oral SIV infant macaque infection 
model in which we generally challenge at 4 weeks of age to reflect early breast milk 
transmission of HIV in humans (4, 208, 347, 350). Finally, we tested two heterologous 
prime-boost regimens using either recombinant adenovirus 5 expressing SIVmac239 Gag 
(rAd5-SIVgag; Groups G and H) or recombinant modified vaccinia virus Ankara expressing 
SIVmac239 Gag, Pol and Env (rMVA-SIVgpe; Group J) that were kindly provided by the 
International AIDS Vaccine Initiative (IAVI, Brooklyn, NY), and Dr. B. Moss (NIAID, NIH, 
Bethesda, MD), respectively (208). The heterologous boosts were administered 3 weeks 
(rAd5-SIVgag), or at 3 and 6 weeks (rMVA-SIV constructs) after the initial mc26435 
vaccination. In the studies described here, the vaccine boosts are reported solely for the 
purpose of revealing all study variables; vaccine immunogenicity will be reported separately 
(manuscript in preparation). Note that all experiments were carried out using mock-infected 
(saline) age-matched infant macaques in parallel (Table 2.2, Groups D, F, I, and K). 
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SIV Infection. 
A subset of animals were infected with 103 TCID50 of SIVmac251 (stock 6/04; (208) 
by the intravenous (IV) route within 72 hours of birth, and then immunized one week later 
with mc26020 (Group B) or mc26435 (Group L) (Table 2.2). SIV-infected animals were 
euthanized when they met criteria established for retrovirus-infected animals (352). 
 
Sample Collection and Preparation. 
EDTA blood samples were collected at week 0 (baseline) and then longitudinally as 
described in Table 2.2. Plasma was collected after centrifugation and stored in multiple small 
aliquots at -800C for virological analysis and antibody testing. PBMC were isolated by 
gradient centrifugation as described (208). At the time of euthanasia, multiple tissues were 
collected, including tonsil, lymph nodes (LN: submandibular, retropharyngeal, bronchial, 
axillary, mesenteric), lung and intestinal tissues (ileum, colon). In addition, from animals that 
received an ID vaccination, we saved tissue from the dermal inoculation sites (Groups A, B, 
E, F and I). Corresponding skin tissue from orally vaccinated animals was collected as 
control tissue. Each tissue was divided and saved for multiple applications by preparing snap 
frozen (M. tuberculosis culture), formalin-fixed / paraffin-embedded (pathology, M. 
tuberculosis staining), and fresh tissue aliquots (immunogenicity). The isolation of cell 
populations from tonsil, LNs and intestinal tissues was performed as described previously 
(208). 
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CD4+ T Cell Measurement. 
A Complete Blood Count (CBC) was performed on an ABX Pentra 60+ electronic 
cell counter (ABX Diagnostics, Irvine, CA) with manual differential counts. Absolute counts 
and percentages of CD4+T cells in PBMC were determined using antibodies specific for 
rhesus macaque CD3 and CD4 using flow cytometric analysis and CBC values as described 
(4).  
 
SIV Replication. 
Plasma samples were analyzed for viral RNA by a quantitative reverse transcription-
PCR (qRT-PCR) assay as described (54).  
 
M. tuberculosis-specific Plasma Antibodies. 
The presence of IgG antibodies against the M. tuberculosis PSTS1 antigen was determined in 
longitudinally collected plasma samples using a recently described multiplex microbead 
immunoassay based on the Luminex system (Austin, TX) (162). Relative antibody levels are 
reported as mean fluorescence intensity (MFI) (162). Sera from M. tuberculosis-uninfected 
and M. tuberculosis-infected rhesus macaques were used as negative and positive controls, 
respectively.  
 
Pathology Evaluation. 
Gross pathology evaluation was performed at necropsy. Formalin-fixed, paraffin-
embedded tissues were cut into 5 micron sections and stained with hematoxylin and eosin 
(H&E) according to standard protocols. Lung sections from an adult macaque infected 
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experimentally with virulent M. tuberculosis were kindly provided by Dr. P. Luciw for 
comparison (197). In addition, Ziehl-Neelson stained sections were examined for the 
presence of acid-fast bacilli (AFB). Tissue section slides were read in their entirety by a 
nonhuman primate pathologist blinded with respect to treatment groups.  
 
M. tuberculosis Isolation. 
Snap frozen tissues, stored at -80°C, were shipped to the National Animal Disease 
Center (USDA-ARS, Ames, IA) to recover viable mycobacteria  using three different culture 
methods: (i) the Fast Indicator Tube test (MGIT), (ii) Middlebrook 7H12 media (BacTec), 
and (iii) Solid Culture media to determine colony forming units (CFU). As rAMtb 
auxotrophic mutants cannot grow in standard mycobacterial growth media culture, the media 
was supplemented with pantothenate with or without lysine (mc26020) or leucine (mc26435). 
A tissue was considered positive if one of three culture methods yielded mycobacterial 
growth. M. tuberculosis positive control samples were run in parallel for quality assurance.  
 
Statistical Analysis. 
Data were analyzed using GraphPad Prism software (GraphPad Software, Inc., La 
Jolla, CA). Antibody data at specific time points (see text) were compared between two or 
more groups after log10 transformation using a nonparametric Mann-Whitney test or One 
Way Anova analysis (Kruskal-Wallis test with Dunn’s comparisons), respectively. Area-
under-the-curve analysis of antibody levels was also performed on log10-transformed data 
using GraphPad Prism Software. P values ≤0.05 were considered significant. 
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RESULTS 
Confirmation of vaccine exposure by the oral and intradermal route 
All three vaccine strains were attenuated for replication. We, therefore, wanted to 
confirm that they were able to induce seroconversion to validate the biological significance 
of our safety assessment that includes lack of mycobacterial dissemination in an 
immunocompromised host. Plasma antibodies to the M. tuberculosis specific antigen PSTS1 
were measured after oral and intradermal vaccination with the various rAMtb vaccines. 
Independent of the vaccine strain, all SIV-uninfected vaccinated animals developed M. 
tuberculosis-specific plasma IgG antibodies to the PSTS1 antigen (Figure 2.2), but the 
magnitude was dependent on the vaccine strain and the route of administration. In fact, 
animals that received the mc26020 vaccine at the PO and ID route at 1 week of age (Group 
A) developed relative antibody levels reaching up to 104 MFI by 4 weeks (Figure 2.2A).  
Similar data were obtained in animals orally primed with mc25157, and receiving a 
homologous ID boost (Groups C and E; Figure 2.2B). Consistent with more stringent 
attenuations in replication (deletions of the leuCD and panCD loci), oral vaccination with the 
mc26435 vaccine strain (Groups G and J) PSTS1 antibodies during weeks 4-6 post 
immunization were significantly lower levels (p<0.001) compared to mc26020 and mc25157 
vaccinated infant macaques. Furthermore, the route of vaccine administration influenced the 
magnitude of antibody induction in plasma, with ID mc26435 vaccinated animals (Group H) 
developing significantly higher (p=0.0119) antibody levels than PO vaccinated animals 
(Groups G and J). Although there was a trend towards higher PSTS1 antibody levels in PO 
mc26435 vaccinated infants compared to mock-immunized animals between weeks 5-8 post 
vaccination, this difference did not reach statistical significance. PSTS1 antibody levels, 
however, were significantly higher in mc26435 vaccinated infants compared to mock-
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immunized animals by area-under-the curve-analysis of antibody levels from week 0 to week 
16 (p=0.0229). The magnitude of PSTS1 antibodies in animals infected with SIV prior to 
vaccination with rAMtb mc26020 (Group B) or mc26435 (Group L) was reduced compared to 
SIV-uninfected animals (Figures 2.2A and 2.2C), likely due to SIV-induced 
immunosuppression. 
 
Safety assessment of rAMtb-SIV vaccine strains 
The safety profile of the various rAMtb vaccine strains was evaluated based on the 
combined assessment of (i) clinical observations (e.g. breathing difficulties), (ii) 
histopathological evaluation of multiple tissues, (iii) detection of AFB in tissues, and (iv) 
recovery of viable mycobacterial bacilli from tissues. A vaccine was considered to have no or 
only a minimal safety risk if AFB could not be detected, mycobacterial bacilli could not be 
recovered from any tissues, histopathology of lung and other tissues/organs appeared 
essentially normal, and no clinical symptoms were observed. In contrast, a vaccine strain was 
considered unsafe if one or more tissues tested positive for any of the following: AFB 
positive, M. tuberculosis culture positive, or granuloma detection during histopathological 
examination.  
We assessed the safety of the rAMtb vaccine strains in a stringent two-step study. 
First, the rAMtb vaccine strains were administered to immunologically immature infant 
macaques at one week of age. Next, if no clinical signs of M. tuberculosis infection were 
observed and no viable mycobacteria could be recovered from tissues, we tested the vaccine 
in infant macaques infected with highly pathogenic SIVmac251 at one week prior to rAMtb 
vaccination to reflect HIV-induced immunosuppression in HIV-1 infected human infants.  
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(i) Clinical safety assessment  
SIV infection (Groups B and L) was confirmed by measuring plasma viral RNA 
levels. Consistent with our prior studies (4, 208, 350, 351), all six infant macaques developed 
high peak viremia (>107 copies/ ml of plasma) (Figure 2.3A) and viremia persisted at high 
levels. The loss of CD4+ T cells is a hallmark of HIV/ SIV disease progression in adults, but 
not a reliable clinical marker of virus-infected infants (4). Furthermore, as CD4+ T cells 
represent the vast majority of T cells at birth and CD8+ T cell numbers continue to increase 
after birth, a decline in the percentage of CD4+ T cells is characteristic of the normal 
developmental process after birth. In fact, a decline in CD4+ T cells was observed in all 
experimental groups and was not limited to only SIV-infected infants (4) (Figure 2.3). 
Compared to age-matched control animals (mock-vaccinated animals), SIV-uninfected 
vaccinated animals showed similar peripheral blood CD4+ T cell frequencies. In addition, the 
CBC values in SIV-uninfected rAMtb vaccinated infants remained normal throughout the 
study period (data not shown). 
A more critical factor in the evaluation of infant health is weight gain. All vaccinated 
SIV-uninfected infants showed weight gain similar to the age-matched control animals 
(Figure 2.3). In contrast, consistent with previous studies (4, 209), SIV-infected animals 
showed poor weight gain (Figure 2.3). Although wasting is also a common symptom of 
HIV/SIV-associated disease in adults (95), the lack of weight gain is much more detrimental 
in infants. Due to failure to thrive and symptoms associated with rapid progression to simian 
AIDS (e.g. reoccurring episodes of diarrhea, poor appetite and lethargic behavior), the SIV 
infected animals were euthanized between 6 and 10 weeks after SIV infection (Figure 2.3). 
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Despite this apparent immunosuppression as a result of SIV infection, these animals did not 
show clinical symptoms typically associated with M. tuberculosis infection. SIV-uninfected 
infants that received the mc26020 or mc26435 vaccines (Group A or Groups G, H, and J, 
respectively) showed normal weight gain (Figure 2.3). 
Clinically, no symptoms indicative of M. tuberculosis infection (e.g. breathing 
difficulties, coughing) were observed at any time during the study period. Similarly, no 
adverse signs of vaccination with rAMtb-SIV vaccines were observed, with the exemption of 
local reactivity in ID vaccinated animals. These animals showed a local inflammatory 
response following ID inoculations and developed indurations. In mc26020 vaccinated 
animals, indurations resolved over time. Due to the short follow-up time in mc25157 
vaccinated animals, it could not be determined whether the local inflammation would have 
resolved over time.  
 
(ii) Histopathological evaluation  
To thoroughly assess the safety of the rAMtb vaccine strains in infants, several tissues 
collected at necropsy were evaluated for TB pathology: (i) the dermal inoculation site or 
corresponding skin samples from orally rAMtb or mock vaccinated animals, (ii) axillary LNs 
that drained the dermal inoculation site, (iii) the lung as the primary site of TB-specific 
pathology, (iv) the lung-draining bronchial LNs, and (v) the spleen as a more distal lymphoid 
indicator of M. tuberculosis dissemination (Table 2.3).  
 
Consistent with clinical signs of inflammation (see above), histopathological 
examination of mc25157 vaccinated animals at 4 or 6 weeks of age (Groups C and E, 
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respectively) revealed that moderate to severe pyogranulomatous dermatitis had persisted at 
the ID inoculation sites, whereas dermal tissues from mc26020 animals appeared essentially 
normal (Table 2.3). In contrast to mc26020 and mc25157 vaccinated animals, ID vaccination 
with mc26435 (Group H) did not result in an inflammatory response at the site of inoculation 
(Table 2.3). The mild dermatitis that was observed in some of the vaccinees independent of 
the vaccine strain was occasionally noted in skin from orally or mock-vaccinated animals as 
well and thus was probably not due to vaccination (Table 2.3). Consistent with a potential 
spread of mycobacteria in mc25157 vaccinated animals (Groups C and E), the majority of the 
axillary LNs of mc25157 vaccinated animals showed moderate hyperplasia and 
pyogranulomatous inflammation, whereas SIV-uninfected animals vaccinated with mc26020 
or mc26435 showed only mild histopathological changes (Table 2.3).  
Evidence of pulmonary TB lesion or granuloma formation in the lung indicative of M. 
tuberculosis infection were markedly absent from the vaccinated animals. In fact, the lungs 
of animals vaccinated with mc26020 (not shown) and mc26435 (Figure 2.4E) were 
histologically indistinguishable from lungs of mock-vaccinated infant macaques (Figure 
2.4C). Among the 10 animals vaccinated with mc25157, six developed small granulomas in 
their lungs (Figure 2.4D). However, these lesions were smaller and less frequent when 
compared to granulomas induced by virulent M. tuberculosis infection (Figures 2.4A, 2.4B).  
In infants infected with SIV prior to rAMtb vaccination, histopathological changes 
typical for SIV infection such as lymphoid depletion and mild hyperplasia were commonly 
observed in various lymphoid tissues (Table 2.3). Although pneumonitis was detected in 
some SIV-infected rAMtb vaccinated animals, the histopathology was not typical for M. 
tuberculosis-induced lung pathology. Importantly, SIV-infected animals did not develop 
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granuloma in the lung or other tissues after vaccination with mc26020 or mc26435 (Figure 
2.4F). Thus, SIV-induced immunosuppression in infant macaques vaccinated with rAMtb 
strains did not result in TB-induced disease or pathology. 
 
(iii) Strain-dependent differences in mycobacterial dissemination  
Miliary tuberculosis is one of the most severe complications of M. tuberculosis 
infection. Although the rAMtb vaccine strains tested in the current study were replication 
attenuated, the degree of attenuation in replication and immune evasion differed between the 
strains (Table 2.1). Therefore, we tested the same tissues that were examined for TB-
associated pathology for the presence of mycobacteria. First, tissue sections were stained 
with Ziehl-Neelson dye to detect AFB. However, even in pathogenic M. tuberculosis 
infection mycobacteria detection by AFB staining can be infrequent. Therefore, different 
culture methods using optimized growth medium specially supplemented for the auxotrophic 
strains were used to determine whether live mycobacteria could be recovered from any of the 
tissues. AFB were only rarely (1-2 bacilli per tissue), if at all, detected at dermal inoculation 
sites after mc26020 or mc26435 vaccination. Importantly, AFB were detected in tissue from 
only 1 of 3 SIV-infected infant macaques that received the mc26020 vaccine, and only at one 
site, the axillary LN that drained the ID inoculation site. AFB were not detected by Ziehl-
Neelson staining in any other tissues in this animal. Live mycobacteria could be recovered 
from the same axillary LN of this animal, but not from any other tissue samples.  
 
In contrast, all infant macaques vaccinated with mc25157, the rAMtb vaccine strain 
that contained deletions that may increase its immunogenicity and yet result in higher 
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replication relative to mc26020, tested positive for AFB in their dermal tissues, and in 6 of 10 
animals AFB were also detected in at least one other tissue (Table 2.4). Furthermore, live 
mycobacteria could be recovered from several tissues of these animals (Table 2.4). Due to 
the widespread mycobacterial dissemination and more severe immunopathology in mc25157 
vaccinated infant macaques, strain mc25157 was considered unsafe and not further pursued 
as a candidate M. tuberculosis-SIV vaccine. Remarkably, all tissues from SIV-uninfected 
(n=20) and also from SIV-infected (n=3) mc26435 vaccinated animals were negative for 
AFB and viable mycobacteria could not be recovered by any of the culture methods applied 
in any of these tissues. 
In summary, the data indicate that rAMtb-SIV vaccine strains can be administered 
orally or intradermally during the first week of age to infant macaques.  Although vaccine 
strain mc25157 caused dissemination of mycobacteria, the live attenuated vaccine strains 
mc26020 and mc26435 demonstrated a better safety profile in infant macaques. In particular, 
strain mc26435 was safe in SIV-uninfected (Groups I and K) and in immunocompromised 
SIV-infected infant macaques (Groups G, H, and J) by all safety criteria applied in this study.  
DISCUSSION 
An effective vaccine against HIV is not available, and the only approved TB vaccine, 
BCG, is not safe in immunosuppressed individuals. This safety concern is of particular 
importance in resource-poor countries affected by the dual epidemics of TB and HIV. In 
particular, TB infection rates among children have risen in association with HIV prevalence 
and about 1% HIV-infected infants develop disseminated BCG after vaccination. Although 
ART coverage now extends to 42% of HIV-infected mothers, only about 23% of their 
newborn infants receive ART (369, 381) and remain at risk for HIV acquisition by breast-
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feeding. These facts underscore the need for a novel safe vaccine to prevent pediatric HIV 
and TB infections. The current study represents an important first step towards the 
development of an orally administered highly attenuated M. tuberculosis vaccine expressing 
HIV antigens as a potential pediatric combination HIV-TB vaccine.  
BCG was originally administered orally, but this route was discontinued due to 
cervical lymphadenitis and parapharyngeal complications. The oral route may be more 
advantageous for a pediatric HIV-TB vaccine because a mucosally administered vaccine 
could also induce local immune responses protective against orally transmitted HIV by 
breast-feeding. In fact, experiments in mice have shown that orally fed BCG can infect the 
submaxillary peri-glandular lymph nodes and Peyer’s patches (180), and that M. tuberculosis 
can bind to tonsillar M cells (32, 235). Thus, we assessed the safety of three distinct 
recombinant attenuated M. tuberculosis H37Rv strains engineered with or without the SIV 
Gag gene in SIV-uninfected and in SIV-infected, and thus immunosuppressed, infant 
macaques both by the oral and intradermal route. BCG vaccination of SIV-infected macaques 
has previously been shown to exacerbate SIV disease progression and to cause dissemination 
of M. bovis bacilli (66, 308, 395). In accordance with a recent proposal to improve the 
classification of TB disease severity in human children by combining multiple factors 
ranging from disease pathogenesis criteria to bacteriological evaluation and clinical data 
(387), vaccine safety in infant macaques was rigorously assessed in the current study by 
comprehensive clinical examination, histopathological evaluations, and multiple M. 
tuberculosis culture methods.  
For safety evaluation, animals were grouped by vaccine strain independent of the 
route of administration, immunization interval, or prime-boost regimen. The panCD deletion 
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in strain mc25157 was not sufficient to prevent mycobacterial dissemination in infant 
macaques, and although granuloma size and frequencies in the lung were limited in 
comparison to macaques infected with pathogenic TB (197), the strain was deemed 
unsuitable for use in immunocompromised hosts. In contrast to mc25157, the safety profile of 
the dual deletion strain mc26020 (ΔpanCDΔlysA) was improved. Only one of three SIV-
infected infant rhesus macaques showed evidence of M. tuberculosis dissemination, and only 
in the axillary lymph node that drained the ID inoculation site. Whether or not this limited 
mycobacterial dissemination in immunosuppressed SIV-infected infant macaques correlates 
with reduced risk for future dissemination or reactivation at other sites, however, remains to 
be determined. Although we previously confirmed the safety of this strain, these studies were 
performed only in SIV-uninfected adult cynomolgus macaques (184). Thus, the current data 
support our hypothesis that auxotroph mutant M. tuberculosis strains can be developed as 
safe vaccine candidates for use in immunocompromised individuals.  
M. tuberculosis is a slowly replicating bacterium and encodes genes that limit the host 
immune response, permitting bacilli to persist within a host, often in a latent state (103, 191). 
To be safe and effective, a live attenuated M. tuberculosis vaccine requires a balance between 
replication and immunogenicity. In infants with immature immunity, low-level replication 
may be required to induce Mtb-specific immune responses and promote persistent immune 
memory responses. However, if replication is too robust, attenuated M. tuberculosis strains 
may result in granuloma formation and bacillary dissemination as was observed with 
mc25157. In addition to attenuating replication, deletions in mycobacterial genes encoding 
immune interference may be necessary to enhance AMtb immunogenicity. 
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Based on the results with mc25157 and mc26020, the strain mc26435 was designed 
with deletion in both the panCD and the leuCD loci (ΔpanCDΔleuCD). An additional 
deletion was introduced in the secA2 locus that interferes with apoptosis in M. tuberculosis-
infected macrophages (13, 133). The deletion of this locus has been associated with both 
enhanced apoptosis of mycobacteria-infected macrophages in vitro, and with increased 
antigen-specific CD8+T cell responses in vivo, likely due to enhanced cross-presentation of 
mycobacterial antigens to dendritic cells (13, 133). A similar AMtb strain (ΔlysAΔsecA2) has 
previously been demonstrated to be safe and immunogenic in neonatal SCID mice (100% 
survival for up to 642 days) in which BCG is generally lethal (268). In fact, our results here 
show that the rAMtb strain mc26435 was well tolerated and did not cause any TB-like disease 
symptoms in 20 of 20 infant macaques vaccinated within one week of age. Importantly, the 
safety of this strain was confirmed in infant macaques infected with highly pathogenic SIV 
prior to mc26435 vaccination. The tissue pathology of these SIV-infected infant macaques 
was consistent only with SIV-induced pathology, yet no signs of TB pathology were detected. 
Furthermore, there was no histopathological evidence of rAMtb dissemination and live 
mycobacteria could not be recovered from any tissues studied, even under optimal 
supplemented culture conditions for the attenuated M. tuberculosis strain.  
No other TB vaccine candidate has been tested under such stringent conditions in 
infant macaques, a model for infant TB vaccination. Analogous to our study, the safety of a 
ΔleuCDΔpanCD auxotroph M. tuberculosis vaccine strain was recently evaluated in SIV-
uninfected and SIV-infected adult macaques (297). Vaccination of adult macaques with this 
attenuated M. tuberculosis strain did not cause adverse effects, AFB were not detectable, and 
viable mycobacterial bacilli could not be recovered from longitudinally collected blood 
	   49 
samples or tissues at the time of euthanasia (297). The adult SIV-infected animals were 
followed for up to 1 year, further supporting the conclusion that auxotroph attenuated M. 
tuberculosis strains do not confer a safety risk in immunosuppressed individuals. The safety 
profile of the rAMtb strain mc26435 in SIV-infected infant macaques is consistent with this 
conclusion.  
A potential caveat of our study is the relatively short follow-up time in SIV-infected 
infants. In HIV-infected children and SIV-infected neonatal macaques, disease is often more 
severe and progression is accelerated. In the current study, SIV-infected infants were 
euthanized between 6 and 10 weeks after SIV infection due to failure to thrive. Therefore, 
vaccine-induced M. tuberculosis-associated pathology or dissemination had to manifest 
within a relatively short time period in SIV-infected animals to be detected, and we cannot 
draw any conclusions about long-term outcome. It should be emphasized though that M. 
tuberculosis dissemination was observed in multiple infant tissues collected at 4 or 6 weeks 
after vaccination with mc25157 by pathology, histology and culture assays. The latter data 
imply that lung pathology and M. tuberculosis dissemination should be detectable within a 
10-week time frame, especially in immunosuppressed SIV-infected animals.  
To our knowledge, this is the first study demonstrating that an attenuated M. 
tuberculosis strain does not cause disease in an infant nonhuman primate model of neonatal 
TB vaccination and SIV infection that is highly relevant to human infants, including those at 
risk for perinatal HIV infection. Our data show that all three vaccines were able to induce 
persistent vaccine-specific antibody responses in infant macaques, albeit the magnitude was 
dependent on the level of replication-attenuation (mc26020=mc25157>mc26435) and the 
route of vaccine administration (ID>PO). The persistence of these antibodies suggests that 
	   50 
the rAMtb vaccines primed the infant immune system. Despite the low PSTS1 M. 
tuberculosis-specific plasma antibody responses after oral and intradermal administration in 
infant rhesus macaques, the rAMtb vaccine strain mc26435 (that contains a mycobacterial 
expression plasmid encoding SIV Gag) was effective in inducing both SIV and TB-specific 
CD4+ and CD8+T cell immune responses in systemic and mucosal tissues (manuscript in 
preparation). Therefore, the rAMtb strain mc26435 should be further explored and optimized 
as a valid TB vaccine candidate that could replace BCG and as a combination vaccine to 
protect against HIV and TB infection in infants. Considering that immune correlates of 
protection against HIV or TB acquisition are not well defined, these vaccines will ultimately 
need to be tested for efficacy against an HIV/SIV and M. tuberculosis challenge.  	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To address the safety concern associated with the current BCG
vaccine, we hypothesized that a rationally attenuated strain of hu-
man-adapted M. tuberculosis might be a better vaccine platform
than bovine-adapted M. bovis BCG. We developed auxotroph
mutants of human M. tuberculosis strain H37Rv in which myco-
bacterial genes important for replication and persistence were de-
leted or modified to attenuate replication. In addition, in an at-
tempt to increase immunogenicity, several genes important for
the evasion of host immune responseswere deleted. The construc-
tion of these attenuated M. tuberculosis strains, their safety, and
their immunogenicity profiles in comparison to those of the li-
censed BCG vaccine in SCID mice have been reported previously
(16, 19, 28, 30–32). Some of these TB vaccine candidates were also
characterized in nonhuman primates as an important step toward
potential human clinical trials. Vaccine safety, immunogenicity,
and efficacy data obtained with nonhuman primates would be
expected to be highly relevant to humans (19). Attenuated M.
tuberculosis vaccine strains mc26020 and mc26030 were safe and
well tolerated in adult cynomolgus macaques and did not cause
TB but provided only partial protection against an intrabronchial
M. tuberculosis challenge (19). On the basis of these data, we de-
veloped novel, replication-attenuated M. tuberculosis vaccine
strains with increased immunogenicity.
Because of obvious ethical concerns, pediatric HIV-TB vaccine
safety assessments and challenge studies of efficacy cannot be per-
formed with HIV-infected human infants. To account for the in-
fant’s relatively inexperienced and still developing immune sys-
tem early after birth, we therefore chose to test vaccine safety in
infant macaques that show immune system ontogeny after birth
similar to that of human infants. In a first step toward the gener-
ation of a pediatric combination HIV-TB vaccine, we constructed
attenuated M. tuberculosis strains that express the simian immu-
nodeficiency virus (SIV) gag gene. The safety profiles of three dis-
tinct recombinant attenuated M. tuberculosis-SIV vaccine candi-
dates with different degrees of attenuation of replication and/or
immunogenicity (Table 1) were initially tested in healthy, non-
SIV-infected infant rhesus macaques. None of these vaccine can-
didates induced clinical symptoms of TB. The vaccine strain
(mc25157) that was attenuated predominantly for immune eva-
sion and less for replication causedM. tuberculosis dissemination
to multiple tissues and was therefore excluded as a potential pedi-
atric vaccine. The safety of the two other vaccine candidates, re-
combinant attenuatedM. tuberculosis-SIVmc26020 andmc26435,
was then evaluated under even more stringent conditions with
immunosuppressed SIV-infected infant macaques, analogous to
HIV-infected human infants. The infant macaque model of SIV
infection is a well-established animal model of pediatric HIV in-
fection and is suitable for the testing of the safety and efficacy of
intervention strategies for a wide range of infectious diseases (1, 3,
4, 24, 38). Vaccination of SIV-infected infantmacaques with these
two recombinant attenuated M. tuberculosis-SIV strains did not
cause TB-like lung pathology. Importantly, in animals vaccinated
with mc26435, local or systemic dissemination of mycobacteria
did not occur, and live mycobacteria could not be recovered from
any tissues under optimal culture conditions. The data represent
an important step in the clinical testing of these novel live atten-
uated M. tuberculosis vaccine candidates and suggest that a com-
bination recombinant attenuated M. tuberculosis-HIV vaccine
could be a safe alternative to BCG for the pediatric population as a
whole but more importantly for the extreme at-risk group of in-
fants infected with HIV.
MATERIALS AND METHODS
Animals. Newborn rhesus macaques (Macaca mulatta) from the SIV-
negative and type D retrovirus-free colony at the California National Pri-
mateResearchCenter (CNPRC;Davis, CA)were hand reared in a nursery.
Animals were housed according to the Guide for the Care and Use of Lab-
oratory Animals and the standards outlined by the American Association
for Accreditation of Laboratory Animal Care; all animal protocols were
reviewed and approved by the University of California at Davis Institu-
tional Animal Care and Use Committee prior to study initiation. Animals
were randomly assigned to the various study groups and were between 3
and 7 days of age at the first immunization (see Table 2). For vaccinations
and blood collections, animals were immobilized by intramuscular injec-
tion of ketamine-HCl (Parke-Davis, Morris Plains, NJ) at 10 mg/kg of
body weight. Trained veterinary staff monitored the animals daily for
clinical symptoms associatedwith TB (e.g., breathing difficulty, coughing,
increased mucus secretion, lethargic behavior, weight loss) and/or SIV
infection.
Vaccine strains and immunization regimens.The three recombinant
attenuatedM. tuberculosis vaccine strains tested in the current study were
rationally attenuated from wild-type M. tuberculosis strain H37Rv. M.
tuberculosis H37Rv was modified through several deletions in genes sup-
porting replication to increase vaccine safety and in genes important for
mycobacterial immune evasion to enhance immunogenicity (5). As out-
lined in Table 1, strain mc26020 was predominantly attenuated for repli-
cation with deletions in the lysA and panCD loci (!lysA!panCD), no loci
important for immune evasion were deleted. We demonstrated previ-
ously that deletion ofRD1 fromM. tuberculosisH37Rv results in an atten-
uated strain with intermediate replication relative that of the parental
strain (30). Strain mc25157 was designed primarily to test for enhanced
immunogenicity (!nuoG) with attenuation for intermediate replication
(!panCD !RD1) or no replication (!leuCD !panCD for mc26435). The
construction of the recombinant attenuated M. tuberculosis vaccine
strains has been previously described (19, 28, 31–33, 42, 49). In these prior
studies, the deletions introduced were stable and reversions were not ob-
served (19, 28, 31–33, 42, 49). Prior to their use in rhesus macaques, the
safety and immunogenicity of all three recombinant attenuatedM. tuber-
culosis strains were confirmed in mice (19, 28, 31–33, 42, 49). The recom-
TABLE 1 Recombinant attenuatedM. tuberculosis vaccine strains used in this study
Vaccine strain Groups
Deletion(s) attenuating:
Reference(s)Replication Immune evasion
mc26020 (!lysA !panCD)a A, B !lysA !panCD (low)d None 19, 30-33, 42, 49
mc25157 (!nuoG !panCD !RD1 pSIV Gag)b C–F !panCD !RD1 (intermediate) !nuoG 28, 30
mc26435 (!leuCD !panCD !secA2 pSIV Gag)c G–L !leuCD !panCD (low) !secA2 28
a !lysA !panCD, deletions of the lysA and the panCD loci.
b !nuoG !panCD !RD1, deletions of the nuoG, panCD, and RD1 loci; pSIV GAG, insertion of a full-length SIVmac239 Gag insert.
c !leuCD !panCD !secA2, deletions of the leuCD, panCD, and secA2 loci.
d Replication levels are shown in parentheses.
Pediatric HIV-TB Vaccine Safety in Infant Macaques
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inant attenuated M. tuberculosis mc25157 and mc26435 vaccine strains
were furthermanipulated to incorporate amycobacterial expression plas-
mid with a full-length SIVmac239 Gag insert (28). Expression of SIV Gag
in vaccine preparations was confirmed by Western blotting immunola-
beled with a horseradish peroxidase (HRP)-conjugated V5 antibody as
previously described (Fig. 1A) (28). Immunogenicity was confirmed in
C57BL/6 mice (Fig. 1B).
An overviewof the vaccination schedule, including the route and dose,
is provi ed in Table 2. Bri fly, strain c26020 was administered both .o.
and intradermally (i.d.) at 1 week of age and animals were followed up for
6 months (group A). Animals vaccinated with mc25157 were primed p.o.
and received a homologous i.d. booster vaccination at either 2 (group C)
or 3 (group E) weeks. Animals were euthanized at week 4 or 6, respec-
tively, to test for vaccine-induced immune responses and M. tuberculosis
dissemination in various tissues. The time intervals were selected on the
basis of our previous pathogenesis and pediatric HIV/SIV vaccine studies
in the infant macaque p.o. SIV infection model, in which we generally
challenge at 4 weeks of age tomimic early breastmilk transmission ofHIV
in humans (2, 23, 37, 38). Finally, we tested two heterologous prime-boost
regimens using either recombinant adenovirus 5 expressing SIVmac239
Gag (rAd5-SIVgag; groups G and H) or recombinant modified vaccinia
virus Ankara expressing SIVmac239 Gag, Pol, and Env (rMVA-SIVgpe;
group J) that were kindly provided by the International AIDS Vaccine
Initiative (Brooklyn, NY) and B. Moss (National Institute of Allergy and
Infectious Diseases [NIAID], NIH, Bethesda, MD), respectively (23). The
heterologous boosts were administered at 3 weeks (rAd5-SIVgag) or at 3
and 6weeks (rMVA-SIV constructs) after the initialmc26435 vaccination.
In the studies described here, the vaccine boosts are reported solely for the
purpose of revealing all of the study variables; vaccine immunogenicity
will be reported separately (unpublished data). Note that all experiments
were carried out using parallel mock-infected (saline), age-matched in-
fant macaques as controls (Table 2, groups D, F, I, and K).
SIV infection. A subset of animals were infected with 103 50% tissue
culture infective doses of SIVmac251 (stock 6/04) (23) by the intravenous
(i.v.) route within 72 h of birth and then immunized 1 week later with
mc26020 (group B) ormc26435 (group L) (Table 2). SIV-infected animals
were euthanizedwhen theymet criteria established for retrovirus-infected
animals (40).
Sample collection and preparation. EDTA blood samples were col-
lected at week 0 (baseline) and then longitudinally as described in Table 2.
Plasma was collected after centrifugation and stored in multiple small
aliq ots at!80°C for virological analysis and antibody testing. Peripheral
blood mononuclear cells (PBMC) were isolated by gradient centrifuga-
tion as described previously (23). At the time of euthanasia, multiple
tissues were collected, including tonsil, lymph node (LN; submandibular,
retropharyngeal, bronchial, axillary, andmesenteric), lung, and intestinal
tissues (ileum, colon). In addition, from animals that received an i.d.
vaccination, we saved tissue from the dermal inoculation site (groups A,
B, E, F, and I). Corresponding skin from p.o. vaccinated animals was
collected as control tissue. Each tissue sample was divided and saved for
multiple applications as follows: snap-frozen (M. tuberculosis culture),
formalin fixed and paraffi embedded (pathology, M. t berculosis stain-
FIG 1 Vaccine-induced SIV-specific CD8" T cell responses in mice. (A)
Western blotting result showing SIVgag protein expression in mc26435 lysate
(lane 1) and its absence inmc26434 lysate expressing the control plasmid (lane
2). Lane 3 represents the molecular weight (MW) ladder. Recombinant atten-
uated M. tuberculosis whole-cell lysates were immunoblotted with HRP-con-
jugated anti-V5 antibodies and developed using chemiluminescence. The
principal recombinant SIVgag band migrates at approximately 55 kDa. One
lower-molecular-weight breakdown product is also observed in mc26435 ly-
sate. (B) C57BL/6 mice were immunized subcutaneously with 107 CFU of the
attenuated M. tuberculosis vaccine strain mc26434 (n # 5) or with mc26434
that contained the SIV Gag expression cassette (named mc26435, n# 5). One
week after immunizatio , sple ocytes were isolated and AL11-SIVgag te-
tramer-specific CD8" T cell responses were determined by flow cytometric
analysis. Shown are the average percentages $ standard deviations of AL11-
SIVgag tetramer-specific CD8" T cells. Note that mc26435-immunized mice
mounted AL11-SIVgag-specific CD8" T cell responses significantly higher
than those of mc26434-immunized mice (P % 0.02), albeit the absolute fre-
quencies of tetramer-positive CD8" T cells were low.
TABLE 2 Study outline
Group Sizea
SIV
(i.v.)
Vaccin tion
Sample
collection points
(wk)
Age at
necropsy
(wk)
Prime
strain
Dose(s)
(CFU) Route(s)
Age
(wk)
Boost
strain Dos Ro te( )
Age
(wk)
A 3 No mc26020 109, 106 p.o., i.d. 1 None 0, 2, 4, 6, 8, 10,
12, 16, 20, 24
24
B 3 Yes mc26020 109, 106 p.o., i.d. 1 None 0, 2, 4, 6 6
C 5 No mc25157 109 p.o. 0 mc25157 109 CFU i.d. 2 0, 2, 4 4
D 2 No Mock p.o., i.d. 0 Mock p.o., i.d. 2 0, 2, 4 4
E 5 No mc25157 109 p.o. 0 mc25157 109 CFU i.d. 3 0, 3, 6 6
F 2 No Mock p.o., i.d. 0 Mock p.o., i.d. 3 0, 3, 6 6
G 6 No mc26435 109 p.o. 0 rAd5SIV 9& 109 PFU i.m.b 3 0, 3, 6, 9, 12, 16 16
H 6 No mc26435 106 i.d. 0 rAd5SIV 9& 109 PFU i.m. 3 16
I 4 No Mock p.o., i.d. 0 Mock i.m. 3 16
J 8 No mc26435 109 p.o. 0 rMVASIV 108 PFU i.m. 3, 6 0, 3, 6, 9, 12, 16 18
K 3 No Mock p.o. 0 Mock i.m. 3, 6 16
L 3 Yes mc26435 109 p.o. 1 None 0, 1, 2, 4, 6, 8, 10 6–10
a Number of animals.
b i.m., intramuscular.
Jensen et al.
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Table 2.3.  Histopathological Evaluations 
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Table 2.4.  M. tuberculosis Detection 
  
for a pediatric HIV-TB vaccine, because a mucosally adminis-
tered vaccine could also induce local immune responses pro-
tective against HIV transmitted p.o. by breast-feeding. In fact,
experiments with mice have shown that p.o. fed BCG can infect
the submandibular lymph nodes and Peyer’s patches (18) and
that M. tuberculosis can bind to tonsillar M cells (6, 26). Thus,
we assessed the safety of three distinct recombinant attenuated
M. tuberculosis H37Rv strains, engineered with or without the
SIV gag gene, in non-SIV-infected and in SIV-infected, and
thus immunosuppressed, infant macaques by the p.o. and i.d.
routes. BCG vaccination of SIV-infected macaques has previ-
ously been shown to exacerbate SIV disease progression and to
cause dissemination of M. bovis bacilli (9, 35, 48). In accor-
dance with a recent proposal to improve the classification of TB
disease severity in human children by combining multiple fac-
tors ranging from disease pathogenesis criteria to bacteriolog-
ical evaluation and clinical data (47), vaccine safety in infant
macaques was rigorously assessed in the current study by com-
prehensive clinical examination, histopathological evaluation,
and multiple M. tuberculosis culture methods.
For safety evaluation, animals were grouped by vaccine
strain independent of the route of administration, immuniza-
tion interval, or prime-boost regimen. The panCD deletion in
strain mc25157 was not sufficient to prevent mycobacterial dis-
semination in infant macaques, and although granuloma size
and frequency in the lung were limited in comparison to those
of animals infected with pathogenic TB (21), the strain was
deemed unsuitable for use in immunocompromised hosts. In
contrast to the safety profile of mc25157, that of dual deletion
strain mc26020 (!panCD !lysA) was improved. Only one of
three SIV-infected infant rhesus macaques showed evidence of
M. tuberculosis dissemination, and only in the axillary lymph
node that drained the i.d. inoculation site. Whether or not this
limited mycobacterial dissemination in immunosuppressed
SIV-infected infant macaques correlates with a reduced risk of
future dissemination or reactivation at other sites, however,
TABLE 4M. tuberculosis detection
Group(s) (strain), no.
of animals, tissue type AFB
MGITa BacTecb Solid culturec
Result" # ## ### " # ## ### " # ## ###
A (mc26020), 3
Skin 0/3 NTd NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Lung 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Axillary LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Spleen 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
B (SIV#mc26020), 3
Skin 0/3 NT NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Lung 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Axillary LN 1/3e 2/3 1/3 0/3 0/3 2/3 1/3 0/3 0/3 3/3 0/3 0/3 0/3 1/3
Spleen 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
C, E (mc25157), 10
Skin 10/10 NT NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 2/10 4/10 1/10 3/10 2/10 5/10 0/10 3/10 2/10 5/10 1/10 3/10 1/10 5/10
Lung 1/10 5/10 1/10 1/10 3/10 3/10 5/10 1/10 1/10 5/10 1/10 1/10 3/10 7/10
Axillary LN 5/10 2/10 1/10 3/10 4/10 2/10 3/10 2/10 3/10 3/10 1/10 3/10 3/10 8/10
Spleen 0/10 0/10 5/10 5/10 0/10 0/10 10/10 0/10 0/10 0/10 4/10 4/10 2/10 10/10
G, H, J (mc26435), 20
Skin 0/20 NT NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 0/20
Lung 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 0/20
Axillary LN 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 0/20
Spleen 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 0/20
L (SIV#mc26435), 3
Skin 0/3 NT NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Lung 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Axillary LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Spleen 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
a MGIT results:", no growth;#,!24 days;##, 18 to 24 days;###,$18 days.
b BacTec results:", no growth;#,!24 days;##, 18 to 24 days;###,$18 days.
c Solid culture results:", no growth;#,$5 CFU;##, 5 to 50 CFU;###,!50 CFU.
d NT, not tested.
e Samples positive for AFB or outgrowth of mycobacteria are in bold.
Jensen et al.
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FIGURES 
 
 
Figure 2.1.  Vaccine-induced SIV-specific CD8+ T cell responses in mice. A) Western blot 
result showing SIVgag protein expression in mc26435 lysate (Lane 1) and its absence in 
mc26434 lysate expressing the control plasmid (Lane 2). Lane 3 represents the molecular 
weight ladder. rAMtb whole cell lysates were immunoblotted with HRP-conjugated anti-V5 
antibodies and developed using chemiluminescence. The principal recombinant SIVgag band 
migrates at approximately 55 kDa. One lower molecular weight breakdown product is also 
observed in mc26435 lysate. B) C57BL/6 mice were immunized subcutaneously with 107 
CFU of the attenuated M. tuberculosis vaccine strain mc26434 (n=5) or with mc26434 that 
contained the SIV Gag expression cassette (named mc26435, n=5). One week after 
immunization, splenocytes were isolated and AL11-SIVgag tetramer specific CD8+ T cell 
responses were determined by flow cytometric analysis. The figure shows the average 
percentages ± SD of AL11-SIVgag tetramer-specific CD8+ T cells. Note that mc26435 
immunized mice mounted significantly higher AL11-SIVgag-specific CD8+ T cell responses 
than mc26434 mice (p<0.02), albeit absolute frequencies of tetramer positive CD8+ T cells 
were low. 
 
 
  
A! B!
mc^2 6434 mc^2 6435
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
P<0.02
c264  
T
e
tr
a
m
e
r-
p
o
s
it
iv
e
 C
D
8
+
T
 C
e
lls
 (
%
) 
p < 0.02 
c2643  
SIVgag!
75kd!
50kd!
   1        2      MW !
	   55 
 
Figure 2.2.  M. tuberculosis-specific plasma IgG antibody responses. Plasma antibody 
responses to PSTS1 antigen were measured by multiplex microbead array analysis. Average 
antibody levels plus standard deviations for mock-vaccinated animals (black lines, closed 
circles), SIV-infected and vaccinated animals (red lines, diamonds), and non-SIV-infected 
vaccinated animals (blue lines, triangles) are shown for each vaccine candidate. Data are 
reported as MFIs. The experimental groups are listed in parentheses in the top right corner of 
each panel. The mock-vaccinated animals used for groups A and B are the same animals used 
as controls for groups G, H, J, and L. Note that in panel A, one of three non-SIV-infected 
vaccinated animals had high PSTS1 antibody levels at day 0 (MFI of 666 compared to MFIs 
of 40 and 18 in the other remaining animals, and therefore, the average baseline antibody 
levels at day 0 appear higher than those of groups B, I, and K. Similarly, in panel C, 2 of 6 
animals vaccinated i.d. and 2 of 14 animals vaccinated p.o. with mc26435 had PSTS1 MFIs 
(antibody levels) of 100 at day 0, explaining the higher MFI values at day 0 than those of 
groups I, K, and L. 
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Figure 2.3.  Plasma SIV viremia and clinical parameters. A) Numbers of SIV RNA 
copies per milliliter of plasma in samples longitudinally collected from each animal are 
shown. Each symbol represents an individual animal. The experimental group of each animal 
is shown in parentheses. B) The average increase in weight over the birth weight (kilograms) 
is shown for the animals in each of the three vaccine groups (dark blue, yellow, and light 
blue lines) and for SIV-infected and subsequently vaccinated animals (red line) in 
comparison to the weight gain of mock-vaccinated animals (gray line). The averages of 
absolute numbers ± standard deviations C) and average percentages ± standard deviations of 
CD4+ T cells D) in peripheral blood are shown for animals vaccinated after prior SIV 
infection (red lines, diamonds) and for vaccinated non-SIV-infected (blue lines, triangles) 
animals in comparison to mock-vaccinated animals (black lines, circles). Note that panels C 
and D include the SIV-infected animals vaccinated with mc26020 (n = 3) or mc26435 (n = 3). 
For this analysis, vaccinated animals (n = 33) included animals from groups A, C, E, G, H, 
and J and mock-vaccinated animals (n = 11) included animals from groups D, F, I, and K. 
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Figure 2.4.  Pathology evaluation of lung tissue. Formalin-fixed, paraffin-embedded tissues 
were stained with H&E and blindly analyzed for histological changes due to vaccination 
and/or SIV infection. A) Lung tissue (magnification, x100) of an adult rhesus macaque 
infected with pathogenic M. tuberculosis (197). B) The same tissue shown in panel A at x200 
magnification. Note the central necrosis, mineralization, and granuloma formation and the 
presence of multinucleate giant cells. C) Lung section of a mock-immunized infant macaque. 
D) Representative lung section of an mc25157-vaccinated infant macaque with 
granulomatous tissue and signs of extensive atelectasis. Panels E and F show essentially 
normal lung sections from non-SIV-infected E) or SIV-infected F) infant macaques after 
mc26435 vaccination. The sections in panels C to F are at x100 magnification. 
  
didate M. tuberculosis-SIV vaccine. Remarkably, all tissues from
non-SIV-infected (n ! 20) and also from SIV-infected (n ! 3),
mc26435-vaccinated animal were negative for AFB, and viable
mycobacteria could not be recovered from any of these tissues by
any of the culture methods used.
In summary, the data indicate that recombinant attenuatedM.
tuberculosis-SIV vaccine strains can be administered p.o. or i.d. to
infantmacaques during the first postnatal week. Although vaccine
strain mc25157 caused dissemination of mycobacteria, the live
attenuated vaccine strains mc26020 and mc26435 demonstrated a
better safety profile in infant macaques. In particular, strain
mc26435 was safe in non-SIV-infected (groups I and K) and in
immunocompromised, SIV-infected infant macaques (groups G,
H, and J) by all of the safety criteria used in this study.
DISCUSSION
An effective vaccine against HIV is not available, and the only
approved TB vaccine, BCG, is not safe in immunosuppressed in-
dividuals. This safety concern is of particular importance in re-
source-poor countries affected by the dual epidemics of TB and
AIDS. In particular, TB infection rates among childre have risen
in association with HIV prevalence, nd about 1% of HIV-in-
f cted infants develop diss minated BCG disease after vaccina-
tion. Although ART coverage now extends to 42% of HIV-in-
fected mothers, only about 23% of their newborn infants receive
ART (43, 45) and the rest remain at risk for HIV acquisition by
breast-feeding. These facts underscore the need for a novel safe
vaccine to prevent pediatric HIV and TB infections. The current
study represents an important first step toward the development
of a p.o. administered highly attenuated M. tuberculosis vaccine
expressing HIV antigens as a potential pediatric combination
HIV-TB vaccine.
BCG was originally administered p.o., but this route was
discontinued due to cervical lymphadenitis and parapharyn-
geal complications. The p.o. route may be more advantageous
FIG 4 Pathology evaluation of lung tissue. Formalin-fixed, paraffin-embedded tissues were stained with H&E and blindly analyzed for histological changes due
to vaccination and/or SIV infection. (A) Lung tissue (magnification,"100) of an adult rhesus macaque infected with pathogenic M. tuberculosis (21). (B) The
same tissue shown in panel A at"200magnification.Note the central necrosis,mineralization, and granuloma formation and the presence ofmultinucleate giant
cells. (C) Lung section of a mock-immunized inf nt macaque. (D) Representative lung section of an mc25157-vaccinat d infant macaqu with granulomatous
tissue and signs of extensive atelectasis. Panels E and F show essentially normal lung sections fromnon-SIV-infected (E) or SIV-infected (F) infantmacaques after
mc26435 vaccination. The sections in panels C to F are at"100 magnification.
Pediatric HIV-TB Vaccine Safety in Infant Macaques
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CHAPTER 3:  A NEONATAL ORAL MYCOBACTERIUM TUBERCULOSIS-SIV 
PRIME / INTRAMUSCULAR MVA-SIV BOOST COMBINATION VACCINE 
INDUCES BOTH SIV- AND MTB-SPECIFIC IMMUNE RESPONSES IN INFANT 
MACAQUES2 
 
OVERVIEW 
Mother-to-child-transmission of HIV by breast-feeding remains a major obstacle in 
the eradication of HIV infection.  Compared to adults, HIV-infected infants have more rapid 
disease and show higher susceptibility to co-infections like tuberculosis (TB).  Although the 
Bacille Calmette-Guérin vaccine can be administered at birth to protect against TB, BCG can 
disseminate in HIV-infected infants and increase mortality.  Thus, a pediatric combination 
vaccine to stop both HIV and TB infection in infants is urgently needed.  Towards the goal of 
developing a pediatric combination HIV-TB vaccine to prevent both oral HIV acquisition by 
breast-feeding and TB infection, we tested and optimized an immunization regimen using a 
novel live attenuated Mycobacterium tuberculosis vaccine engineered to express simian 
immunodeficiency (SIV) antigens followed by heterologous MVA-SIV boosting in the infant 
macaque model.   
A single oral dose of the attenuated Mtb-SIV vaccine strain mc26435 during the first 
week of life was sufficient to induce persistent TB-specific immune responses.  SIV-specific 
immunity was induced at low but comparable magnitudes after oral or intradermal priming, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 This chapter has been reproduced/amended from Jensen et al. (151). 	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and was enhanced following MVA-SIV boosts.  T cell responses were most pronounced in 
intestinal tissues and oral lymph nodes.  Importantly, in addition to plasma SIV-specific IgG 
and IgA antibodies, infant macaques developed mucosal SIV-specific IgA in saliva and 
intestinal IgA and IgG.  While future SIV and Mtb challenge studies will be needed to 
determine the protective efficacy of the Mtb-SIV / MVA-SIV vaccine, infants at high risk for 
oral HIV acquisition by breast-feeding and TB infection could profoundly benefit from an 
effective combination vaccine. 
INTRODUCTION 
The coverage of antiretroviral therapy (ART) for HIV-infected mothers has increased 
substantially, yet many resource-poor countries are still afflicted by rising rates of HIV 
mother-to-child-transmission (MTCT) (338). Infant ART coverage remains below 30% and 
ART prophylaxis does not span the entire breast-feeding period (338). The majority of 
pediatric HIV infections occur in sub-Saharan Africa where tuberculosis (TB) burden is also 
high. HIV-infected infants face a higher risk of TB infection (165), and pregnant women co-
infected with HIV and TB are more likely to transmit both HIV and TB to their infants (122, 
165). The Bacille Calmette-Guérin (BCG) vaccine for prevention of TB infection can 
disseminate in HIV-infected infants with a case fatality of 75% (128). The high morbidity 
and mortality associated with HIV and TB disease in infants underscore the urgent need for a 
safe neonatal vaccine to prevent pediatric HIV and TB infections.  
Currently, BCG is the only live attenuated vaccine approved for administration in 
neonates at birth. BCG-inherent adjuvant properties likely enhance pediatric immune 
responses because a single BCG dose induces robust cellular immunity comparable to 
responses in adults. These compelling facts provided the rationale for the development of 
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combination HIV-TB vaccines. In fact, based on murine TB efficacy data with a recombinant 
auxothroph BCG vaccine expressing an African consensus HIV-1 clade A Gag immunogen 
(rBCG.HIVA) (4, 122, 348, 359), phase I clinical trials have been initiated in African 
neonates.  The restriction of preclinical BCG-HIV immunogenicity and safety studies to 
murine models or adult macaques (4, 27, 122, 136, 281, 348), however, is problematic.  
Substantial differences in i) infant and adult immune function, ii) immune development 
between neonatal mice and human newborns, and iii) inherent limitations of BCG-derived 
vaccines (importantly the safety risk for immunocompromised individuals and lack of 
relevant protective TB antigens), argue for the tandem pursuit of alternative regimens.  
We hypothesized that a live attenuated human-adapted Mycobacterium tuberculosis 
(Mtb) vaccine similar to BCG but with an improved safety profile could be safe and 
protective, even in immunosuppressed infants.  We chose human-adapted Mtb H37Rv in lieu 
of M. bovis-derived BCG because Mtb contains known immunodominant epitopes for 
humans that are absent in BCG (46, 73). Secondly, we intentionally deleted specific H37Rv 
genes important for replication and immune evasion, whereas BCG was attenuated only 
through serial passaging. Rhesus macaques are an ideal and validated animal model in which 
to evaluate our combination vaccine due to their extremely sensitivity to Mtb and to simian 
immunodeficiency virus (SIV) (214, 307, 393), and the shared immunological, 
developmental and physiological similarities between human infants and neonatal macaques 
(217, 290, 309). The translational potential of our vaccine for application in human infants at 
risk for HIV is supported by our data demonstrating that neonatal SIV-infected macaques 
could be safely vaccinated with the live attenuated auxotroph Mtb vaccine mc26435 (152).   
Towards the long-term goal of developing a pediatric HIV-TB vaccine, the current 
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study tested whether this highly attenuated recombinant Mtb-SIV vaccine can efficiently 
prime both Mtb and SIV-specific immunity.  To establish proof-of concept, we deemed the 
expression of only a single SIV antigen, SIV Gag, by mc26435 sufficient. SIV Gag contains 
numerous immunogenic T cell epitopes, and several vaccine studies support the importance 
of SIV Gag-specific T cell responses in the control of viral replication (266, 324, 331). 
Indeed, our data demonstrate that (i) a single dose of mc26435 induced both Mtb- and SIV-
specific immune responses in infant macaques, (ii) vaccine-induced SIV immunity was 
enhanced and broadened by heterologous MVA-SIV Gag, Pol and Env boosts, and (iii) the 
combined oral Mtb-SIV Gag prime/ intramuscular MVA-SIV regimen effectively induced 
mucosal and systemic immune responses.   
MATERIALS AND METHODS 
Animals.   
Infant rhesus macaques (Macaca mulatta), obtained from the SIV-negative and type 
D retrovirus-free CNPRC colony (UC Davis, CA), were nursery-reared and housed 
according to the “Guide for Care and Use of Laboratory Animals” and standards by the 
AAALAC.  Animal protocols were approved by the UC Davis Institutional Animal Care and 
Use Committee.  For all interventions, animals were immobilized by 10mg/kg body weight 
of ketamine-HCl (Parke-Davis, Morris Plains, NC), injected intramuscularly (IM).   
 
Vaccine Strains and Immunization Regimens.  
The construction, attenuations and safety profiles of the Mtb H37Rv-derived vaccine 
strains mc26435 and mc26020 have been described previously (152, 184, 268, 293, 296, 344, 
397).  Briefly, in strain mc26020, the panCD and lysA loci were deleted to generate a highly 
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replication-attenuated double-auxotroph strain.  The double-auxotroph strain mc26435 
(ΔpanCDΔleuCD) was further modified by deleting the secA2 locus, and engineered to co-
expresses a mycobacterial codon-usage-optimized full length SIVmac239 Gag cassette.  SIV 
Gag expression from vaccine cultures was confirmed by immunoblot using a V5 antibody-
HRP.  
Infant macaques (n=8) were orally (PO) vaccinated with mc26435 at birth (3-7 days 
old = week 0), IM boosted at 3 and 6 weeks with MVA-SIV expressing SIV Gag, Pol, and 
Env (kindly provided Dr. B. Moss and Dr. P. Earl, NIAID, NIH, Bethesda, MD) (79, 178, 
348), and followed for 18 weeks (Group A). Age-matched control animals (n=3) were mock 
vaccinated with saline (Group B).  To test how replication attenuation affects Mtb-specific 
immune responses, three infants were vaccinated both PO and intradermally (ID) with strain 
mc26020 without boosting, and followed for 24 weeks (Group C).  
 
Sample Processing.   
Blood and saliva samples were collected prior to all interventions and throughout the 
study period.  Plasma was stored at -80° C for antibody measurement. At the time of 
euthanasia, tonsils, lymph nodes (LN: axillary, mesenteric, retropharyngeal and 
submandibular), and intestinal tissues (colon and ileum) were collected, and mononuclear 
cell suspensions (MNC) were prepared as described (208).  Saliva was collected using Weck-
Cel sponges (Beaver Visitec), immediately snap frozen, and later eluted as described At the 
terminal time point, 2-3 grams of fresh stool were added to 0.5% BSA in 5ml sterile PBS 
supplemented with 1/100 protease inhibitor cocktail (Sigma, P8340) and snap-frozen. Fecal 
extracts were prepared by vortexing the thawed contents until complete homogenization, 
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removing debris by ultracentrifugation (4˚C, 10 min), filtration (0.45µm), and concentration 
to 0.5ml using an Amicon Ultra-4 50K centrifugal filter unit (Millipore). 
 
SIV-specific Antibodies and Immunoglobulin (Ig) Measurements.  
Anti-SIV IgG and IgA antibodies in plasma and fecal extracts, and salivary IgA were 
measured by ELISA as described (208).  Briefly, plates were coated overnight with 100ng 
SIVmac251 Env rgp120 (Immune Technology, New York, NY) or 100µl 1/400 SIVmac239 
lysate (Advanced Biotechnologies, Columbia, MD) per well in PBS.  Antibodies against the 
lysate are termed “Gag, Pol”-specific because Env protein is undetectable at the dilution used.  
Total IgA or IgG in saliva or fecal extracts were measured by capture ELISA (24, 152) using 
goat anti-monkey IgA (AlphaDiagnostics, San Antonio, TX) or goat anti-monkey IgG (MP 
Biomedicals), respectively, to capture Ig.  The following day, plates were washed, blocked 
and loaded with diluted samples and a monkey serum standard containing known amounts of 
Ig, SIV-specific IgA or SIV-specific IgG.  After overnight incubation (4˚C), the plates were 
developed with biotinylated goat anti-monkey IgA or anti-human IgG antibody 
(SouthernBiotech, Birmingham, AL), and avidin-labeled peroxidase (Sigma). The SIV Env 
or Gag, Pol-specific IgA or IgG antibody concentrations in each secretion were normalized to 
total IgA or IgG concentration.  The specific activity (ng IgA or IgG antibody per µg total 
IgA or IgG) was deemed significant if it was greater than the mean + 3SD of negative 
controls. 
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Antigen-specific T Cell Responses.   
1x106 blood or tissue MNC were treated with 0.5mg anti-CD28 and anti-CD49d (BD 
Biosciences, San Jose, CA) in 1ml supplemented RPMI plus i) no stimulant, ii) 5ng/ml PMA 
/500ng/ml Ionomycin (Sigma, St. Louis, MO) iii) 10 µg SIVmac239 p27 Gag peptide pool, 
iv) 10 µg SIVmac239 Env peptide pool (both: AIDS Research and Reference Reagent 
Program), v) 25 µg purified protein derivative (Tuberculin PPD, Statens Serum Institute, 
Copenhagen, Denmark), vi) 10 µl BCG vaccine (105 CFU; Statens Serum Institute), vii) 50 
µg Mtb H37Rv recombinant culture filtrate protein-10 reference standard (rCFP), viii) 50 µg 
Mtb H37Rv whole strain lysate, or ix) 25 µg Antigen 85b reference standard (Ag85b; all 
from BEI Resources Manassas, VA). Cells were cultured for 6 hrs (37°C, 5% CO2) with 1x 
Brefeldin A (eBioscience, San Diego, CA) treatment after the first hour.  Cells were stained 
using a fixable live/dead discriminator (Invitrogen) and antibodies against rhesus macaque 
CD3, CD4, IL-2, TNF-α, IFN-γ, (BD Biosciences, San Jose, CA) and IL-17A (eBioscience). 
When cell counts permitted, unstimulated MNC suspensions were stained for markers of T 
cell memory (CD45RA, CCR7) and mucosal homing (CD103).  All panels included 
fluorescence-minus-one controls.  Paraformaldehyde-fixed samples were acquired on a 
LSRII instrument and analyzed using FlowJo software with Boolean gating (TreeStar, 
Ashland, OR).  Antigen-specific T cell responses were corrected for background responses in 
unstimulated controls and are reported as percentage of CD4+ or CD8+ T cells. 
 
Statistical Analysis.   
Data were analyzed using Prism (GraphPad, Inc., La Jolla, CA). Correlations between 
IgA in various compartments (plasma, saliva, intestine) were analyzed using the Spearman 
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rank test to determine the effect of antibody transudation versus mucosal antibody production. 
Frequencies of CD103 positive T cell populations were compared by applying a two-tailed 
Student’s t-test with Welch’s correction.  P values ≤0.05 were considered significant. 
RESULTS 
TB-specific immunity after a single prime with attenuated Mtb 
We have previously shown that mc26435 induces plasma IgG antibodies to the 
mycobacterial antigen PSTS-1, albeit at significantly lower levels than the more replication-
competent strain mc26020 (152). In contrast, independent of replication capacity, the 
magnitude and persistence of Mtb-specific peripheral blood T cell responses were similar in 
mc26020 and mc26435 vaccinated infant macaques (Figure 3.1A/B, Table 3.1).  Mtb-specific 
T cell responses consisted primarily of cells producing IL-2, IFN-g, TNF-α or IL-17 (Figure 
3.1C, Table 3.1), but dual and triple polyfunctional T cells were detected at multiple time 
points (Figure 3.1D). Although only PPD and Ag85b-specific responses were consistently 
evaluated due to limited infant blood volumes, mc26435 vaccinated animals also developed 
rCFP10-specific CD4+ and CD8+ T cell responses, indicating that mc26435 elicited responses 
to human immunodominant epitopes that are absent in BCG (Figure 3.1D). Broad 
polyfunctional Mtb-specific T cell responses were also elicited in multiple tissues (Figure 
3.1E).  Consistent with the oral route of immunization, Mtb-specific T cell responses were 
induced in tonsils and LN draining the oropharynx (Table 3.1), with the highest Mtb-specific 
T cell responses developing in ileum and colon (Table 3.1).  
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SIV-specific T cell immune responses in peripheral blood and tissues 
A single oral immunization with mc26435 was sufficient to induce SIV Gag-specific 
T cell responses by 3 weeks of age (Figure 3.2A), prior to MVA-SIV boosting.  SIV Gag-
specific T cell frequencies did not increase after MVA-SIV boosts (Figure 3.2B), but dual 
and triple cytokine-producing T cells increased in frequency and diversity (Figure 3.2C), 
suggesting improved quality of SIV Gag responses. In addition, SIV–specific T cell 
immunity increased in breadth through induction of Env-specific T cells. SIV Gag and SIV 
Env-specific T cell responses were observed at multiple time points indicative of induction of 
SIV-specific T cell memory in blood and tissues (Table 3.2).   
Consistent with oral priming, frequencies of CD103 positive central memory 
(CD3+CD4+CD45RA-CCR7+, TCM) and effector/effector memory (CD3+CD4+CD45RA+/-
CCR7-, TE/EM) CD4+ T cell populations were higher in multiple tissues of vaccinated animals 
compared to mock animals, including the ileum (CD4+TE/EM: p=0.0326), colon (CD4+TE/EM: 
p=0.0032), and the retropharyngeal LN (CD4+TCM: p=0.0239) draining the oropharynx 
(Figure 3.3A). Similarly, a higher percentage of ileal CD8+ TCM expressed CD103 compared 
to mock animals (p=0.0028). The biological meaning of decreased CD103+CD8+TE/EM cells 
in axillary LN is questionable because CD103 is a mucosal homing marker, and 
CD103+CD8+TE/EM frequencies were similar in all other tissues (Figure 3.3A). Due to limited 
cell numbers, memory and homing markers were only evaluated on total CD4+ and CD8+ T 
cell populations.  However, tissues with higher CD103+ T cell frequencies generally also had 
higher numbers of SIV-specific T cells. Thus, SIV-specific T cells were most pronounced in 
intestinal tissues (Figure 3.3B), but also detectable in at least one other tissue of each 
vaccinated animal (Figure 3.3C). Responses were directed to SIV Gag and SIV Env and 
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consisted of single and polyfunctional T cells with CD8+T cells being induced at higher 
frequencies and in more tissues than SIV-specific CD4+T cells (Figure 3.3C).   
 
Induction of systemic and mucosal SIV-specific antibodies 
In contrast to SIV-specific T cell responses, anti-SIV Gag, Pol plasma IgG antibodies 
were rarely detected prior to boosting, but ultimately developed in all animals after the 
MVA-SIV boosts. Anti-SIV Gag, Pol- and anti-SIV Env-specific plasma IgG responses 
peaked at week 8 and were maintained at high levels (Figure 3.4A/B). Plasma SIV Env 
specific IgA antibodies also peaked by 8 weeks, but subsequently declined, while SIV Gag-
specific IgA antibodies showed a more variable pattern (Figure 3.4A/B).  
Considering the potential importance of mucosal antibodies in preventing MTCT of 
HIV by breastfeeding, we measured anti-SIV Gag, Pol and anti-SIV Env-specific IgA in 
mucosal compartments of vaccinated animals.  Even though SIV Gag was a component of 
both the mc26435 prime and the MVA-SIV boosts, anti-SIV Gag, Pol-specific IgA was 
present in saliva of only 1 of 8 vaccinated animals, whereas anti-SIV Env-specific salivary 
IgA antibodies developed in 4 vaccinees (Figure 3.4C).  At euthanasia, we detected anti-SIV 
Env- or anti-SIV Gag, Pol-specific IgA and IgG intestinal antibodies in 4 of 8 and 6 of 8 
animals, respectively. One of 8 animals (#41690) failed to develop SIV-specific intestinal 
IgG or IgA antibodies (Figure 3.4D), despite high plasma antibodies to SIV Env. In fact, 
plasma anti-Env IgA levels did not correlate with those in stool (p = 0.9768; R = -0.0238) or 
in saliva (p = 0.3333; R= -1.000), suggesting that anti-Env-specific IgA in the secretions was 
derived from local mucosal synthesis rather than passive serum transudation (data not shown). 
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DISCUSSION  
Protective immunity against TB is thought to be primarily mediated by T cells (2, 80, 
399), while prevention of HIV infection requires broadly-neutralizing antibodies (11) and T 
cell immunity to control early viral replication should HIV infection occur (117, 324). 
Towards the long-term goal of developing a pediatric HIV-TB vaccine, the main study 
objective was to provide proof of concept that a highly attenuated Mtb strain expressing SIV 
antigens could induce both SIV and Mtb–specific immune responses in infant macaques. To 
prevent TB and HIV infections, vaccine-induced memory responses need to be elicited and 
persist at sites of pathogen entry and replication, i.e. the lung TB, and the oropharynx and 
intestinal tract, respectively.  Thus, a secondary goal was to prove that the oral mc26435 
prime/ IM MVA-SIV boost regimen could effectively induce persistent mucosal and 
systemic dual immune responses.   
Indeed, our results show that a single oral immunization with mc26435 is sufficient to 
induce broad and persistent Mtb and SIV-specific T cell responses in blood and tissues. Mtb-
specific T cell responses were elicited to multiple TB antigens, including CFP, a known 
immunodominant antigen in humans that is absent in BCG (73).  Although we did not 
include a BCG control group in this first study, evidence from mouse studies shows that 
strain mc26435 is as immunogenic as BCG (manuscript in preparation, Ranganathan et al.).  
Furthermore, PPD-specific CD4+ and CD8+T cell frequencies in infant macaques after a 
single oral mc26435 immunization are comparable to PPD-specific ELISPOT responses 
(3,000-5000 SPU/106 PBMC or 0.3-0.5% PBMC) elicited by an auxotrophic recombinant 
BCG-SIV vaccine and by standard BCG in adult macaques (4). Some mc26435-vaccinated 
animals had predominantly IL-17A-producing Mtb-specific T cells in tissues. The role of IL-
17 in TB is still controversial, but some studies suggest a protective role of Th17 cells in the 
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lung (107, 172, 206, 262, 399).  The current study lacked the analysis of Mtb-specific lung 
responses, but future studies will thoroughly assess the quantity, quality and breadth of the 
lung responses to determine the potential of mc26435 vaccination to protect against TB 
infection. 
SIV-specific tissue T cell responses were measured in sites draining the oropharynx, 
in the intestinal tract as an important site for vaccine-induced SIV immunity to prevent CD4+ 
T cell depletion, and the axillary LN as representative distal site following oral priming.  
SIV-specific T cell responses were most consistently induced in intestinal tissues and the 
tonsils.  Interestingly, intestinal tissues and lymph nodes draining the oral cavity also 
contained significantly higher frequencies of CD103+ memory CD4+
 
and CD8+ T cells 
compared to mock-immunized infants indicative of mucosal homing.  
Support for the successful induction of mucosal immunity was further provided by 
the presence of SIV-specific IgG and IgA antibodies in intestine and mucosal IgA in saliva.  
Because the SIV Env immunogen was only present in the MVA-SIV boosts and because the 
intestinal antibodies had specificity for SIV Env and SIV Gag, Pol antigens, likely the 
mucosal (PO) prime and systemic (IM) boosts contributed to the development of the 
intestinal antibody response. The role of IgA in protection against oral SIV infection remains 
to be demonstrated conclusively. In the HIV Thai vaccine trial, systemic HIV Env-specific 
IgA antibodies correlated with an increased risk of HIV acquisition (34).  However, 
mucosally-induced SIV Env-induced antibodies persisting at mucosal sites might be 
important for protection against oral HIV infection in infants.  Passive immunization studies 
demonstrated that systemic administration of antiviral IgG, which transudates into the saliva, 
could confer protection against oral infection by high in vitro neutralization and/or ADCVI 
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activity (92, 285, 349). Experiments assessing different vaccine-induced antibody functions 
will be essential in future studies (91).  Oral SIV challenge studies will be needed to 
determine the relative contribution of SIV-specific T cell responses, SIV-specific salivary 
and intestinal IgA, and intestinal IgG responses in preventing or controlling infection.  
In conclusion, the results of the current study, in combination with our previous 
safety assessment of mc26435 in infant macaques, provide the basis for future development 
of auxotrophic Mtb strains candidates as feasible and safe platform for a pediatric 
combination HIV-TB vaccine.  Further optimization of this approach will include the testing 
a cocktail of attenuated Mtb strains expressing SIV Env, Gag and Pol and boosting Mtb-
specific responses. While an attenuated Mtb prime/ heterologous viral boost vaccine strategy 
may not be sufficient to render sterilizing immunity, this approach may reduce viral 
transmission rates or viral loads in infants that do become infected.  Future SIV and Mtb 
challenge studies will evaluate the efficacy of this or other combination vaccines, but if 
successful, they could confer protection against both HIV and TB during the early period of 
life, and potentially through adolescence and into adulthood.  
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Table 3.1.  Mtb-specific single cytokine T cell responses.   
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Table 3.2.  SIV-specific single cytokine T cell responses 
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Fig. 1. Mtb-Specific T cell responses in PBMC. Panels A and B: CD4+ and CD8+ T cytokine responses after in vitro BCG or PPD stimulation of longitudinally collected blood
samples from a representative animal vaccinated with strain mc26020 (panel B) or with strain mc26435 (panel C), respectively. Note, only single-functional responses are
shown. Panel C: polyfunctional T cell responses in a representative animal in longitudinally collected blood samples. Panel D: T cell responses are induced against a number of
Mtb-specific antigens (PBMC data from a representative animal). Panel E: the percentage of animals with vaccine-induced single and polyfunctional PPD-specific T cell
responses in tissues. T cells were isolated from selected tissues (tonsil, submandibular LN, ileum, colon and axillary LN) from all animals in group B. Using a gray scale
gradient, the percentage of vaccinated animals that have PPD-specific cytokine producing T cells in all five tissues (indicated as ‘5’) is indicated in black, whereas animals
lacking PPD-specific responses in all five tissues (indicated as ‘0’) are shown in white. Data are stratified by CD4+ and CD8⁄ T cells. CFP,Mtb culture filtrate protein; lysate,Mtb
whole cell lysate; BCG, Bacille Calmette–Guérin vaccine strain; Ag85b, antigen 85b.
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Figure 3.1.  Mtb-specific peripheral blood T cell responses. Panels A and B: CD4+ and 
CD8+ T cytokine responses after in vitro BCG or PPD stimulation of longitudinally collected 
blood samples from a representative animal vaccinated with strain mc26020 (panel B) or with 
strain mc26435 (panel C), respectively. Note, only single-functional responses are shown. 
Panel C: polyfunctional T cell responses in a representative animal in longitudinally collected 
blood samples. Panel D: T cell responses are induced against a number of Mtb-specific 
antigens (PBMC data from a representative animal). Panel E: the percentage of animals with 
vaccine-induced single and polyfunctional PPD-specific T cell responses in tissues. T cells 
were isolated from selected tissues (tonsil, submandibular LN, ileum, colon and axillary LN) 
from all animals in group B. Using a gray scale gradient, the percentage of vaccinated 
animals that have PPD-specific cytokine producing T cells in all five tissues (indicated as 
‘5’) is indicated in black, whereas animals lacking PPD-specific responses in all five tissues 
(indicated as ‘0’) are shown in white. Data are stratified by CD4+ and CD8+ T cells. CFP, 
Mtb culture filtrate protein; lysate, Mtb whole cell lysate; BCG, Bacille Calmette–Guérin 
vaccine strain; Ag85b, antigen 85b. 
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 Fig. 2. SIV-specific peripheral blood T cell responses Panel A: cytokine production following SIV Gag stimulation in peripheral T cells at week 3 for all mc26435-primed
animals in group B. Panel B: CD4+ (left panel) and CD8+ (right panel) T cell cytokine production in response to in vitro SIV Gag stimulation in longitudinally collected blood
samples of a representative animal after vaccination. Panel C: SIV-specific single, dual and triple positive cytokine responses in peripheral blood CD4+ (left panel) and CD8+
(right panel) T cells at weeks three (post-prime, pre-boost), eight (post-boosts) and 16. Distinct cytokines or combinations thereof are indicated by different colors in the
graph legend.
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Figure 3.2.  SIV-specific peripheral blood T cell responses. Panel A: Cytokine production 
following SIV Gag stimulation in peripheral T cells at week 3 for all mc26435-primed 
animals in Group B.  Panel B: CD4+ (left panel) and CD8+ (right panel) T cell cytokine 
production in response to in vitro SIV Gag stimulation in longitudinally collected blood 
samples of a representative animal after vaccination. Panel C:  SIV-specific single, dual and 
triple positive cytokine responses in peripheral blood CD4+ (left panel) and CD8+ (right 
panel) T cells at weeks 3 (post-prime, pre-boost), 8 (post-boosts) and 16. Distinct cytokines 
or combinations thereof are indicated by different colors in the graph legend. 
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A.  Vaccine-enhanced Expression of CD103 by Memory and Effector T Cell Populations
B.  SIV Gag-specific T Cell Responses in Mucosal Tissues
C.  SIV-specific Polyfunctional T Cell Responses in Tissues
SIV Gag SIV Env
Fig. 3. Homing and SIV-specific T cell responses in tissues. Panel A: animals primed with strain mc26435 and boosted with MVA-SIV (gray bars) have higher percentages of
memory and effector T cells expressing CD103 compared to unvaccinated animals (white bars). Memory and effector/effector memory cells were defined within the CD4+ or
CD8+ T cell populations as CD45RA!CCR7! (TCM) or CD45RA+/!CCR7! (TE/EM), respectively, before measuring CD103 expression. Statistical significance using a one-tailed t-test
was calculated using log-transformed values. Shown are mean values ± SEM. Tissues are abbreviated as follows: tonsil (TON), submandibular lymph node (SUB),
retropharyngeal lymph node (RET), ileum (ILE), colon (CO), mesenteric lymph node (MES), axillary lymph node (AX), and PBMC. Panel B: CD4+ (left panel) and CD8+ (right
panel) T cell single cytokine production in response to in vitro SIV Gag stimulation of tissue cell populations. Each bar represents the sum of all single cytokine responses in the
relevant tissue (see legend for cytokine color coding). Shown are data for all animals that were vaccinated orally with strain mc26435 and boosted with MVA-SIV. The three
bars for each animal represent from left to right: colon (C), ileum (I), and tonsil (T). Panel C: the percentage of animals with vaccine-induced single and polyfunctional T cell
responses to SIV Gag (left panel) or SIV Env (right panel). T cells were isolated from tonsil, submandibular LN, retropharyngeal LN, ileum, colon, mesenteric LN, and axillary LN
of all vaccinated animals. Data are stratified for single and dual cytokine producing CD4+ and CD8⁄ T cells. Using a gray scale gradient, animals with T cells from all seven
tissues producing no cytokine(s) in response to SIV are indicated by ‘0’ (white) and animals with all seven tissues producing cytokine(s) are shown as ‘7’ (black).
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Figure 3.3.  Homing and SIV-specific T cell responses in tissues. Panel A: Animals 
primed with strain mc26435 and boosted with MVA-SIV (gray bars) have higher percentages 
of memory and effector T cells expressing CD103 compared to unvaccinated animals (white 
bars).  Memory and effector/effector memory cells were defined within the CD4+ or CD8+ T 
cell populations as CD45RA-CCR7- (TCM) or CD45RA+/-CCR7- (TE/EM), respectively, before 
measuring CD103 expression.  Statistical significance using a one-tailed t-test was calculated 
using log-transformed values. Shown are mean values ± SEM.  Tissues are abbreviated as 
follows: tonsil (TON), submandibular lymph node (SUB), retropharyngeal lymph node 
(RET), ileum (ILE), colon (CO), mesenteric lymph node (MES), axillary lymph node (AX), 
and PBMC. Panel B: CD4+ (left panel) and CD8+ (right panel) T cell single cytokine 
production in response to in vitro SIV Gag stimulation of tissue cell populations. Each bar 
represents the sum of all single cytokine responses in the relevant tissue (see legend for 
cytokine color coding). Shown are data for all animals that were vaccinated orally with strain 
mc26435 and boosted with MVA-SIV. The three bars for each animal represent from left to 
right: colon (C), ileum (I), and tonsil (T). Panel C: The percentage of animals with vaccine-
induced single and polyfunctional T cell responses to SIV Gag (left panel) or SIV Env (right 
panel).  T cells were isolated from tonsil, submandibular LN, retropharyngeal LN, ileum, 
colon, mesenteric LN, and axillary LN of all vaccinated animals.  Data are stratified for 
single and dual cytokine producing CD4+ and CD8* T cells.  Using a gray scale gradient, 
animals with T cells from all seven tissues producing no cytokine(s) in response to SIV are 
indicated by ‘0’ (white) and animals with all seven tissues producing cytokine(s) are shown 
as ‘7’ (black). 
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Fig. 4. SIV-specific plasma and mucosal IgG and IgA antibodies. Panels A and B: anti-SIV Gag, Pol or anti-SIV Env IgG (left graphs) and IgA (right graphs) antibody
development in plasma following oral priming with strain mc26435 plus MVA-SIV boosts. Note that IgG values are represented on a log scale and IgA values are plotted
linearly. Panel C: SIV Gag, Pol (left panel) and Env (right panel) specific activity for IgA in saliva following priming with strain mc26435 plus MVA-SIV boosts. Panel D: the
specific activity for intestinally-secreted anti-SIV Gag, Pol (black) and anti-SIV Env (gray) IgA (left) and IgG (right) antibodies following priming with strain mc26435 plus
MVA-SIV boosts. Intestinal antibodies were only measured at the time of euthanasia. One (⁄) or two stars (⁄⁄) above bars indicate that antibody measurements for anti-SIV Env
or anti-SIV Gag, Pol, respectively, exceeded mean background levels ± 3SD.
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Figure 3.4.  SIV-specific plasma and mucosal IgG and IgA antibodies.  Panel A and 
Panel B:  Anti-SIV Gag, Pol or anti-SIV Env IgG (left graphs) and IgA (right graphs) 
antibody development in plasma following oral priming with strain mc26435 plus MVA-SIV 
boosts.  Note that IgG values are represented on a log scale and IgA values are plotted 
linearly.  Panel C: SIV Gag, Pol (left panel) and Env (right panel) specific activity for IgA in 
saliva following priming with strain mc26435 plus MVA-SIV boosts.  Panel D: The specific 
activity for intestinally-secreted anti-SIV Gag, Pol (black) and anti-SIV Env (gray) IgA (left) 
and IgG (right) antibodies following priming with strain mc26435 plus MVA-SIV boosts.  
Intestinal antibodies were only measured at the time of euthanasia.  One (*) or two stars (**) 
above bars indicate that antibody measurements for anti-SIV Env or anti-SIV Gag, Pol, 
respectively, exceeded mean background levels ± 3SD.  
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CHAPTER 4:  STRIKING A BALANCE: VACCINE-INDUCED IMMUNE 
ACTIVATION OUTWEIGHS BENFICIAL ANTI-SIV ENV ANTIBODY 
RESPONSES 
 
OVERVIEW 
Over 3.3 million infants and children are infected with HIV.  Despite global 
initiatives to eliminate mother-to-child transmission (MTCT) of HIV by 2015, pediatric ART 
provision is significantly restricted compared to adults.  Oral breast milk exposure to HIV 
accounts for up to 44% of MTCT but abstinence from breastfeeding is not recommended. We 
have previously shown that oral vaccination at birth with live attenuated Mycobacterium 
tuberculosis (Mtb) strains expressing SIV genes safely induces persistent SIV-specific 
cellular and humoral immune responses both systemically and at the oral and intestinal 
mucosa.  Here we tested the ability of oral Mtb vaccine strains expressing SIV Env and Gag 
proteins, followed by systemic heterologous (MVA-SIV Env/Gag/Pol) or homologous (Mtb-
SIV Env/Gag/Pol) boosting, to protect neonatal macaques against oral SIV challenge.   
Two important results were observed.  First, a subset of heterologously-boosted 
animals that developed higher specific activities of SIV Env-specific mucosal IgA antibodies 
and higher avidities of SIV Env-specific plasma IgG antibodies had significantly lower viral 
titers at peak viremia and were better able to control viral replication.  These animals also 
maintained CD4+ T cell populations better and exhibited higher levels of IL-17-expressing T 
cells in the colon compared to non-controller animals.  Secondly, we observed that 
vaccination induced persistent immune activation.  Vaccine-induced immune activation 
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increased frequencies of CCR5-expressing CD4+ T cells in blood, oral lymph nodes and 
intestinal tissues, thus expanding the pool of available SIV target cells and likely enhancing 
the rate of infection in vaccinated animals.  While vaccination is intended to increase 
immune activation in the immature immune environment of the infant, it will be important to 
elucidate whether immune activation was the mechanism of enhanced SIV infectivity.   
INTRODUCTION 
Pediatric HIV infections occur as a result of vertical exposures in utero, intrapartum 
or from oral exposure to virus in breast milk.  In the absence of therapy, infant exposure to 
HIV-1 during breastfeeding causes 39-44% of mother-to-child transmission (MTCT) events 
(68, 111, 237, 334).  Independent of the transmission route, pediatric HIV infections progress 
at an accelerated rate and with high mortality.  Without antiretroviral therapy, fewer than 
50% of HIV-infected infants will reach two years of age (237) frequently succumbing to 
secondary infections like TB.   MTCT following oral HIV exposure in breast milk is rare in 
developed countries with readily available testing, antiretroviral (ART) therapy and safe, 
nutritional alternatives to breast milk.  However, in resource-limited regions where one or 
more of these interventions are unavailable, there are high rates of MTCT during 
breastfeeding.  Sub-Saharan Africa carries the greatest burden of the pediatric HIV epidemic 
exacerbated by limited resources with which to prevent new and treat existing infections of 
HIV (304, 382).  
The WHO campaign to eliminate MTCT by 2015 recommends highly active 
antiretroviral therapy (HAART) for expectant mothers throughout pregnancy, ART to the 
infant from a minimum 0-6 weeks and standardized HIV testing when needed (30, 370, 384).  
However, in regions with high rates of pediatric HIV infection, neonates who breastfeed 
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during their first few months have at least six-times greater survival benefit compared to 
formula-fed infants (25, 76), indicating that HIV exposure in breast milk may confer fewer 
overall health risks compared to the nutritional and immune factor deficiencies of 
breastfeeding alternatives.  In response to increased health and survival of breastfed infants, 
some countries have adopted policies that extend the advised infant ART prophylaxis period 
until one-week post-breastfeeding cessation to confer added protection (75).  Although 
proven effective in controlled studies, interventions aimed at reducing oral MTCT of HIV 
have failed in application due to antiretroviral therapy access and infrastructure limitations 
(178, 252, 340, 344), allowing unnecessary vertical HIV transmission events to occur.  Until 
significant improvements can be made to improve access to anti-HIV interventions during 
the pre- and antenatal periods, alternative approaches, such as pediatric HIV vaccine 
development, should be pursued in tandem (148, 149).   
A successful vaccine to prevent MTCT of HIV by breastfeeding likely needs to be 
administered early after birth and with an accelerated immunization regimen. Few pediatric 
vaccines, however, are approved for use at birth.  The live attenuated Mycobacterium bovis 
bacillus Calmette-Guérin (BCG) vaccine to prevent tuberculosis has been demonstrated to 
drive the development of persistent and robust cellular immunity after administration at birth, 
despite the immaturity of the neonate’s immune system; BCG is even used to adjuvant 
immunity to other vaccines administered in tandem (202, 230, 245, 321, 353).  BCG 
vaccination though is not safe for infants that are HIV-infected, immunosuppressed or at high 
risk of HIV infection due to potential bacterial dissemination (126, 127).  We hypothesized 
that vaccination with human-adapted Mtb containing specific deletions in genes necessary for 
replication, immune evasion and virulence could also induce robust and long-lived cellular 
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immune responses in infants and at a magnitude comparable to BCG.  Further, targeted 
attenuations and inclusion of immunodominant epitopes such as ESAT-6 and CFP-10 should 
translate into a safer and more immunogenic vaccine in immunosuppressed infants.  
Additionally, recombinant plasmids with HIV genes can be co-expressed by attenuated Mtb 
to drive the development of dual immunogenicity specific to both HIV and Mtb.  In fact, our 
previous studies in infant rhesus macaques have characterized the ability of attenuated 
recombinant Mtb strains expressing SIV antigens (Mtb-SIV) to safely induce persistent 
cellular and humoral immune responses (151).   
Based on these data, the current study tested whether oral priming with recombinant, 
attenuated M. tuberculosis strains mc26208 and mc26435 expressing SIV Env and Gag 
proteins, respectively, followed by MVA-SIV Env/Gag/Pol or homologous systemic 
boosting could protect infant macaques against oral SIV exposure in breast milk.  To more 
closely recapitulate HIV acquisition by breastfeeding in human infants, we developed and 
applied a repeated low-dose oral SIVmac251 challenge model.  Unexpectedly, however, our 
results showed that vaccinated infant macaques, independent of boost regimen, had a two-
fold higher risk of infection per oral SIVmac251 exposure compared to unvaccinated animals.  
Subsequent analysis revealed that vaccination was associated with increased systemic 
immune activation.  Importantly, tissues indicated as potential SIV entry sites following oral 
exposure to virus in breast milk, namely the lymph nodes draining the oropharynx and 
intestinal tissues, showed elevated frequencies of CCR5-positive CD4+ T cells. 
Despite these intriguing data, a subset of vaccinated infants was able to partially 
control viral replication.  At the time of when oral SIV challenges were started, these animals 
had the highest plasma anti-SIV Env IgG avidities and the highest mucosal anti-SIV Env IgA 
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specific activities in salivary and intestinal secretions.  Thus, plasma IgG and mucosal IgA 
antibodies directed against SIV envelope appeared to be critical in the early control of SIV 
infection.  In addition, these animals were also able to maintain intestinal IL-17-producing T 
cells and experienced a less severe loss of CD4+ T cells in blood, mucosal and lymphatic 
tissues.  Combined, these results suggest that our attenuated Mtb-SIV vaccination strategy 
was able to induce strong antibody response in infant macaques, but that vaccine-induced 
persistent immune activation appeared to promote enhanced infectivity following low-dose 
oral exposure to SIV. 
MATERIALS AND METHODS 
Animals.   
Infant rhesus macaques (Macaca mulatta) were vaginally delivered by colony dams 
from the SIV-negative and type D retrovirus-free colony at the California National Primate 
Research Center (CNPRC, Davis, CA) and were nursery-reared.  Animals were housed 
according to the “Guide for Care and Use of Laboratory Animals” and the standards outlined 
by the American Association for Accreditation of Laboratory Animal Care; all animal 
protocols were reviewed and approved by the University of California, Davis Institutional 
Animal Care and Use Committee prior to study initiation.  Trained animal technicians 
monitored animals daily for any clinical symptoms of TB infection.  Animals were randomly 
assigned to groups and were between 3-7 days of age at the first immunization (Table 4.1, 
“birth/week 0”).  For all vaccinations and blood draws animals were immobilized by 
10mg/kg body weight of ketamine-HCl (Parke-Davis, Morris Plains, NC), injected 
intramuscularly.  Complete blood counts (CBC) were performed on each peripheral blood 
sample by the CNPRC Clinical Laboratory. 
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Vaccine Strains.   
The vaccine strains described in this study were derived from the human-adapted M. 
tuberculosis strain H37Rv as described (151, 152, 268).  Briefly, the parental strain mc26434 
was engineered with panCD and leuCD locus deletions to produce a highly attenuated double 
auxotroph strain unable to express essential nutrients pantothenate and leucine complemented 
by an additional deletion at the secA2 locus, a nonessential secretion system important for 
bacterial growth and host immune response restriction.  Strain mc26434 was further designed 
to co-express full length SIVmac239 i) gag (mc26435), ii) env (mc26208) or iii) pol 
(mc26440) multimer cassette that was codon-optimized for expression by mycobacteria.  SIV 
protein expression was confirmed in vaccine cultures by immunoblot using a V5 antibody-
HRP (data not shown).  Furthermore, we demonstrated recently that strain mc26435, despite 
its low replication capacity, could safely induce persistent M. tuberculosis- and SIV-specific 
T cell and antibody responses in neonatal macaques following oral vaccination at birth (151, 
152). 
 
Immunizations.   
The vaccination regimen is outlined in Table 4.1.  All study animals were evaluated 
in parallel with Group A age-matched mock-vaccinated control animals (n=6).  Infant 
macaques in Group B were orally (p.o.) vaccinated with 109 colony forming units (CFU) 
each of strains mc26435 and mc26208 at birth and boosted intradermally (i.d.) at week 3 with 
a trivalent cocktail of 107 CFU each of strains mc26435, mc26208 and mc26440 (n=6).  A 
second vaccine group, Group C (n=8), was also p.o. immunized with 109 CFU each of strains 
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mc26435 and mc26208 at birth before receiving systemic boosts intramuscularly (i.m., 
divided over 4 injection sites) at weeks 3 and 6 with recombinant modified vaccinia virus 
Ankara expressing SIVmac239 Gag, Pol (MVA vJH4) and MVA-SIV Env (MVA-SIV; each 
at 108 infectious units).  MVA-SIV was kindly provided Dr. B. Moss and Dr. P. Earl (NIAID, 
NIH, Bethesda, MD) (79, 348, 386).  
 
SIV Challenge.   
At week 9, weekly oral, low-dose exposures to virulent SIVmac251 were 
administered under anesthesia to all animals.  Each dose contained 5x103 TCID50 (6/04 stock 
grown in rhesus macaque PBMC; previously described (208)) in a volume of 1ml.  Animals 
were challenged weekly until SIV viral RNA levels in plasma indicated persistent infection 
for a minimum of 3 consecutive timepoints (Table 4.1).  Three animals- #42380 (Group A), 
#42918 (Group B) and #42958 (Group C)- failed to become infected following 10 low-dose 
exposures.  Beginning with the 11th exposure, these three animals received 2x104 TCID50 
SIVmac251 orally, a dose that resulted in persistent viremia in all three animals.  All animals 
were followed for a minimum of 10 weeks post-SIV infection but were euthanized when they 
met criteria established for retrovirus-infected animals (352). 
 
SIV RNA Analysis.  
Longitudinal plasma samples were used for virological analysis by reverse 
transcription polymerase chain reaction (RT-PCR) for SIV RNA as described (54) with a 
limit of detection of about 30 copies/ml.  Data are reported as SIV RNA copy equivalents per 
ml of plasma. 
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Sample Collection and Processing.   
EDTA-anticoagulated blood, saliva and stool were longitudinally collected prior to all 
interventions throughout the study period.  Plasma was isolated from whole blood by 
centrifugation and stored in multiple small aliquots at -80°C.  Saliva was collected using 
Weck-Cel sponges (Windsor Biomedical, Newton, NH), snap frozen immediately after 
collection, and later eluted from sponges as described (24).  When collectable, 2-3 grams of 
fresh stool were added to 0.5% BSA in 5ml sterile PBS supplemented with 1/100 protease 
inhibitor cocktail (Sigma, P8340) and snap-frozen. Fecal extracts were later prepared by 
vortexing the thawed contents until complete homogenization, debris was removed by 
ultracentrifugation and filtration and the extracts were concentrated to roughly 0.5ml using 
an Amicon Ultra-4 50K centrifugal filter unit (Millipore).  At the terminal timepoint, 
bronchoalveolar lavages (BAL) were collected.  Recovered BAL fluid was spun to pellet 
cells; cells were preserved in 10% DMSO in FBS and stored in liquid nitrogen while 
supernatant was aliquoted and stored separately at -80°C.  In addition, cervicovaginal fluid 
(CVF) was collected from female animals at necropsy using Weck-Cel sponges and snap 
frozen at -80°C.   
At the time of euthanasia, multiple tissues, including tonsil, lymph nodes (LN: 
axillary, mesenteric, retropharyngeal and submandibular), spleen, intestinal tissues (colon 
and ileum) and oral mucosal tissues (sublingual mucosa and gingiva) were collected.  Tissues 
were divided into multiple aliquots and i) formalin-fixed/ paraffin-embedded, ii) preserved in 
RNAlater or iii) placed in complete media for fresh tissue analysis as previously described 
(208).  Single cell suspensions for cellular immunogenicity assays were prepared using 
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gradient centrifugation (whole blood, spleen), gentle homogenization (lymph nodes, tonsil) 
or collagenase digestion and gradient centrifugation (mucosal tissues) as described 
previously (208).  
 
SIV-specific Antibody Measurements.   
ELISA was used as previously described (208) to measure anti-SIV IgG and IgA 
antibodies in plasma, saliva and fecal extracts, as well as BAL fluid and CVF secretions from 
the terminal timepoint.  Briefly, plates were coated overnight with 100ng per well of SIV 
Env rgp120mac251 (Immune Technology, New York, NY) or 100µl per well of 1/400 
SIVmac239 viral lysate (Advanced Biotechnologies, Columbia, MD) in PBS.  Antibodies 
against the lysate are termed Gag, Pol-specific because the lysate lacked detectable Env 
protein at the dilution used.  Total IgA or IgG in extracts was similarly measured by ELISA 
(24, 152) using goat anti-monkey IgA (AlphaDiagnostics, San Antonio, TX) or goat anti-
monkey IgG (MP Biomedicals), respectively, to capture Ig.  The following day, plates were 
washed, blocked and loaded with diluted samples and a monkey serum standard containing 
known amounts of Ig, SIV-specific IgA or IgG.  After overnight reaction at 4˚C, the plates 
were developed with biotinylated goat anti-monkey IgA (AlphaDiagnostics) or anti-human 
IgG antibody (Southern Biotech, Birmingham, AL), avidin-labeled peroxidase (Sigma), 
TMB and sulfuric acid stop solution (Sigma). The SIV Env or Gag, Pol-specific IgA or IgG 
antibody concentration measured in each secretion was normalized in accordance with the 
total IgA or IgG concentration.  The specific activity (ng IgA or IgG antibody per µg total 
IgA or IgG) was deemed significant if it was greater than the mean + 3SD of negative 
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controls.  Anti-SIV Env IgA values for assayed mucosal secretions and plasma at select 
timepoints (Table 4.2). 
 
Antigen-specific T Cell Responses.   
1-2x106 mononuclear cells (MNCs) from blood or tissue single cell suspensions were 
added to round-bottom tubes and treated with 0.5 µg purified anti-CD28 and anti-CD49d 
(BD Biosciences, San Jose, CA) in 1ml supplemented RPMI plus 1) no stimulant, 2) PMA (5 
ng/ml)/Ionomycin (500 ng/ml) (Sigma, St. Louis, MO) 3) 10 µg SIVmac239 p27 Gag peptide 
pool (peptides 5243-5299, AIDS Research and Reference Reagent Program #6204), 4) 10 µg 
SIVmac239 Env peptide pool (peptides 6708-6719, AIDS Research and Reference Reagent 
Program #6883), 5) 25 µg purified protein derivative (PPD) (Tuberculin PPD, Statens Serum 
Institute, Copenhagen, Denmark) or 6) 25 µg recombinant Antigen 85b protein reference 
standard (Ag85b) (NR-14870, NIH Biodefense and Emerging Infections Research Resources 
Repository, NIAID, NIH).  Appropriate antigen concentrations were determined by prior 
titration experiments using known antigen-reactive donor cells.  Due to small infant sample 
volumes and corresponding low cell counts, priority for SIV- and M. tuberculosis-specific T 
cell responses was given to SIV Gag and to PPD antigens, respectively.  
Stimulated cells were incubated at 37°C and 5% CO2 for one hour, then treated with 
1x Brefeldin A (eBioscience, San Diego, CA) and incubated for an additional five hours.  
Cells were then washed and stained using a fixable live/dead discriminator (Invitrogen) and 
antibodies against rhesus macaque CD3, CD4, CD45RA, CCR7 IL-2, TNF-α, IFN-γ, 
granzyme B (all BD Biosciences, San Jose, CA) and IL-17A (eBioscience).  Cells were fixed 
in 1% paraformaldehyde and stored in the dark at 4°C until flow cytometric analysis.  When 
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cell counts permitted, unstimulated MNC suspensions were stained with antibodies against 
markers for T cell activation (CD69), T cell exhaustion (PD-1) and intestinal/mucosal 
homing (CD103).  In a retrospective analysis, expression of activation markers was measured 
on cryopreserved PBMC and tissue cell suspensions from historical animals (151, 152).  
Cells were quickly thawed at 37°C, immediately washed 2x in 37°C AIM-V media 
supplemented only with antibiotics and allowed to rest overnight at 37°C/5% CO2.  Cells 
were rewashed the next day prior to staining for CCR5, CD69 and Ki-67 (all BD 
Biosciences).  All staining panels were evaluated using fluorescence-minus-one (FMO) 
controls and assays were run in parallel with isotype-specific controls when cell counts 
permitted.  Samples were acquired on a LSRII instrument and analyzed using FlowJo 
software with Boolean gating (TreeStar, Ashland, OR).  Antigen-specific T cell responses are 
represented as the percentage of positive cells within the CD4+ or CD8+ T cell populations 
after correction for background responses in unstimulated controls. 
 
Histopathology and Immunohistochemistry.   
Formalin-fixed, paraffin-embedded tissues were cut into 5µm serial sections and 
H&E stained to evaluate SIV-induced pathology by a nonhuman primate pathologist blinded 
with respect to treatment groups.  A tissue disease score scale was used to measure disease 
severity: 0- no indications of SIV-associated pathology, 1- mild disease, multifocal, 2- mild 
disease, diffuse, 3- moderate disease, multifocal, 4- moderate disease, diffuse, 5- severe 
disease with mild T cell depletion and 6- severe disease with massive T cell depletion. 
Similarly, tissues were evaluated in a blinded manner for TB-indicative pathologies. 
In addition, colon sections were analyzed by immunohistochemistry to quantitate the 
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frequencies of CD3 (BD Biosciences) and IL-17 (eBioscience) single- and double-positive T 
cells.  Sections were treated with Target Retrieval Solution pH 6.1 (Dako, Carpinteria, CA), 
blocked using Background Snipper (Biocare Medical, Concord, CA) and incubated with 
either rabbit anti-CD3 (1:100, Thermo Scientific, Rockford, IL) or mouse anti-IL-17 (1:50, 
eBioscience) antibodies at 4°C overnight.  Sections were stained using secondary fluorescent 
antibodies (goat anti-rabbit IgG Alexa Fluor 488 and goat anti-mouse IgG Alexa Fluor 594 at 
1:200, Invitrogen, Grand Island, NY), counterstained with DAPI and coverslipped with 
Prolong Gold Antifade (Invitrogen) before imaging with a Leica DMI6000B inverted 
microscope equipped with rotating excitation filter wheel, photometrics HQ2 camera and 
high performance imaging software (Simple PCI, Hamamatsu Corporation, Sewickley, PA). 
Image processing and analysis was carried out using Adobe Photoshop (Adobe Systems Inc., 
San Jose, CA) and Image J program (Wayne Rasband, NIH). 
 
M. tuberculosis Isolation.  
Multiple tissues were snap frozen and stored at -80°C until shipment to the National 
Animal Disease Center (USDA-ARS, Ames, IA) to recover viable mycobacteria  using three 
different culture methods: i) the Fast Indicator Tube test (MGIT), ii) Middlebrook 7H12 
media (BacTec), and iii) Solid Culture media to determine colony forming units (CFU). 
Because vaccine strains are auxotrophic, pantothenate and leucine supplemented media was 
used to ensure maximal bacterial recovery. A tissue was considered positive if one of three 
culture methods yielded mycobacterial growth. M. tuberculosis positive control samples were 
run in parallel for quality assurance.  The analysis was performed in a blinded manner.   
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MHC Class I Allelic Typing.  
Snap frozen splenic cell pellets were typed for common MHC Class I variants Mamu-
A*01, A*02, A*08, A*11, B*01, B*03, B*04, B*08, B*17, chosen for their possible roles in 
restricting SIV infection and/or control of viremia (Table 4.1).  Genotyping was completed 
by the MHC Genotyping Service at the University of Miami Miller School of Medicine and 
the established methods have been previously reported(104, 156, 195, 390). 
 
Statistical Analysis.   
Data were analyzed using GraphPad Prism and InStat software (GraphPad Software, 
Inc., La Jolla, CA) with assistance provided by the UNC CFAR Biostatistics Core.  The 
probabilities of infection per SIV exposure for mock or vaccinated animals were used to 
calculate the relative risk of infection per exposure and data were plotted using a Kaplan 
Meier plot and analyzed by logrank test.  Nonparametric one-way ANOVA (Kruskal-Wallis 
test) was used to compare three or more groups and nonparametric, two-tailed Mann-
Whitney tests using 95% confidence intervals were used to compare data between only two 
groups.  Whisker plots always represent 10-90% confidence with the central line at the 
sample mean.  Error bars indicate the standard error of the mean (SEM) except in the weight 
plot in which error bars indicate standard deviation (SD).  Correlations between IgA in 
various compartments (plasma, saliva, intestine) were analyzed to determine the effect of 
antibody transudation versus mucosal antibody production.  P values ≤0.05 were considered 
statistically significant. 
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RESULTS 
Vaccine efficacy following repeated low-dose oral SIV challenge  
Previous challenge studies have exposed animals to relatively high doses of SIV to 
ensure infection but such dosing may not recapitulate the lower viral loads found in breast 
milk.  Although HIV viral loads in human breast milk are highly variable by individual and 
can fluctuate considerably throughout the breastfeeding period, the establishment of a low-
dose challenge model was important to more closely mimic HIV transmission in human 
infants by breast milk (388).  In the current study, 5x103 TCID50 SIVmac251 was administered 
once weekly by the oral route to establish a repeated low-dose oral SIV infection model in 
infant rhesus macaques.   
Among the mock-vaccinated animals (Group A), two infants became infected 
following a single exposure and one animal each became infected after two, five, and seven 
exposures (Table 4.1 and Figure 4.1A).  The animal (#42409) that became persistently 
infected after 7 low-dose oral challenges experienced transient plasma viremia at two 
consecutive time points with plasma SIV RNA levels of 550 and 380 copies/ml, followed by 
undetectable viral RNA at the subsequent time point.  To ensure the validity of this finding, a 
second plasma sample from the same time point was tested and confirmed to be SIV RNA 
negative by PCR.  Peak viremia in mock-vaccinated animals ranged from 7.3x106 - 3.4x108 
viral RNA copies/ml plasma and viral replication was maintained at high levels in all animals 
(Figure 4.1A).  One mock-vaccinated animal (#42380) was SIV-negative by PCR after 10 
low-dose challenges (Table 4.1).  Beginning at week 11, subsequent challenge of this infant 
with a higher dose of SIVmac251 (2x104 TCID50) resulted in detectable plasma viremia 
(Figure 4.1A). Similarly, one animal each in Group B and Group C remained uninfected after 
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10 low-dose oral SIV exposures; these animals also became infected after the high dose 
challenge (Table 4.1; Figure 4.1B-C).   
Although statistically not significant, vaccinated animals in Group B and Group C 
appeared to require fewer low-dose oral SIV exposures for persistent infection (Figure).  In 
fact, four of the six Group B animals became infected after a single exposure and one 
additional animal after two exposures. Similarly, five and two of eight Group C animals 
required only one or two low-dose SIV challenges, respectively, to become systemically 
infected (Figure 4.1B-C).  Only 50% of Group A animals, but 83% (Group B) and 88% 
(Group C) of vaccinated animals required ≤2 challenges for transmission.  Using the number 
of challenges required for SIV transmission (Table 4.1), the probability of SIV infection per 
exposure was 0.23 for Group A animals compared to 0.45 in the combined vaccinated 
animals of Group B and Group C, resulting in a transmission risk per exposure of 1.96 in 
vaccinated compared to unvaccinated infant macaques.  Thus, with the caveat of small group 
sizes, vaccination nearly doubled the risk of infection with each challenge dose compared to 
the unvaccinated animals (Figure 4.1D).  No difference in SIV transmission efficiency was 
observed between Group B and C animals, suggesting that the vaccine prime, and not the 
vaccine boost, was primarily associated with the observed enhanced infectivity.   
Once infected, the peak viremia in animals primed and homologously boosted with 
attenuated M. tuberculosis-SIV (Group B) was comparable to mock-vaccinated animals 
(2.4x106 - 1.4x108) (Figure 4.1A-B).  In Group C animals that were heterologously boosted 
with MVA-SIV, two distinct patterns of plasma viremia were observed (Group C) (Figure 
4.1C).  While five animals had peak viremia (1.6x107 – 4.3x107) that were indistinguishable 
from Group A and Group B animals, three animals (#42924, #42944 and #42958) had lower 
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peak viremia (6.5x105  - 7.8x106 copies/ml) and continued to show reduced or controlled 
levels of virus in plasma.  A similar trend was observed in the one Group B animal (#42918, 
peak viremia 2.4x106) that required a high dose oral SIV challenge to establish infection.  
The differences in virus levels at peak viremia and at viral set point (week 20) were 
significant between the ‘controller’ and ‘non-controller’ Group C animals with p= 0.0154 
and p= 0.0357, respectively (Figure 4C). 
Thus, overall, 16 of the 20 animals in Groups A, B and C maintained high plasma 
SIV levels throughout the study, as is typically observed for SIV-infected infant macaques.  
To determine whether partial control of SIV replication could be maintained in the four 
vaccinated animals with reduced peak viremia, we followed these animals for 34 weeks. 
Although viremia was consistently reduced until week eight post-infection, animal #42958 
lost control of viral replication after eight weeks and plasma viremia began to increase 
(Figure 4.1C). Two animals, #42944 and #42918, maintained reduced viremia and plasma 
viremia steadily decreased in animal #42924 (Figure 4.1B-C).  Therefore, the attenuated M. 
tuberculosis-SIV vaccination and boost regimen may have provided some benefit resulting in 
reduced SIV replication in a subset of animals.   
Resistance to low-dose SIV challenge was not associated with protective MHC alleles 
(Table 4.1).  Because animals were assigned to treatment groups within three days of birth, 
MHC allele genotypes could not be evaluated prior to group assignment.  However, 
retrospective MHC genotyping revealed no bias towards protective MHC alleles in animals 
with partial control of SIV replication or in animals requiring high-dose challenges for 
infection.  For example, animals #42376 and #42380 (Group A) both expressed the 
‘protective’ variants A*01 and B*17, but animal #42376 became infected following a single 
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SIV dose while animal #42380 remained uninfected after 10 low-dose challenges and 
required a high dose to become infected.  The Group B animal #42918 that required a high-
dose SIV challenge expressed the protective A*01 allele but also the non-protective B*01 
allele.  Trim5α genotyping was not performed because a recent study demonstrated that 
mucosal SIVmac251 challenges are not influenced by the Trim5α alleles (86). 
 
Clinical markers of disease progression and vaccine safety 
The four vaccinated infant macaques that were able to partially control viremia 
(termed ‘controllers’), animals #42918 (Group B), #42924, #42944 and #42958 (all Group C), 
showed normal weight gain and did not experience significant CD4+ T cell loss in peripheral 
blood (Figure 4.2A).  In contrast, animals unable to suppress viral replication plateaued or 
even lost weight with time (p=0.0017 by one-way ANOVA, Figure 4.2A) and showed CD4+ 
T cell loss in peripheral blood and in multiple tissues, shown longitudinally in PBMC and for 
mesenteric LN and submandibular LN (Figure 4.2B-D).  This difference in peripheral blood 
CD4+ T cell frequencies was statistically significant at 7-8 weeks after SIV infection and also 
at necropsy (p= 0.0095 and 0.028, respectively, by t-test).  
Consistent with this finding, immunohistochemical analysis of colon tissues from 
controller and non-controller vaccinated animals confirmed that animals with better control 
of virus replication had CD3+ T cell numbers comparable to those of age-matched SIV-
uninfected animals, whereas T cell frequencies were significantly lower in non-controller 
animals (Figure 4.3A).  Furthermore, we observed greater numbers of IL-17+ and CD3+IL-
17+ dual positive cells in the colons of controller animals (quantified in Figure 4.3B).  IL-17 
positive CD4+ T cells have been suggested to be primary target cells of HIV and SIV because 
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terminal differentiation via the Th17 lineage may promote higher CCR5 and α4β7 integrin 
expression (11, 34, 43, 47, 51, 80, 213).  In the current study, the Group C animals with 
controlled viremia had significantly higher frequencies of CD3+IL-17+ cells in colon tissues 
than animals with uncontrolled high viremia (p=0.0014 by one-way ANOVA; Figure 4.3B).  
The SIV-induced depletion of IL-17-producing T cells contributes to the loss of intestinal 
mucosal integrity, a phenotype commonly associated with HIV/SIV infection.  IL-17A, a 
proinflammatory cytokine important for sustaining the integrity of the mucosal barrier, 
commonly declines after HIV/SIV infection (23, 24) but is maintained in long-term non-
progressor patients (292).   
Breakdown of mucosal surface immunity could lead to the establishment of intestinal 
opportunistic infections.  Histopathological analyses of the ileum and colon tissues indicated 
that mock vaccinated and non-controller animals experienced more opportunistic infections, 
as was evident by cryptosporidiosis.  While 17% of mock vaccinated, 60% of Group B non-
controllers and 100% of Group C non-controllers were positive for cryptosporidiosis in the 
ileum, this infection was not detected in controller animals.  The difference in the occurrence 
of opportunistic infections per group was statistically significant only for the ileum (one-way 
ANOVA p= 0.0107) (Figure 4.4A), but similar data were observed in the colon. 
Overall SIV-induced pathology though was comparable across all groups. In 
lymphoid tissues, SIV-induced pathology ranged from mild hyperplasia to severe disease 
with massive T cell depletion (Figure 4.4B).  The average tissue pathology disease score in 
both vaccinated groups was lower than the average score in mock vaccinated animals, but 
this difference did not reach statistical significance unless the Group B/C non-controller 
animals were combined prior to comparison to mock-vaccinated animals (p=0.02 by two-
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tailed t-test), because two animals in Group B had low tissue disease scores despite high 
plasma viremia,.  Therefore, we could not detect an apparent correlation between partial 
control of plasma virus replication and overall tissue pathology.  
Consistent with our previous data in healthy and SIV-infected infant macaques 
vaccinated with mc26435, no pathology indicative of tuberculosis disease was detectable 
(152).  Furthermore, viable mycobacteria could not be recovered from the axillary LN, 
mesenteric LN, spleen, lung and bronchial LN tissues tested (data not shown).  Importantly, 
we have now demonstrated that attenuated Mtb-SIV vaccines can be safely administered to 
neonates prior to SIV infection, as shown in the current study, and after SIV infection (152) 
with no risk of adverse safety concerns.   
 
Maintenance of vaccine-induced Mtb-specific T cell responses despite SIV infection 
M. tuberculosis-specific immune responses were longitudinally measured by cytokine 
production following in vitro stimulation with M. tuberculosis purified protein derivative 
(PPD).  Vaccination at birth with strains mc26208 and mc26435 induced M. tuberculosis-
specific T cell responses in peripheral blood (Figure 4.5), which persisted despite SIV-
induced immunosuppression and could be detected in multiple tissues at the time of necropsy 
(data not shown).  The magnitudes of M. tuberculosis-specific T cell responses were 
consistent with previous studies (151).  Interestingly, i.d. boosting with strains mc26208, 
mc26435 and mc26440 in Group B animals did not appear to increase M. tuberculosis-
specific T cell responses compared to Group C animals that were not boosted for M. 
tuberculosis responses (Figure 4.5).  
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Role of SIV-specific antibodies in the control of SIV replication 
Consistent with previous results, Groups B and C animals in the current study 
developed SIV Gag, Pol- plasma IgG and IgA antibodies in response to vaccination (151).  In 
addition, Group C animals developed plasma anti-SIV Env IgG and IgA antibodies, and 
intestinal and salivary anti-SIV Env IgA in saliva. The induction of the SIV Env-specific 
antibody response appeared to be a result of the MVA-SIV boosts only, because Group B 
animals did not develop SIV Env-specific antibodies prior to SIV infection despite being 
primed and boosted with SIV Env expressing mc26208.  Thus, although vaccine cultures 
were tested in mice, it will be necessary to optimize strain mc26208 for in vivo production 
and secretion of SIV Env in macaques.  
Group C plasma SIV Env-specific IgG antibodies at the time of challenge (week 9) 
were associated with reduced viremia in the first few weeks post-SIV infection (Figure 4.6A).  
Thus, the controller animals in Group C had higher SIV Env-specific plasma IgG antibody 
levels than non-controller Group C animals and these inversely correlated with viremia at 2 
and 4 weeks post-infection (p= 0.0368 and p= 0.0154, respectively).  In addition, a trend of 
higher SIV Env-specific plasma IgG antibody avidities at the time of challenge inversely 
correlated with plasma viremia during the first few weeks after SIV infection (Figure 4.6B).  
Although greater concentrations and higher avidities of anti-Env plasma IgG were 
insufficient to prevent SIV infection, these antibodies might have helped to control early viral 
replication, as suggested by reduced peak viremia and viral set points (see Figure 4.1C).  
Antibody function was insufficient to prevent SIV acquisition likely because avidity indices 
were relatively low (Figure 4.6B) and we could not detect antibody-dependent cell-mediated 
virus inhibition (ADCVI) (data not shown). 
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Plasma IgA antibodies specific for SIV Env or SIV Gag, Pol were detectable only in 
Group C animals at the time of challenge.  The plasma SIV-specific IgA antibody levels 
differed significantly between Group A, Group B, and Group C animals (p< 0.0001 for anti-
SIV Env IgA and p= 0.0018 for anti-SIV Gag, Pol IgA; Figure 4.7AB), but there was no 
difference in IgA responses between controller and non-controller animals.  Unlike the 
inverse correlations between plasma SIV-specific IgG antibodies and viremia, SIV Env-
specific plasma IgA antibodies were not associated with reduced viremia (data not shown).  
In contrast to plasma IgA antibodies, the salivary and intestinal SIV Env-specific IgA levels 
at the time of challenge inversely correlated with plasma peak viremia in Group C animals 
(p= 0.0154 and r2= -0.8333; Figure 4.7C; p= 0.0028 and r2= -0.9636; Figure 4.7D).  There 
was a strong positive correlation between SIV Env-specific salivary and intestinal IgA (p= 
0.0123 and r2= 0.8895), but not with plasma SIV Env IgA (p= 0.911) indicating that the SIV 
Env IgA antibodies in saliva and intestine were produced locally and were not due to 
transudation.  Inverse correlations of peak viremia with i) plasma IgG and ii) mucosal IgA 
are indicative of a contribution from both systemic and mucosal antibodies for partial control 
of SIV replication in the controller animals.   
To assess the capacity of infant macaques to secrete antibodies at mucosal surfaces 
distal to the site of vaccination, we measured SIV Env-specific IgA in CVF of female 
animals and in BAL of all vaccinated animals at the terminal timepoint only (Table 4.2).  
BAL samples could not be acquired at the time of challenge for risk of introducing 
microabrasions in the oral mucosa.  The single measurement of SIV Env IgA at the terminal 
time point did not allow any conclusion regarding their induction by vaccination or in 
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response to SIV infection, and whether these antibodies played any role in controlling SIV 
replication.  
 
Vaccine-induced T cell responses in blood and tissues 
Consistent with our previous results (151), all vaccinated animals in Groups B and C 
had detectable SIV Gag-specific T cell responses in peripheral blood prior to SIV infection, 
but responses were not consistently detected at all time points and varied in magnitude (data 
not shown).  Although there might have been an anamnestic SIV Gag-specific CD8+ T cell 
response in Group B and Group C animals compared to mock-vaccinated infants at 2 weeks 
post-oral SIV challenge, there was no correlation between peak viremia and SIV-specific 
CD4+ T cell (Spearman r= -0.0707; p= 0.7671) or CD8+ T cell responses (Spearman r= 
0.0425; p= 0.8587).   
After SIV infection and at the time of necropsy, differentiation between vaccine-
induced and SIV infection-induced SIV-specific T cell responses was not possible.  In 
general, oral priming with mc26435 and mc26208 followed by systemic MVA-SIV boosts 
induced comparable SIV-specific T cell responses in tissues in SIV-infected and SIV-naïve 
infant macaques (151) (data not shown).  There were no statistically significant differences in 
SIV-specific T cell responses in tissues between vaccine Groups B and C animals. 
Interestingly though, vaccinated animals showed greater frequencies of granzyme B-
expressing peripheral blood CD8+ T cells at the time of challenge compared to mock-
vaccinated animals and this enhancement was maintained post-SIV infection (p ≤0.002; 
Figure 4.8A).  This finding is noteworthy because infants generally show reduced production 
of cytotoxic granules and immature effector cell degranulation compared to adults (22, 271).  
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The enhanced cytotoxic function was confirmed by a more pronounced granzyme B release 
following in vitro SIV Gag stimulation in the peripheral blood CD8+ T cells of vaccinated 
animals compared to Group A animals (Figure 4.8B), but due to the large variations across 
animals, differences in SIV-specific CTL function were only statistically significant at week 
13 (p= 0.0094; Figure 4.8B).  In addition to improved granule production and degranulation 
by SIV-specific CD8+ T cells, vaccinated animals had higher frequencies of T cells 
expressing the mucosal homing marker CD103 (Figure 4.9).  Enhanced mucosal tissue 
trafficking by effector cell populations following vaccination could translate into improved 
effector cell function against pathogens encountered at mucosal sites.  In fact, among the 
vaccinated animals, controller animals had significantly higher CD103-positive CD4+ and 
CD8+ T cells in intestinal tissues, and this trend, although not significant, was conserved in 
mesenteric LN, submandibular LN and tonsil T cell populations. 
Cytotoxic function of CD8+ T cells in vaccinated animals might have been negatively 
impacted by enhanced frequencies of PD-1-positive CD4+ and CD8+ T cells in vaccinated 
compared to mock animals at the time of challenge (Figure 4.10A).  Interestingly, 
frequencies of PD-1-positive peripheral blood CD4+ T cells of controller animals were 
similar to mock animals and less similar to vaccinated non-controller animals.  Increased 
populations of exhausted PD-1-expressing T cells in the periphery of vaccinated animals 
prompted us to ask whether T cell exhaustion was associated with vaccine-induced immune 
activation.  Indeed, more peripheral blood CD4+ T cells from vaccinated compared to 
unvaccinated animals expressed the activation marker CD69 (Figure 4.10B).  At the time of 
necropsy, T cells from the mock-vaccinated animals expressed greater frequencies of CD69 
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in all tissues to vaccinated animals (Figure 4.11B), but PD-1 positive T cells were still higher 
in vaccinated animals (Figure 4.11A).   
We, therefore, further evaluated non-specific immune activation in peripheral blood 
and tissues at the time of necropsy, and attempted to determine whether specific immune 
activation profiles would stratify with better control of viremia.  We already alluded to the 
fact that controller animals showed better preservation of IL-17 producing T cells in the 
colon (Figure 4.3).  Ex vivo analysis of basal IL-17 production by T cells of blood and tissue 
showed that controller animals seemed to produce predominantly IL-17 whereas non-
controller animals showed higher frequencies of TNF-α-positive T cells.  In fact, the ratio of 
TNF-α:IL-17 producing T cells was low in controller animals, indicating conserved 
expression of IL-17 and low levels of pro-inflammatory TNF-α production (Figure 4.12).  In 
contrast, vaccinated animals unable to control viral replication exhibited higher ratios of 
TNF-α:IL-17 producing T cells (Figure 4.12).  In every tissue analyzed, controller animals 
had the lowest ratios, followed by mock-vaccinated Group A animals, then vaccinated non-
controller animals exhibited the highest ratios of TNF-α:IL-17-producing T cells (Figure 
4.12).  Differences in the ratio of TNF-α:IL-17 producing T cells were statistically significant 
by one-way ANOVA, except for the submandibular CD4+ T cells (p values ranged from 
0.0063-0.3695 for CD4+ and 0.0110-0.0373 for CD8+ T cells).   
In addition to the distinct TNF-α:IL-17 ratios, the expression of the single cytokines 
IL-2, IFN-γ, IL-17, and TNF-α in unstimulated, ex vivo T cells at the terminal time point was 
characteristic between the four controller animals and the other vaccinated animals (shown 
for PBMC and colon in Figures 4.13 and 4.14, respectively).  To determine the vaccine effect 
on basal cytokine expression, historical samples from SIV-naïve, orally mc26435 primed /IM 
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MVA-SIV boosted infant macaques were evaluated for basal cytokine expression profiles at 
the terminal timepoint (151).  The data show that controller animals exhibited cytokine 
expression profiles resembling those observed in vaccinated, SIV-naïve animals (Table 4.3, 
Group D).  Again, most noteworthy was the robust colon IL-17 production by SIV-naïve and 
controller animals compared to Group B and C non-controller animals (Figure 4.14).  
Without additional studies, it is difficult to speculate if these expression patterns would 
change over time, but the ‘snapshot’ of total nonspecific cytokine production suggests that 
even partial control of viremia limited SIV-induced immune activation and prevented the loss 
of IL-17-expressing T cells in the colon of controller animals. 
 
Potential immune correlates of vaccine-induced enhanced SIV acquisition 
The observed high background cytokine responses in unstimulated cell suspensions at 
necropsy suggested unresolved immune activation, a hallmark of SIV infection.  However, as 
we had observed enhanced infectivity in the vaccinated animals compared to unvaccinated 
controls, we retrospectively tested for immune activation at the time of challenge.  Indeed, 
quantification of basal cytokine production in PBMC T cell populations at the time of 
challenge revealed that vaccinated animals had significantly greater numbers of both CD4+ 
and CD8+ T cells actively producing IL-2, TNF-α and IFN-γ (Figure 4.15).  In contrast, 
mock-vaccinated animals showed very low amounts of background activation by comparison.  
Only IL-17-expressing T cell frequencies did not differ between vaccinated and unvaccinated 
animals (Figure 4.15).  The non-specific production of IL-2, TNF-α and IFN-γ was indicative 
of an environment promoting CD4+ T cell activation, which could potentially translate into 
enhanced HIV/SIV infectivity (56, 83, 341).  This assumption was further strengthened by 
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the fact that T cells expressing the activation marker CD69 were also found at higher 
frequencies in vaccinated compared to unvaccinated animals at the time of challenge (Figure 
4.16).  Non-specific T cell activation was observed independent of the boost regimen in both 
Group B and Group C animals suggesting that it was predominantly the common mc26435 
and mc26208 prime that was responsible for the immune activation phenotype.  Likely as a 
result of persistent immune activation, PD-1-expressing T cell populations were more 
pronounced in vaccinated animals at the time of challenge (Figure 4.16). 
To confirm vaccine-induced T cell activation in the absence of SIV-induced immune 
activation, we retrospectively measured markers of T cell activation in SIV-naïve, orally 
mc26435 primed /systemically MVA-SIV boosted infant macaques. These samples were 
derived from animals of our previous immunization studies (151, 152) and their 
immunization regimens are listed in Table 4.3. Group D most closely mirrored the 
immunization schedule used in the current SIV challenge study with oral mc26435 priming 
and MVA-SIV boosting.  Group F animals were also orally primed with strain mc26435 but 
were boosted instead using adenovirus 5-SIV (Ad5-SIV).  Finally, to test for route-specific 
effects of neonatal Mtb-SIV vaccination, Group G animals received intradermal priming with 
strain mc26435 and an Ad5-SIV boost.  
Indeed, CD69- and Ki67-positive peripheral blood T cell frequencies were higher in 
all vaccinated compared to unvaccinated historical animals (Figure 4.17A).  Importantly, 
increased activated CD4+ T cell frequencies were also observed in retropharyngeal LN and 
colon of all SIV-naïve, mc26435-vaccinated animals compared to mock-vaccinated animals 
(Figure 4.17CD). Although only shown for CD4+ T cells, CD69 and Ki-67 expression 
patterns were duplicated in CD8+ T cell populations.  To test whether this vaccine-induced 
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immune activation resulted in increased target cell frequencies for SIV, we additionally 
quantitated CCR5-positive CD4+ T cell frequencies in SIV-naïve, orally mc26435-primed 
infant macaques.  Indeed, significantly greater frequencies of CD4+ T cells in the peripheral 
blood, retropharyngeal LN and colon expressed the HIV/SIV co-receptor and activation 
marker CCR5 (Figure 4.17).  It should be reiterated that elevated CCR5-positive T cell 
populations were observed in all mc26435 primed infant macaques independent of the route 
of mc26435 priming and the type of boost.  The samples used for this retrospective analysis 
match the prime in the current study, but are representative of a later time point post-prime as 
these animals were followed for 16-18 weeks.  However, we rationalized that any immune 
activation induced by the prime should decrease over time. Therefore, the fact that we could 
detect immune activation at these later time points, similar to activation observed in the 
current study at 9 weeks post-prime, even further underlines the potential importance of our 
findings of increased target cell availability at the time of oral SIV challenge, and indicates 
the need for more thorough analysis of immune activation after vaccination.  
DISCUSSION 
Previous work characterized the development of a novel combination vaccine using 
attenuated Mtb engineered to co-express SIV antigens to elicit dual immunogenicity against 
both SIV and Mtb.  We demonstrated that oral and intradermal vaccination with strain 
mc26435 at birth was safe in healthy and immunosuppressed, SIV-infected neonatal 
macaques (152), and that vaccination could elicit SIV and Mtb cellular and humoral immune 
responses (151).  This current study aimed to evaluate the ability of the vaccination regimen 
to protect against repeated low-dose oral SIV challenge.   
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Two unexpected intriguing results were obtained.  First, the majority of vaccinated 
animals required fewer low-dose oral SIV exposures to become infected than the mock-
vaccinated animals, and this enhanced risk of oral SIV infection was associated with vaccine-
induced immune activation.  Secondly, although vaccination did not protect animals from 
SIV acquisition, a subset of vaccinated animals developed more robust SIV Env-specific IgA 
in mucosal secretions and higher avidity Env-specific plasma IgG antibodies that correlated 
with reduced viremia.  In addition, we observed persistent immune activation in vaccinated 
animals, independent of the boost regimen, suggesting that vaccination may have enhanced 
infectivity. 
Consistent with our previous studies, the oral mc26435 prime/IM MVA-SIV boost 
regimen induced both SIV and Mtb-specific immune responses (151).  The addition of strain 
mc26208 to the vaccine prime to improve immune response breadth did not appear to affect 
either immunogenicity or efficacy in the current study.  The Group B animals, despite 
priming and homologous boosting with Mtb strains individually expressing SIV Gag, Pol and 
Env, made little-to-no SIV Env- or Gag, Pol-specific plasma IgG.  In fact, the lack of plasma 
SIV Env-specific antibody responses in Group B suggests that the SIV Env insert was 
unstable and not expressed at sufficient levels to induce immune responses in infant 
macaques despite in vivo expression in mice (Ranganathan et al., manuscript in preparation).  
Therefore, improved Mtb-SIV vaccine strains optimized for persistent in vivo SIV antigen 
expression need to be developed for forthcoming macaque studies as antibody responses are 
critical for the prevention of HIV acquisition in humans (82). 
Our results showed that the avidity of SIV Env specific plasma IgG antibodies at the 
time of challenge inversely correlated with reduced peak viremia. Thus, animals with lower 
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peak viremia and reduced viremia throughout the course of infection had developed SIV Env 
specific IgG antibodies with higher avidity than vaccinated animals with persistently high 
viremia.  Interestingly, HIV Env specific plasma IgG antibodies were an immune correlate 
identified in the RV144 HIV vaccine trial (110, 188, 398) and although could not prevent 
HIV acquisition through neutralization, instead likely prevented infection through a 
mechanism of infectious virion capture or ADCVI (193).  The SIV Env IgG antibodies 
elicited in the current infant study did not mediate ADCVI (data not shown).  Furthermore, 
the avidity indices of the plasma SIV Env-specific IgG antibodies were relatively low when 
compared to SIV challenge studies with partial protection in adult macaques in which avidity 
indices were 3 to 4-fold higher (272, 397).  Thus, while our vaccine regimen was able to 
induce SIV Env-specific antibodies, their functional capacity was severely limited.  
Additionally, the current vaccine regimen was not designed to elicit neutralizing antibodies.   
It remains unclear what vaccine characteristics are important for driving the 
development of antibodies that are broadly-neutralizing, have high binding avidities and are 
persistently secreted at mucosal surfaces.  Antibody development early during acute HIV 
infection appears to be a dynamic process, one that we are just beginning to understand.  For 
example, Yates et al. recently reported that early after HIV infection, gp41, and not gp120, 
anti-Env IgA is produced both systemically and mucosally, but that gp41 antibodies were 
rapidly depleted due to ablated production and a short half-life (391).  The ontogeny of 
antigen-specific mucosal B cell responses, whether induced following vaccination or 
infection, remains uncharacterized, but its understanding is essential for prior to designing 
immunogens to induce the development of robust, broadly-neutralizing and/or high-avidity 
mucosal antibodies.  
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Interestingly, our study revealed that SIV Env specific mucosal IgA antibodies in 
saliva and intestinal secretions contributed to reduced viremia in some animals.  The 
controller animals showed the highest mucosal SIV Env specific IgA activities at the time of 
challenge, and these higher IgA antibodies in mucosal secretions were correlated with 
reduced peak viremia and continued reduced virus replication compared to non-controller 
animals.  In contrast, plasma IgA antibodies did not appear to influence virus acquisition or 
replication.  This data supports the conclusion that mucosal IgA might be critical in 
controlling early virus replication at mucosal entry sites (20, 230).  It should be pointed out 
that the specific SIV Env IgA activities induced by the current vaccination regimen have not 
been achieved by other pediatric SIV vaccination regimen (217, 360).  In fact, with the 
caveat of different immunogens and study parameters, the specific activities of anti-Env 
mucosal IgA antibodies was comparable to measurements in SIV vaccine study adults (272, 
397, (82, 110, 188, 193, 333, 398).  This is a remarkable finding because infants produce 
very little IgA at birth and due to limited VDJ rearrangements, epitope recognition by IgA 
antibodies is highly restricted (121, 303, 327).  Improved understanding of the vaccine 
components best able to enhance the development of antibody breadth, avidity and secretion 
at mucosal surfaces will dramatically improve the protective efficacy of vaccines against 
mucosally transmitted pathogens. It will be important to more thoroughly understand the 
implications of age-dependent antibody development for vaccine design.  Our results here 
provide proof-of-concept that mucosal IgA can be robustly induced by infant vaccination.  
The induction of mucosal immunity by our vaccine regimen was further support by 
the presence of increased frequencies of CD103 positive T cells in lymph nodes draining the 
oropharynx and in intestinal tissues.  Although we could not detect any apparent correlations 
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between SIV-specific T cell responses and control of viremia, vaccinated animals did show 
improved cytotoxic T cell function. CTL responses have been identified as an important 
mechanism of HIV/SIV control (96, 117-119, 194, 247, 279, 305).  In infants, CTLs/ are 
generally reduced compared to the older individuals (6, 311, 312), and thus it is essential that 
a pediatric HIV vaccine will induce cytotoxic effector function.  Despite improved granzyme 
expression and release in vaccinated animals in the current study, the percentage of granzyme 
B expressing CD8+ T cells in vaccinees never even reached levels typically observed in 
healthy unvaccinated adult macaques (Jensen, unpublished data).  Together these data 
demonstrate that the oral Mtb-SIV prime/IM MVA-SIV boost regimen was able to 
effectively induce SIV-specific T and B cell responses at mucosal and systemic sites, but SIV 
immunity lacked sufficient functional competence to prevent oral SIV acquisition.   
In fact, despite partial control of viremia in a subset of animals, the risk of oral SIV 
acquisition per low-dose oral exposure seemed to be enhanced in the vaccinated compared to 
the unvaccinated infant macaques.  This finding was indicative of potential vaccine-induced 
immune activation that could have promoted SIV infection.  Mycobacteria are known to have 
intrinsic adjuvant activity, best illustrated by their inclusion in Freund’s complete adjuvant.  
A recent study reported that human infants vaccinated with BCG at birth showed peripheral 
immune activation that peaked about 10 weeks post-vaccination (320).  This time point is 
similar to when repeated low-dose oral SIV exposures were started at 9 weeks after Mtb-SIV 
priming.  However, in contrast to BCG, the double auxotroph Mtb strains used in this study 
are considered replication-incompetent within a mammalian system.  In fact, we could never 
recover live mycobacteria from tissues in supplemented cultures.  Still, we clearly 
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demonstrated that activated peripheral blood T cells occurred at greater frequencies in 
vaccinated than unvaccinated animals at the time of oral SIV challenge initiation.   
Importantly, using historic samples from animals in our previous Mtb-SIV 
immunization studies, we could document that vaccination induced an increase in CCR5-
positive CD4+ T cells and CD14+ monocytes in blood and tissues.  Thus, vaccination with 
Mtb-SIV resulted in increased frequencies of potential SIV target cells at anatomic sites 
indicated as entry sites following oral SIV exposure (208, 360, 361, 389).  If our findings can 
be repeated and confirmed, they would have major global health implications.  It should be 
clearly stated that unvaccinated and vaccinated animals did not statistically differ in their 
relative risk of SIV infection per oral exposure, but we observed a trend towards enhanced 
risk of SIV infection in vaccinated infant macaques and could associate increased infection 
risk with vaccine-induced persistent immune activation and increased SIV target cell 
availability. South African researchers have previously voiced concern about early BCG 
vaccination and its potential for immune activation that could promote HIV acquisition (126, 
127, 150).  Conclusive studies, however, are missing.  
The goal of a successful pediatric HIV vaccine to prevent breast milk transmission of 
HIV relies on striking the delicate balance between vaccine-induced immune activation to 
prompt the development of innate immune responses to effectively prime adaptive immune 
responses without inducing an inflammatory milieu that can persist in the infant host and 
accelerate HIV acquisition.  This will be a difficult and challenging task, requiring a deep 
understanding of pediatric immune development, the kinetics of immune responses to 
mycobacterial vaccine strains, the optimization of relevant immunogens and the mechanisms 
of vaccine-induce immune activation.  Further, improved quantitative read-outs to evaluate 
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the potential of T and B cell responses effective for preventing HIV/SIV acquisition or limit 
virus replication will positively impact immunogen optimization.  Our data provide insight 
into the complex mechanisms underlying successful vaccine design. We do not consider the 
observed lack of vaccine efficacy a defeat, but instead as a stepping stone that will guide us 
in our future pediatric HIV vaccine design. 
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TABLES 
 
 
 
Table 4.1.  Study outline and challenge schedule.  a Animals not expressing alleles in this 
list are intentionally blank. b Vaccine doses for strains mc26435, mc26208 and mc26440 were 
109 CFU and 108 IU for MVA-SIV boosts.  p.o. = oral, i.d.= intradermal, i.m.= 
intramuscular. c Grey boxes indicate the duration of weekly challenges by animal.  Positive 
viremia for three consecutive time points was required to confirm systemic infection. 
Increased SIV challenge doses (2x104 TCID50) were administered weekly after 10 low-dose 
exposures failed to result in infection; high-dose challenges are indicated in dark grey boxes.  
The inherent lag between bleed date and viral PCR data resulted in additional challenges that 
were not required for infection, which is why some higher dose challenges occur after 
determined infection age. d Denotes the number of weekly oral challenges required for 
persistent SIV infection as determined by viral RNA in plasma.  A (+) indicates timepoint 
one week prior to the first detection of virus and is the probable time of infection. e Transient 
viremia was observed in animal #42409 for two consecutive weeks (13 and 14, indicated by 
hashing), followed by undetectable viral RNA in plasma at week 15; at week 16, SIV RNA 
was observed in plasma. 
 
 
 
 
 
!
Group Animal Sex MHC Class Ia 
Immunization (Route)b SIV Challenge (5x103 TCID50, PO)
c Nx 
(wk) Week 0 3 6 9 10 11 12 13 14 15 16 17 18 19 20 21 No.d 
                      
A 
42376 F A*01, A*11, B*17, B*29 
PBS        
(PO) 
PBS        
(ID + IM) 
PBS         
(IM) 
+             1 21 
42380 F A*01, A*11, B*17, B*29         +  c c  9c 27 
42386 F   +            2 22 
42388 F A*11, B*17, B*29     +         5 25 
42409 M A*08       +       7e 25 
42434 M  +             1 21 
                      
B 
42903 F  
mc26435     
+    
mc26208 
(PO) 
mc26435    
+       
mc26208    
+       
mc26440    
(ID) 
 
+             1 21 
42918 M A*01, B*01           +c c c 11d 34 
42925 F  +             1 21 
42943 M A*01  +            2 21 
42947 F A*01 +             1 20 
42950 M  +             1 20 
                      
C 
42899 F A*01, B*01 
mc26435     
+     
mc26208 
(PO) 
MVA-SIV 
(IM) 
MVA-SIV 
(IM) 
+             1 20 
42906 F B*01 +             1 22 
42924 F A*01  +            2 34 
42929 F A*02, B*01  +            2 20 
42937 M A*11, B*01, B*08 +             1 21 
42944 M   +            2 33 
42949 M A*11 +             1 21 
42958 F       +     c c  6d 33 
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Table 4.2  Anti-Env IgA in plasma and mucosal secretions.  Plasma, saliva and stool 
samples were collected longitudinally from study animals when possible; cervicovaginal 
fluid (CVF, female animals only) and bronchoalveolar lavage (BAL) samples were collected 
only at terminal timepoints.  Intestine IgA values are secretory antibody produced within the 
intestinal mucosa. Note that plasma samples are recorded as total anti-Env IgA (ng/ml) while 
mucosal antibodies are reported as specific activities (anti-Env IgA/total IgA; ng/µg). NT*= 
not tested, sample tube broke; NT (grey box)= not tested because animals were male; ND= 
not detected or sample was not significantly greater than assay background (concentrations ≥ 
background +3SD). 
 
 
 
 
 
 
Intestine CVF BAL
Group Animal, Sex Week,6 Week,9 Week,9 Nx Week,9 Nx Nx
42376 F ND ND ND 8.10 ND 1.00 0.57
42380 F ND ND ND 74.40 NT* 76.45 19.34
42386 F ND ND ND 281.80 ND 5.25 35.72
42388 F ND ND ND 29.10 ND 2.52 27.97
42409 M ND ND ND 6.30 ND NT 20.48
42434 M ND ND ND 6.50 ND NT 0.00
42903 F ND ND ND 10.80 ND 0.84 0.00
42918 M ND ND ND 29.20 ND NT 110.06
42925 F ND ND ND 92.60 ND 19.34 125.04
42943 M ND ND ND 10.10 ND NT 34.93
42947 F ND ND ND 14.70 ND 4.82 13.00
42949 M ND ND ND 4.50 ND NT 0.00
42899 F 31.7 381.0 35.07 24.10 NT* 83.20 46.30
42906 F 76.7 471.6 39.25 7.80 ND 3.74 41.39
42924 F 66.8 415.1 70.70 28.00 11.22 0.00 44.04
42929 F 132.5 1335.8 29.69 29.70 ND 78.79 1226.33
42937 M 99.1 224.1 12.79 23.20 ND NT 78.42
42944 M 18.8 278.6 34.69 7.00 7.45 NT 9.51
42947 M 45.8 259.6 10.46 30.10 ND NT 30.33
42958 F 346.8 3626.3 97.80 41.80 8.26 13.25 34.09
Specific1Activities1(ng1Env1IgA/ug1total1IgA)IgA1(ng/ml)
C
Plasma Saliva
A
B
	   116 
 
 
Table 4.3  Study outline for retrospective CCR5 quantification experiment in SIV-naïve, 
vaccinated animals.  Vaccination schedule from historical animals orally primed with strain 
mc26435 at birth and heterologously boosted with either MVA-SIV (Group D) or Ad5-SIV 
(Groups F/G).  Frozen PBMC, retropharyngeal lymph node and colon cell suspensions from 
animals in Groups D-H were assayed for the presence of activation markers CCR5, CD69 
and Ki-67 on T cell and monocyte populations to evaluate possible vaccine-induced 
activation in the absence of SIV infection.  Responses from mock animals (Groups E and H) 
are reported together as ‘mock’.  
 
 
Group Group Size 
Vaccination 
Necropsy 
Age (wks) Prime Boost 
Strain Dose Route Age (wks) Strain Dose Route Age (wks) 
D 8 mc26435 109 CFU PO 0 MVA-SIV 108 PFU IM 3 + 6 18 
E 3 mock  PO 0 mock  IM 3 + 6 16 
           
F 6 mc26435 109 CFU PO 0 Ad5-SIV 9x109 PFU IM 3 16 
G 6 mc26435 106 CFU ID 0 Ad5-SIV 9x109 PFU IM 3 16 
H 4 mock  PO / ID 0 mock  IM 3 16 !
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FIGURES 
 
Figure 4.1.   Viral Loads.  SIV Gag RNA copies per ml plasma were quantified at weekly 
intervals beginning at week 10 of age, with the assay detection threshold reported to be 
around  ≤30 copies/ml.  A) Viral loads in mock-vaccinated Group A animals, B) viral loads 
in homologously-boosted Group B animals and C) viral loads in heterologously-boosted 
Group C animals.  Arrows indicate when weekly low-dose challenges were initiated for all 
groups, and vaccination interventions for animals in Groups B and C.  In Group B (n=1) and 
Group C (n=3), four animals exhibited reduced peak viremia and were able to 
maintain/reduce viral loads compared to other cohort animals.  Due to their ability to 
reduce/control viremia, these four animals were followed longer and are represented in open 
symbols.  The grey bars are arbitrary and are included only as points of reference.  D) 
Kaplan-Meier plot comparing the number of SIV exposures required for animals in either the 
mock-vaccinated Group A (dashed line, n=6) or mc26435-vaccinated Groups B and C (solid 
line, n=14).  While not statistically significant by log-rank (p=0.22), there was a trend 
towards enhanced infectivity in the vaccinated animals compared to mocks, with a relative 
infectivity rate of 1.96 following vaccination. 
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Figure 4.2.  Clinical parameters of SIV infection. A)  Failure to maintain and/or gain 
weight was observed in vaccinated animals that were unable to control SIV viremia (Groups 
B (green) and C (blue)).  No weight gain in Groups B and C was observed in contrast to 
Group A animals (yellow), which continued to gain appropriately until the final two weeks.  
The four vaccinated Controller animals (#42918, #42924, #42944 and #42958, purple) 
showed excellent weight gain throughout.  Weights at week 22 were statistically different 
between Groups B/C and Group A/Controller animals by one-way ANOVA (p=0.0017).  
Error bars indicate the standard deviation within each cohort and weight differences were 
normalized for each animal to birth weight (kg).  The dashed grey line represents the mean of 
healthy male and female nursery-reared neonatal macaques (n=69-2083, depending on age).  
B) CD4+ T cells as a percentage of total CD3+ T cells in peripheral blood by age.  Although 
there is no difference in cell frequencies at the time challenges were initiated (week 9), 
Controller animals exhibit less CD4+ T cell loss with time compared to non-controller 
animals in peripheral blood (p=0.0095 and p=0.028 at weeks 7/8 post-infection and at 
necropsy, respectively).  Controller animals also exhibited a trend of reduced CD4+ T cell 
loss in specific tissues at terminal timepoints (illustrated for C) mesenteric LN and D) 
submandibular LN) compared to non-controller animals in Groups B and C.   
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Figure 4.3.  Immunohistochemical analysis of IL-17 expression and T cell maintenance 
in colon.  A)  IHC was used to evaluate the integrity of the intestinal mucosa (colon) 
following SIV infection.  Controller animals in Group C (#42924, #42944 and #42958) 
exhibited improved CD3 T cell maintenance, IL-17 expression and CD3+IL-17+ co-
expression in colon tissues at the time of necropsy.  White arrows highlight CD3+ (green), 
IL-17+ (red) and CD3+IL-17+ dual-positive events (yellow). DAPI (blue); scale 100 µm.  B) 
Expression patterns from five fields per tissue sample were quantified and plotted to 
enumerate T cell loss in colon tissue following infection with SIV.  Total CD3+ events (left 
plot), IL-17+ cells (center plot) and dual positive cells (right plot) are shown for i) SIV-naïve 
unvaccinated infants (SIV-), ii) SIV-infected unvaccinated infants (SIV+), iii) SIV-infected, 
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vaccinated non-controller infants (Non-Ctrl) and individually for the 3 controller infants in 
Group C iv) #42924, v) #42944 and vi) #42958.  Controller animals exhibited significantly 
more CD3 T cells and IL-17+ cells compared to non-controllers and SIV+ unvaccinated 
animals, although not statistically more than healthy unvaccinated controls by one-way 
ANOVA (p ≤0.0001).  Two animals (#42924 and #42958) exhibited greater frequencies of 
CD3+IL-17+ dual cells compared to non-controllers but dual-positive cells in the colon of 
#42944 were similar to non-controllers, making this difference not statistically significant.  
The controller animals did, however, have greater frequencies of dual positive cells 
compared to SIV-infected unvaccinated animals.  Box and whisker plots indicate median 
values and standard deviation.  K-W= Kruskal-Wallis one-way ANOVA test, with p values 
reported by plot. 
 
 
 
 
 
 
	   121 
 
Figure 4.4.  SIV-induced opportunistic infections and pathology. A) The presence of 
opportunistic infections (primarily cryptosporidium) in the ileum and colon tissues is 
enhanced in vaccinated animals unable to control viremia (Groups B an C) compared to 
mock-vaccinated (Group A) and Controller animals.  There was no indication of 
opportunistic infections in either the ileum or colon of Controller animals.  All Group C 
animals, 3 of 5 Group B animals and 1 of 6 Group A animals had indications of secondary 
infections in the ileum (one-way ANOVA p=0.0107) and 2 of 5 Group C animals, 2 of 5 
Group B animals and no Group A animals had indications of secondary infections in the 
colon (not significant).  B) Blinded pathology reports generated across multiple individually-
scored tissues (axillary LN, bronchial LN, mesenteric LN, retropharyngeal LN, 
submandibular LN, ileum, colon, lung and spleen) were compiled for a total disease score 
(TDS) mean value to indicate the degree of SIV-induced disease at the time of necropsy.  
Scoring rubric: 0- no indications of SIV-associated pathology; 1- mild disease, multifocal; 2- 
mild disease, diffuse; 3- moderate disease, multifocal; 4- moderate disease, diffuse; 5- severe 
disease with mild T cell depletion; 6- severe disease with massive T cell depletion.	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Figure 4.5.  Mtb-specific T cell responses are maintained despite SIV infection.  A) 
Longitudinal CD4 (left) and CD8 (right) peripheral T cell responses in direct response to 
stimulation with purified protein derivative (PPD) in a representative Group B animal (‘non-
controller’; top panels) and Group C animal (‘controller’; bottom panels).  Combinations of 
single and polyfuctional cytokine responses are represented by the legend at right. Responses 
have previously been corrected for background expression in unstimulated cultures. 
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Figure 4.6.  Env-specific IgG antibodies inversely correlate with peak viremia.  A) The 
viral loads (VL) at 2 (left panel) and 4 (right panel) weeks post-infection (PI) for Group C 
animals inversely correlates with the plasma concentrations of anti-gp140 Env IgG binding 
antibody at week 9.  Both viral load and IgG concentrations have been log-transformed.  The 
correlation is statistically significant and strengthens between weeks 2 and 4 post-infection 
(p= 0.0368 and p= 0.0154, respectively).  B) Area-under-the-curve (AUC) calculations 
represented for 0-3 weeks PI (left panel) and 0-5 weeks PI (right panel) against anti-gp140 
Env IgG avidity index values measured in plasma at week 9.  Although not significant, there 
is a trend towards inverse correlations between avidity and viremia; controller animals (open 
symbols) produce antibodies with the strongest avidity. Dark symbols are non-controller 
animals and open symbols are controllers.  Symbols correspond to those used per animal in 
Figure 4.1C for viral load. 
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Figure 4.7  Plasma and mucosal SIV-specific IgA.  A) Plasma anti-Env IgA and B) anti-
Gag, Pol IgA (ng/ml) antibodies are improved in Group C animals following MVA-SIV 
boosting at week 6.  Despite the ability of vaccine strains mc26435, mc26208 and mc26440 to 
express SIV Gag, Env and Pol respectively, Group B animals produce little to no SIV-
specific plasma IgA.  Group C animals all make anti-SIV IgA antibodies in plasma and 
concentrations are enhanced by week 9 following MVA-SIV boosting.  There is not a 
statistically significant difference in the plasma IgA levels for Group C animals depending on 
ability to control viremia.  C) Salivary and D) intestinally-secreted Env-specific IgA specific 
activities plotted against peak viremia (2 weeks PI). There was a significant, inverse 
correlation between peak viremia and salivary and intestinally secreted anti-Env mucosal 
IgA. Dark symbols are non-controller animals and open symbols are controllers.  Symbols 
correspond to those used per animal in Figure 4.1C for viral load. 
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Figure 4.8.  Granzyme B expression longitudinally in CD8+ T cells.  A) The percentage of 
unstimulated peripheral CD8+ T cells expressing granzyme B over time developed more 
quickly in vaccinated animals (Groups B/C) than in mock-vaccinated animals (Group A), 
beginning by week 6.  There is no statistical difference observed between Groups B, C or 
Controller animals in the ability of their CD8+ T cells to produce granzyme B.  The improved 
production of granzyme B following vaccination seemed unaffected by which boost was 
administered.  B) The percentage of granzyme B loss in CD8+ T cells following in vitro SIV 
Gag stimulation of PBMC.  There is a trend of improved antigen-specific CTL degranulation 
in vaccinated animals (Groups B/C) compared to mock-vaccinated animals (Group A), 
although this difference only reached statistical significance at weeks 11 and 13.  
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Figure 4.9.  Expression of mucosal homing marker CD103 improved with vaccination.  
Vaccination improved CD4+ (top panel) and CD8+ (bottom panel) T cell expression of 
mucosal homing marker CD103.  Improved expression of CD103 did not appear to correlate 
with the vaccination boost regimen (not shown) but expression was accentuated in Controller 
animals (purple) compared to non-controller Group B/C (blue) and mock vaccinated (Group 
A) animals.  Group-specific expression differences were significant in the PBMC, colon and 
ileum (CD4+ T cells) and in the colon and ileum (CD8+ T cells), although several tissues 
exhibit a trend of vaccination-induced improved CD103 expression.  PBMC= peripheral 
blood mononuclear cells; CO= colon; IL= ileum; MES= mesenteric LN; SUBM= 
submandibular LN. 
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Figure 4.10.  Expression of T cell activation and exhaustion markers in PBMC.  A)  PD-
1 expression by PBMC CD4+ (top left panel) and CD8+ (bottom left panel) T cells. B) CD69 
expression by PBMC CD4+ (top right panel) and CD8+ (bottom right panel) T cells was also 
enhanced in vaccinated.  One-way ANOVA Kruskal-Walis p values are indicated per plot.	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Figure 4.11.  Expression of T cell activation and exhaustion markers in tissues.  A) 
Tissue expression of PD-1 is distinctly inversed compared to CD69 with the highest levels of 
PD-1 expression in the tissues of Controller animals.  Levels of PD-1 expression were 
statistically significant between groups in CD4+ (upper left panel) T cells in the colon, ileum 
and tonsil and in CD8+ (lower left panel) T cells in the ileum, mesenteric LN, submandibular 
LN and tonsil.  In all tissues evaluated, the Controller animals had more expression of PD-1 
in both T cell populations.  Non-controller animals (Groups B/C) expressed similar levels of 
PD-1 compared to mock-vaccinated (Group A) animals, except in the ileum and tonsil, where 
non-controllers tended to express more PD-1.  B) In contrast to the PBMC at week 9, CD69 
expression at the terminal timepoint was enhanced in the tissues of mock-vaccinated (Group 
A, yellow) animals in both the CD4+ (top right panel) and the CD8+ (lower right panel) T cell 
populations.  Statistical significance was observed in the PBMC, mesenteric LN and 
submandibular LN in the CD4+ T cells and in all tissues in the CD8+ T cells.  No significant 
difference was observed between Groups B/C (blue) and Controller (purple) animals, 
although in every tissue evaluated, the Controller animals have equivalent or less CD69 
expression compared to non-controller animals. All nonparametric one-way ANOVA tests 
were significant and p values are indicated below the legend.  PBMC= peripheral blood 
mononuclear cells, CO= colon; IL= ileum; MES= mesenteric LN; SUBM= submandibular 
LN.  Error bars indicate the SEM per group and p<0.05. 
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Figure 4.12.  Ratio of TNF-α:IL-17 in unstimulated peripheral blood and tissue T cell 
populations.  The ratio of TNF-α:IL-17 expressed basally in unstimulated CD4+ (left) and 
CD8+ (right) T cell populations in A) PBMC, B) submandibular LN (SUBM LN) and C) 
mesenteric LN (MES LN) cell suspensions from the terminal timepoint separated by mock-
vaccinated (Group A, yellow), homologously-boosted vaccinated (Group B, green), MVA-
SIV-boosted vaccinated (Group C, blue) and Controller (Group B/C, purple) animals.  One-
way ANOVA test significances are indicated within each plot.  Only three tissues are 
represented but the trend of higher ratios was conserved in both T cell populations in all 
tissues assayed. 	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Figure 4.13.  Basal cytokine production by PBMC T cells at the terminal timepoint.  
PBMC CD4+ (upper) and CD8+ (lower) T cell cytokine production in the absence of 
stimulation.  The inherent cytokine production profiles sort according to vaccination group 
with the profile of the controller animals matching more similarly to SIV-naïve samples 
(Group D).  Note that only single cytokine-positive events are represented for clarity.   
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Figure 4.14.  Basal cytokine production by colon T cells at the terminal timepoint.  
Colon CD4+ (upper) and CD8+ (lower) T cell cytokine production in the absence of 
stimulation.  The inherent cytokine production profiles sort according to vaccination group 
with the profile of the controller animals matching more similarly to SIV-naïve samples 
(Group D).  Note that only single cytokine-positive events are represented for clarity.   
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Figure 4.15.  Basal cytokine production by T cells at the time of challenge.  Increased 
immune activation following vaccination resulted in significantly greater levels of IL-2, 
TNF-α and IFN-γ in both CD4+ (left) and CD8+ (right) unstimulated T cells from blood at the 
time challenges were started (week 9).  No differences were observed between groups in 
basal production of IL-17 in either T cell population.  Mock vaccinated (Group A), 
homologously-boosted (Group B) and MVA-SIV-boosted (Group C) animals are indicated 
by A, B and C, respectively.  Kruskal-Wallis nonparametric one-way ANOVA significance 
values are reported at	  the base of the figure for each cytokine. 
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Figure 4.16.  Vaccine-induced T cell activation and exhaustion at the time of challenge.   
Expression analysis of PD-1 and CD69 by PBMC T cells at week 9, the time of challenge.  
Greater frequencies of T cells from vaccinated animals, independent of whether they would 
later control viremia, expressed markers of activation and exhaustion compared to 
unvaccinated animals.  One-way ANOVA indicated statistical significance for all 
comparisons except CD69 expression in CD4+ T cells; p values are indicated above. 
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Figure 4.17.  Vaccine-induced upregulation of CCR5 on T cells and monocytes.  CCR5, 
CD69 and Ki-67 expression was assayed on cryopreserved cell suspensions of PBMC, 
retropharyngeal LN and colon from mc26435-vaccinated, SIV-naïve infant macaques (See 
Table 4.3 for Group assignments).  Expression of CCR5 and T cell activation markers was 
enhanced in vaccinated animals in A) PBMC CD4+ T cells (terminal timepoint), B) PBMC 
CD14+ monocytes (terminal timepoint), C) Retropharyngeal LN CD4+ T cells and D) Colon 
CD4+ T cells.  In every tissue, CCR5 expression was significantly enhanced after vaccination.  
Activation does not appear to be dependent on vaccine boost or route.  Despite mc26435 
vaccination at birth, activation does not resolve prior to necropsy at age 16-18 weeks.  
Nonparametric one-way ANOVA Kruskal-Wallis p values are reported under each figure; 
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two-tailed t-tests between treatment groups that were statistically significant are reported as 
asterisks (* p< 0.05, ** p< 0.01).  Even in comparisons without statistical significance, trends 
of enhanced CCR5 and T cell activation marker expression are consistent with significant 
findings.  E) Vaccination significantly expands the frequency of CCR5+ cells; the observed 
enhancement of CCR5 cannot be attributed to greater CCR5 expression on cells already 
expressing the receptor as calculated by quantifying the mean receptor expression per cell.  
There is no difference of CCR5 receptor density means across T cell and monocyte 
populations in different tissues.  Although not statistically significant, there is a slight trend 
towards more CCR5 receptor density per cell in the mock animals (Groups F/H), not the 
vaccinated animals.  Ki-67 was not evaluated in monocytes.  Expression levels from Groups 
F and H mock-vaccinated animals were pooled for this analysis; there was no difference 
between Group F and H expression levels.  Group D= mc26435 (i.d.) prime + Ad5-SIV 
boost; Group E= mc26435 (p.o.) prime + Ad5-SIV boost; Group G= mc26435 (p.o.) prime + 
MVA-SIV boost. i.d.= intradermal; p.o.= oral. 
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CHAPTER 5:  DISCUSSION 
INTRODUCTION 
Infants represent an immunologically vulnerable population with an immature ability 
to recognize and respond to antigenic stimulation.  A complete understanding of the 
mechanisms of immune ontogeny from birth through childhood remain uncharacterized, 
although studies in human cord blood, cross-sectional analyses in human infants and 
translational experiments using nonhuman primates at multiple ages have helped elucidate 
age-dependent changes in immune modulation.  A comprehensive evaluation of the 
maturation of immune function with age will improve the quality of protective interventions 
targeted for young individuals.   
The immaturity of the infant immune system also leads to increased disease 
susceptibility and morbidity following infections.  Compared to an adult able to quickly and 
easily resolve an infection, infants progress more rapidly to severe symptoms and may not be 
able to clear an infection without medical intervention.  For example, neonatal 
Mycobacterium tuberculosis infections can manifest with different pathologies than the same 
infection in adult.  Infant Mtb infections can rapidly progress to miliary or meningeal TB, 
leading to complications in cognitive development, organ failure and death.   
The administration of the BCG vaccine at birth offers protection for infants against 
more extensive TB disease.  BCG, used ubiquitously around the globe to vaccinate >90% of 
newborns, can induce persistent cellular immunity via the Th1 lineage even in the immature 
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immune environment of the infant.  BCG-derived protection, however, wanes dramatically, 
offering little protection against adult pulmonary TB infections.  Further, the live attenuated 
nature of the vaccine is not safe for use in immunosuppressed individuals, such as those 
infected with HIV and the WHO advises against BCG vaccination for infants infected with 
HIV or at high risk for infection.  HIV infection in the infant, like Mtb, rapidly progresses to 
immunosuppression and commonly co-infections with Mtb.  A safe and effective dual 
vaccine is urgently needed. 
Borrowing effective components from BCG but improving elements of safety and 
immune persistence, a highly attenuated human M. tuberculosis strain may have improved 
immunogenicity in infants.  Serial passaging of M. bovis attenuated the bacteria for 
pathogenicity and virulence, but also resulted in loss of immunodominant epitopes important 
for persistent immunity.  Intentional deletions of genes important for replication, immune 
evasion and virulence in Mtb, with the insertion of a recombinant plasmid expressing 
conserved HIV genes could produce a dually immunogenic, safe infant vaccine to protect 
against both Mtb and HIV infections.   
FINDINGS AND IMPLICATIONS 
My central dissertation objective was to test the safety, immunogenicity and 
protective capacity of novel attenuated Mycobacterium tuberculosis strains that expressed 
SIV genes in SIV-naïve and SIV-infected, immunosuppressed rhesus macaques.  Three Mtb 
strains with variable levels of attenuation were compared for safety and immunogenicity; two 
strains were further manipulated to co-express SIV genes in a first attempt to induce the 
development of dually immunogenic infant vaccine.   
Because our vaccine strains share similarities with BCG, it was necessary to first 
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confirm complete safety in immunocompromised infants.  First, we rigorously evaluated the 
safety of the live attenuated Mtb immunogens by vaccinating healthy and SIV-infected, 
immunosuppressed neonates.  Animals were followed for up to six months and safety was 
evaluated using outgrowth cultures supplemented for auxotroph growth, acid-fast staining, 
gross pathology and clinical parameters.  Safety varied according to the severity of the 
bacterial attenuations, with the least attenuated strain (mc25157) causing bacterial 
dissemination by six weeks of age.  Strain mc26020 was moderately attenuated for bacterial 
replication and was mostly safe with a couple of bacilli detectable in only the draining LN of 
one SIV+ animal.  The strain most attenuated for both bacterial replication, immune evasion 
and virulence (mc26435) was next tested and found to be completely safe, even in 
immunocompromised, SIV-infected neonatal macaques.  Strain mc26435 has been evaluated 
most thoroughly of the three strains, tested for safety in healthy (n=20) and SIV-infected 
(n=17) infant macaques with no bacterial dissemination by outgrowth assays, acid-fast bacilli 
in tissues, pathological indications of Mtb infection or clinical symptoms.  Further, vaccine 
safety was independent of whether vaccination occurred before SIV infection. 
To optimize vaccine immunogenicity, we compared i) route of inoculation, ii) boost 
regimens and iii) prime-boost intervals.  Although now infants are intradermally immunized, 
BCG was initially administered orally.  Because we aimed to develop a combination vaccine 
to protect infants against vertical transmission of HIV in breast milk, we hypothesized that an 
oral vaccine would confer the most robust immune response at the site of vaccination and 
sought to compare intradermal and oral vaccination routes for immunogenicity.  We 
observed that animals orally and intradermally vaccinated with strain mc26435 were capable 
of inducing SIV- and Mtb-specific cellular and humoral immune responses.  Interestingly, we 
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did observe some small differences in antibody development depending on the route of 
vaccination.  Intradermally vaccinated animals induced a more robust anti-PSTS1 Mtb 
plasma IgG antibody response compared to orally vaccinated animals (Figure 5.1); anti-
PSTS1 responses also inversely correlated with bacterial attenuation in that the least 
attenuated strains induced the highest magnitude of antibodies.   
While these differences appear trivial in that we observed vaccination route-specific 
differences for one anti-Mtb antibody, the more imperative point is that differences in 
vaccine regimens, such as route of administration, can have important implications in the 
quality and magnitude of immunity elicited in response to vaccination. It is essential to 
consider both how the vaccinated individual responds to the immunogen (e.g. age-associated 
immune immaturity or immunosuppression) and the type of immune response best able to 
induce sterilizing protection.  For example, although there is still much unknown about 
immunomodulation during Mtb infection, TB is primarily mediated by cellular immunity and 
not by antibodies.  An Mtb vaccine candidate, even if capable of inducing stellar humoral 
responses, likely will offer little protection. 
Next, we evaluated the effect of a two or three-week prime-boost interval on the 
development of dual immunogenicity.  While an effective infant vaccine must work quickly 
to protect against exposure of HIV in breast milk, boosting the immune response too soon 
after priming can result in activation induced cell death (AICD).  AICD, Fas-FasL mediated 
programmed cellular death, occurs in instances of repeated exposure at specific T/B cell 
receptors as a mechanism of eliminating autoreactive T/B cells.  However, AICD can also 
occur following secondary exposure to an immunogen for which the primary immune 
response has not yet completed clonal deletion.  In the presence of expanded antigen-specific 
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lymphocytes, a vaccine boost can cause accelerated loss of the specific cells and essentially 
negate the effect of vaccination.  Because we used live attenuated vaccine strains, we 
hypothesized that boosting three weeks post-prime might serve to avoid AICD.  Although we 
did not directly test for AICD, we did not observe any differences in immune development in 
animals boosted at two weeks compared to three weeks, however, animals were only 
followed for a short time and differences may not have been apparent at that early timepoint.   
 After the route of vaccination and the prime-boost interval comparisons offered no 
distinct differences, we next aimed to elucidate the effect of different boost immunogens on 
the quality of the immune response.  Because we primed animals with an attenuated 
bacterium expressing exogenous viral proteins, we hypothesized that the SIV-specific 
responses would likely require a systemic boost.  Two replication-attenuated recombinant 
viral vectors expressing SIV Gag, Pol and Env were evaluated.  Because of its excellent 
ability to prompt the development of the cellular immune response, we tested adenovirus 5-
SIV (Ad5-SIV) following either oral or intradermal priming with mc26435.  Secondly, 
animals orally primed with mc26435 were boosted with modified vaccinia Ankara-SIV 
(MVA-SIV).  In both cohorts, we observe the development and persistence of SIV-specific 
cellular and humoral immune responses; subsequent studies used the MVA-SIV due to the 
challenges associated with Ad5 seroprevalence within the human population.  Following 
MVA-SIV boosting, although there is not typically a distinct boost effect in the SIV-specific 
T cell response, we do observe improvements to the antibody responses. 
 After confirming safety and working to optimize vaccination regimens, we opted to 
evaluate the ability of oral mc26435 vaccination at birth plus MVA-SIV boosting at weeks 3 
and 6 to protect infant macaques against low-dose oral SIV challenges, mimicking human 
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HIV exposure in breast milk.  In addition, a group of animals was also homologously boosted 
with AMtb strains for comparison.   
The study responses were surprising and early viral load data suggested even possible 
vaccination-induced hyperinfectivity because the vaccinated animals were becoming infected 
more quickly than unvaccinated animals.  Indeed, following statistical analysis, we observed 
a 1.96 relative infectivity rate, indicating that vaccination resulted in a nearly 2x 
enhancement in infection.  Despite animals developing and maintaining cellular and antibody 
responses as expected according to previous immunogenicity optimization studies, 
vaccination was accelerating infection.   
To attempt to explain the mechanism by which this was occurring, we performed 
several evaluations.  First, I observed that animals had high cytokine expression background 
in unstimulated samples.  Next, the high background stratified into either TNF-α-producing 
or IL-17-producing.  After comparing the ratios of TNF-α:IL-17, it became apparent that 
vaccinated animals were more likely to have TNF-α expression while the unvaccinated 
animals predominantly produced IL-17.  Interestingly, the trend of increased cytokine 
production was apparent also at the time the SIV challenges were initiated, and not just in the 
tissues at the terminal timepoint.  Although only blood samples were available at week 9 
(start of challenges), TNF-α, IL-2 and IFN- γ were all significantly upregulated in vaccinated 
animals compared to mock-vaccinated controls.  The cytokine production was not specific to 
the vaccine regimen, suggesting that the initial AMtb prime at birth induced similar levels of 
activation in both vaccine groups. Further, despite subsequent SIV infection, increased 
cytokine production was maintained until the terminal timepoints, with vaccinated animals 
expressing greater levels of cytokines in unstimulated tissue cell suspensions as well.   
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To ensure that the observed non-specific immune activation was indeed an artifact of 
vaccination, I evaluated the levels of activation in cryopreserved cell suspensions from SIV-
naïve animals in previous studies with Mtb strains mc26020, mc25157 and mc26435.  In 
vaccinated animals, independent of the vaccine strain, T cells and monocytes were 
significantly more activated compared to mock vaccinated samples from the same study 
cohorts.  Importantly, the CD4+ T cells in retropharyngeal lymph node and colon, and CD4+ 
and CD14+ monocytes in PBMC cell suspensions expressed significantly more CCR5 
compared to unvaccinated animals.  The increase in CCR5 was actually an increase in the 
number of cells expressing the receptor and not just more CCR5 expression on cells already 
the receptor.  Because HIV preferentially infects activated CD4+ cells, most commonly using 
CCR5 as its co-receptor, the implications of increased CCR5 expression in an already 
activated cytokine milieu are incredibly problematic for infants with daily exposures to HIV.  
Although vaccination conferred no protection against the acquisition of SIV, we did 
observe a strong, inverse correlation with the production of anti-Env mucosal IgA from both 
saliva and the intestine with peak viremia.  Three of eight animals in Group C experienced 
reduced peak viremia, reduced viral set points and were able to control/reduce viremia for 
several months after infection.  While other Group C animals experienced enhanced SIV-
induced pathologies and opportunistic infections, the three ‘Controller’ animals had none, 
despite having been SIV-infected for about 10 weeks longer.  Further, the Controller animals 
maintained T cell populations and IL-17 production at the intestinal mucosa better than non-
controllers.  While sterilizing protection is the gold standard of vaccine development, an 
intervention that could delay disease progression, maintain the integrity of the mucosal 
surface and limit immune cell depletion could prove beneficial, particularly in resource-
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limited regions with limited access to ART. 
REMAIMING QUESTIONS AND FUTURE DIRECTIONS 
The experiments outlined as part of this dissertation have contributed to our 
understanding of infant immune development, antigen-specific responses to vaccination and 
the inability of attenuated Mtb vaccine strain mc26435 to protect against oral SIV challenge 
using our vaccination regimen in Chapter 4.  The study questions below aim to specifically 
address the known limitations of completed experiments and help guide the further 
refinement of attenuated Mtb vaccine candidates as dual immunogens.   
 
VACCINE SAFETY 
How long-lived is the vaccine-induced immune activation? Is long-lived activation the 
mechanism of enhanced SIV infection? Would immune activation be resolved more quickly in 
an older individual?  Does BCG induce long-lived activation as well?  
We learned in Chapter 4 that vaccination with mc26435 induced persistent immune 
activation in both peripheral blood and tissues.  Despite waiting to initiate SIV challenges 
until week 9, we hypothesize that the immune activation, including upregulation of CCR5 
expressing-cells, led to enhanced infectivity in vaccinated infants, although future studies 
will be required to confirm if vaccination-induced immune activation is actually the 
mechanism by which we observed increased infectivity.  If we could understand how long 
the non-specific immune activation persists and if there was an age-associated effect in that 
infants were less able to resolve immune activation compared to older individuals, it might 
help elucidate the length of time that infectivity could be enhanced in vaccinated infants.  Of 
particular concern is that the AMtb vaccine strains share significant homology to the live 
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attenuated BCG strain that is used to vaccinate >90% infants worldwide.  If BCG shares the 
ability of AMtb to induce persistent systemic immune activation and upregulation of CCR5 
expression, BCG vaccination may also serve to enhance HIV transmission in infants exposed 
to the virus.  While this hypothesis requires much additional study prior to validation, the 
potential implications of attenuated mycobacteria vaccine-enhanced HIV infection has 
important public health implications, justifying a thorough investigation in the near future.   
 
VACCINE EFFICACY 
Does vaccination with attenuated Mtb vaccine strains induce immune responses comparable 
to BCG vaccination?  How long are specific immune responses maintained? 
Despite the importance of a direct comparison of AMtb vaccination to BCG, study 
group sizes were financially restricted from including a BCG group.  We hypothesized that 
using a human-adapted Mtb vaccine strain could confer immune responses with improved 
persistence, particularly for older individuals who are at risk for pulmonary TB infections 
and for whom BCG-induced immunity has waned.   
 
Does vaccination with AMtb strains protect against Mtb challenge?  Is protection 
comparable to BCG?   
An Mtb challenge study to evaluate Mtb-specific protection will serve to test the dual 
immunogenicity of the recombinant vaccine approach.  Importantly, this study should also 
aim to compare the protective capacities of AMtb and BCG.  Because the live attenuated 
vaccine prime is replication-limited mycobacteria and particularly because Mtb does not 
preferentially infect activated immune cells, we hypothesize that vaccination to protect 
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against Mtb infections could be more successful compared to SIV challenges.  In addition, 
vaccinated animals induced persistent Mtb-specific cellular immune responses, even in the 
absence of boosting Mtb-specific immunity.   
 
Does improved recombinant protein expression and/or secretion improve vaccine 
effectiveness? 
In Chapter 4, we showed that Group B animals that received the homologous AMtb 
strain boost developed no anti-Env or anti-Gag, Pol IgA antibodies prior to SIV infection but 
Group C animals boosted with MVA-SIV induced significant levels of both SIV-specific IgA 
antibodies.  A similar trend was observed for SIV-specific IgG antibodies.  We hypothesize 
that the failure of Group B animals to produce SIV-specific antibodies suggests that 
mc26435-SIV was not successfully producing and/or secreting SIV proteins.  One way to 
potentially improve the antibody responses that we observed to inversely correlate with peak 
viremia would be to enhance the ability of the bacteria to express and secrete recombinant 
SIV proteins.   
Although we observed no vaccine-induced protection, a caveat of the interpretation of 
these data is that the recombinant vaccine strains may not have been optimized to perform as 
expected.  We can illustrate this with the SIV Env-specific antibody responses at weeks 6 and 
9 in Groups B and C in the challenge study (Chapter 4).  Group B animals, primed and 
homologously-boosted with recombinant Mtb-SIV strains were unable to produce any SIV-
specific antibodies prior to SIV infection.  Conversely, Group C animals, boosted instead 
with MVA-SIV vaccinations, all produced SIV-specific antibodies at weeks 6 and 9, prior to 
SIV challenging.  Therefore, if the Mtb-SIV strains were producing SIV antigens as 
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efficiently as the MVA-SIV, we may have observed improved antibody levels in Group B 
animals.  Mtb-SIV vaccination can induce the development of anti-SIV Gag, Pol antibodies, 
so we can pinpoint the failure of the Mtb-SIV Env strain, mc26208.  Therefore, while we are 
unconvinced that homologous boosting with recombinant Mtb stains would be effective 
against SIV challenges, we can not confirm this hypothesis without further strain 
optimization and testing to improve Env expression and secretion.   
 
As a further point, the efficacy of neutralizing antibodies for limiting HIV acquisition 
has been addressed multiple times in this thesis but not explicitly the concept of Mtb-SIV 
vaccine-induced neutralizing antibodies.  We acknowledge that Mtb-SIV strains are not 
designed to elicit the development of Env-specific neutralizing antibodies.  While the 
mechanisms of how broadly neutralizing antibodies are induced through vaccination are not 
fully elucidated, our vaccine regimen could be tailored to drive favorable antibody responses 
by including booster immunogens known to prompt the development of neutralizing 
antibodies, particularly at those mucosal surfaces exposed to virus.  For example, the 
complexities of the HIV envelope protein, such as high rates of mutation, exposed epitopes 
with variable confirmations and concealed conserved sequences, demand intelligent immune 
design.  As more broadly neutralizing antibodies are isolated in the clinic and their functional 
characteristics are deciphered, vaccine boosts can be designed to recapitulate their 
neutralizing function (48, 125, 211, 223, 301).  While much attention has highlighted the 
importance of broadly neutralizing antibodies (bNAbs), the titers of neutralizing antibodies in 
HIV-infected individuals are typically quite low compared to non-neutralizing antibodies 
(273, 366).  Perhaps the difficulties the immune response encounters inducing potent bNAbs 
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in natural infections is indicative of vaccine-induced bNAbs as well.  Humoral mechanisms 
in addition to neutralization, such as ADCVI, provide protective benefits as well and should 
be included during vaccine design discussions (93).  Antibodies recognizing linear epitopes 
also proved beneficial as the primary correlate of protection in the recent RV144 trial (110), 
highlighting an important role for abundant binding antibodies with high avidities for 
reducing HIV transmission.  I hypothesize, however, that, especially in the unique immune 
system of the infant, an effective protective vaccine candidate will require a robust and 
activating prime, such as Mtb-SIV strains, followed by protein, subunit or recombinant viral 
boosting to drive the induction of humoral immunity.  As we gain further understanding 
regarding the induction of neutralizing antibodies, vaccine regimens will only get more 
potent and effective. 
 
MECHANISMS OF VACCINE ACTIVATION 
What mechanism(s) of AMtb vaccination improve mDC function and cause immune 
activation?  
Vaccinated animals exhibit improved myeloid dendritic cell (mDC) function 
following treatment with TLR agonists compared to unvaccinated animals (Figure 5.2A).  
The trend of enhanced mDC function is observed longitudinally in peripheral blood and in 
tissues many weeks after vaccination but it is unclear by what mechanism mDC function is 
improved, considering that mc26435 is a double auxotroph strain and replication-incompetent 
in vivo.  Interestingly, while we observed enhanced mDC cytokine production following TLR 
stimulation in vaccinated animals, mDCs do not exhibit non-specific cytokine production that 
occurs in the T cell populations in the same animals (Figure 5.2B).   
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If the bacteria strains are severely attenuated for replication and unable to propagate 
in vivo, the bacilli should be cleared, allowing the infant to dampen its immune activation 
and return to a state of equilibrium.  Therefore, it is unclear why such robust immune 
activation persists for up to 34 weeks post-mc26435 vaccination.  Elucidating the 
mechanisms of immune activation will be an important component to identify whether or not 
attenuated mycobacteria should be used as infant vaccines.   
 
CONCLUDING REMARKS 
Vaccinology is a tricky subject these days.  Diseases like smallpox, measles and polio 
are so removed from our memories and our developed world that it hardly seems necessary 
to vaccinate; after all- out of sight, out of mind.  Unfortunately, vaccines have been 
negatively discussed as the causative agents for a number of otherwise unexplained health 
complications, most notably for cognitive impairments including the autism spectrum 
disorders, attention deficit disorder (ADD) and attention deficit hyperactivity disorder 
(ADHD).  While these allegations have been formally and scientifically discredited (60, 72), 
national media attention and celebrity endorsements have villainized vaccinations, 
particularly those administered during childhood.  Despite public retractions, the popularity 
of vaccinations has not fully rebounded with more parents opting to delay or altogether 
forego advised vaccination regimens.  At an individual level, this decision is seemingly 
negligible but, at a population level, declining vaccine-conferred immunity has dramatic 
implications for public health.   
In recent years, we have observed this phenomenon in the U.S. with the reemergence 
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of pediatric pertussis and measles infections following declining levels of vaccine coverage.  
Pertussis and measles are two vaccine-preventable infections but parents choosing not 
vaccinate themselves and/or their children have resulted in epidemic levels of infections.  For 
example, in August 2013, the anti-vaccination Eagle Mountain International Church in 
Newark, TX reported over 20 cases of measles within their congregation (313).  The virus, 
brought to the megachurch by a visitor infected while traveling in southeast Asia, readily 
infected many congregants, most of whom were not vaccinated. Another example is the 
severe respiratory infection pertussis, or whooping cough, which is also vaccine-preventable 
and almost exclusively infects infants and young children.  In 2012 the U.S. reported the 
highest number of cases of pertussis since 1955, with increases in 49 states due to failure to 
vaccinate (12, 42).  It seems difficult to justify pediatric morbidity and mortality from 
vaccine-preventable infections. 
The inherent difficulties of designing safe, effective and long-lived HIV vaccine 
candidates has been demonstrated by the lack of success by even the brightest and most 
innovative researchers across the globe. While we have learned an impressive amount since 
HIV was first identified- it’s mechanisms of transmission, entry, replication and integration, 
the necessary immune responses required to combat infection and multiple designer 
therapeutic interventions that can essentially restore patient quality of life - it is apparent that 
HIV is a virus worthy of our utmost respect as virologists.   
In 1984, following a conversation with the co-founder of HIV Robert Gallo, US 
Health and Human Services Secretary Margaret Heckler famously declared that a vaccine 
could be ready for testing in about two years.  While this prediction was perhaps too 
optimistic, the unique challenges surrounding HIV vaccine development continue to elude 
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researchers three decades later.  The best we can offer is our dedicated combinatorial 
approach towards preventing new infections, prolific testing and education, improved access 
to and distribution of HAART therapies alongside continued vaccine development efforts to 
someday live in a world no longer afflicted with HIV. 
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FIGURES 
  
Figure 5.1.  The development of anti-PSTS1 plasma IgG following vaccination. 
Vaccination with one of three distinct bacterial strains by both p.o./i.d. (mc26020 and 
mc25157) or by p.o. only (dark blue) or i.d. only (light blue) induced plasma PSTS1-
specific IgG.  Error bars show standard errors of the mean within a group.  The grey 
line is age-matched, mock-vaccinated control animals.  p.o.= oral; i.d.= intradermal.  
MFI is an arbitrary unit normalized within the Luminex assay. 	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Figure 5.2.  Effects of mc26435 vaccination on myeloid dendritic cells.  A) Vaccination 
with mc26435 enhances the ability of mDCs to produce both IL-12 and TNF-α following 
stimulation with TLR agonists (IL-12 production shown longitudinally in PBMC mDC 
after stimulation with TLR7/8 agonist R848). p values calculated using Mann Whitney 
two-tailed t-test. B) Basal cytokine production in mDC at week 5; values were not 
statistically different between groups.  
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